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Abstract 
Evaluation of platelet dependent thrombosis and the role of dual 
antiplatelet therapy on blood thrombogenicity in patients with type 2 
diabetes mellitus and coronary artery disease 
The prevalence of type 2 diabetes mellitus (T2DM) is rapidly increasing. 
Recurrent thrombotic events and cardiac mortality are higher in T2DM. 
Aims: 
My overall aim was to identify abnormalities in blood thrombogenicity in T2DM 
and assess the response to dual antiplatelet therapy. 
Hypotheses:  
Study 1 ACS study: Patients with T2DM have increased blood thrombogenicity 
following non ST-elevation acute coronary syndromes (NSTE-ACS).  
Study 2 CAD study (double blinded RCT): Addition of clopidogrel to standard 
treatment will reduce blood thrombogenicity in T2DM and stable coronary artery 
disease (CAD).  
Methods:  
Study 1 ACS study: Eighty patients (40 with T2DM) with troponin positive NSTE-
ACS on aspirin and clopidogrel underwent thrombogenicity studies. Study 2 CAD 
study: Ninety patients with T2DM and proven but stable CAD were randomised to 
either clopidogrel 75 mg od or placebo and were studied at base line and one 
week after therapy. I performed i) Badimon chamber study, ii) 
thromboelastography, iii) VerifyNow® aggregometry, iv) scanning electron 
microscopy (SEM), v) Multiplate® aggregometry, vi) biomarkers of platelet 
reactivity assays and vii) serum pro-inflammatory cytokines assays.  
Results:  
In T2DM patients with NSTE-ACS, there was higher thrombus area compared to 
non-diabetic patients. Diabetic thrombus showed lower viscoelastic tensile 
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strength and was more resistant to autolysis. On SEM, fibrin fibres in diabetic 
thrombus were thinner, with higher lateral interlinkage and mesh-like 
organisation. Thrombus correlated inversely with the rate of thrombus retraction. 
P selectin, CD40 ligand and inflammatory cytokines were higher in T2DM. 
Clopidogrel decreased thrombus area in stable CAD patients with T2DM, lowered 
platelet content of thrombus and increased fibrin diameter and density. Fibrin 
fibre diameter correlated negatively with shear elastic force of the thrombus. In a 
post hoc analysis, thrombus area of non diabetic ACS patients’ was similar to that 
of T2DM patients with stable CAD. Thrombus area and point of care tests 
showed no correlation. 
Conclusions:  
T2DM had higher blood thrombogenicity after NSTE-ACS and platelet dependent 
thrombus was reduced in stable CAD patients after clopidogrel therapy. 
Clopidogrel resulted in favourable ultra structural changes to thrombus. Patients 
with T2DM and stable CAD were “ACS equivalent” and addition of clopidogrel 
may improve their clinical outcomes. Novel pharmacotherapy to target fibrin and 
inflammation in T2DM may reduce blood thrombogenicity.  
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Chapter 1 Introduction 
The prevalence of diabetes mellitus is rising at an exponential rate worldwide 
(Wild et al., 2004). It is estimated that the number of people with diabetes will 
double by 2030 (www.rcplondon.ac.uk/2009, Type 2 diabetes: national clinical 
guideline for management in primary and secondary care (update). accessed on 
20th August 2013, diabetes.niddk.nih.gov/dm/pubs/statistics, accessed on 20th 
August 2013). 
Type 2 Diabetes Mellitus (T2DM) is the most common form of diabetes, 
accounting for ninety percent of patients with diabetes mellitus 
(www.who.int/mediacentre/factsheets, accessed on 20th August 2013). T2DM is 
defined as a metabolic disorder of multiple aetiologies and characterised by 
chronic hyperglycaemia secondary to impaired insulin action and or insulin 
secretion resulting in disturbances of carbohydrate, fat and protein metabolism, 
and accompanied by clinical features such as increased thirst, polyuria and 
weight loss. 
The World Health Organisation biochemical diagnostic criteria for diabetes are:  
i. fasting plasma glucose ≥ 7.0mmol/l and 
ii. plasma glucose two hours after ingestion of 75 grams of oral glucose 
load  ≥ 11.1mmol/l 
In the presence of clinical features of diabetes, one of the above is sufficient to 
make a diagnosis of diabetes. (www.who.int/diabetes/publications/en/index.html, 
accessed on 20th August 2013) 
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1.1 Cardiovascular disease in type 2 diabetes mellitus (T2DM) 
1.1.1 Cardiovascular mortality and morbidity in type 2 diabetes mellitus 
Patients with T2DM have a fivefold risk of developing cardiovascular disease 
compared to those without (Preis et al., 2009).  Eighty percent of patients with 
T2DM die of a cardiovascular cause (Fox et al., 2007). More than half of the 
individuals with T2DM have evidence of cardiovascular disease at the time of 
diagnosis of diabetes. Mortality in patients with diabetes but without overt 
coronary artery disease is similar to those without diabetes but with a history of 
myocardial infarction (Haffner et al., 1998; Haffner, 2000; Schramm et al., 2008). 
This has led diabetes mellitus to be labelled as a ‘cardiovascular equivalent’ 
(Laakso, 2008). Diabetes mellitus accounts for 6% of global mortality and 
reduction of life expectancy by a decade (Mulnier et al., 2006). 
Acute myocardial infarction is twice as common in individuals with diabetes 
compared to those without (Schramm et al., 2008). Despite current aggressive 
secondary prevention therapies, mortality after acute myocardial infarction is four 
times higher in patients with diabetes (Ford, 2005; Huxley et al., 2006). The 
prevalence of cardiac disease and age specific cardiovascular mortality is lower 
in women generally. However, women with diabetes not only lack this gender 
related cardiac protection but also have a poorer prognosis from cardiovascular 
illness; their mortality rates are 50% higher than in men (Mulnier et al., 2006; 
Kautzky-Willer et al., 2010). 
There has been a significant reduction in cardiovascular mortality in patients with 
and without diabetes over the last two decades. However, patients with diabetes 
mellitus remain at higher risk than non diabetic patients and the relative risk of 
cardiovascular mortality in patients with diabetes remains around 2.5, unchanged 
over the last fifty years (Hanefeld et al., 1996; Fox et al., 2007) . 
Cardiovascular morbidity in patients with diabetes is difficult to estimate. 
Cardiovascular disease is responsible for significant numbers of hospitalisations, 
longer duration of in-hospital stay and loss of quality adjusted life years (QALY) in 
patients with diabetes (Sampson et al., 2006). Ten percent of patients admitted to 
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hospital at any time in the United Kingdom have diabetes as  a co-morbidity 
(Moore, 2000). In 2004, more than 10% of the National Health Services budget 
was spent on treatment of the complications of diabetes mellitus, with 
cardiovascular complications as the leading cause for hospitalisation (Bottomley, 
2001). The enormity of this problem was reflected from a Cardiologists’ 
perspective in a large North American registry of patients with coronary artery 
disease and one third of those needing percutaneous coronary artery 
revascularisation had diabetes mellitus (Venkitachalam et al., 2009). Patients 
with diabetes experience prolonged stays in hospital, resulting in about 80,000 
additional bed days per year in the UK (Sampson et al., 2006).  In addition, 
diabetes accounts for 2.4 times higher medical expenditure compared to a similar 
population in the absence of diabetes (Roglic et al., 2005)  
1.1.2 Coronary Artery Disease (CAD) in T2DM 
Coronary artery disease (CAD) accounts for the majority of cardiovascular events 
in patients with T2DM. Coronary artery disease manifests as acute myocardial 
infarction (ST elevation and non ST elevation acute coronary syndrome), and 
chronic stable angina (Berry et al., 2007). A significant number of patients with 
T2DM do not survive their first myocardial event (Cho et al., 2002). However, due 
to improved secondary prevention methods, the cardiovascular mortality rate in 
patients with T2DM has fallen over the last two decades (Fox et al., 2007). The 
health and socioeconomic benefits of this improving survival of patients with 
T2DM after an acute cardiac event have been offset by the incidence of higher 
recurrent cardiovascular events (Grundy et al., 1999; Lee et al., 2004). In a large 
scale cohort of patients followed up in the European Action on Secondary and 
Primary Prevention through Intervention to Reduce Events (EUROASPIRE) 
study, T2DM was a strong predictor of mortality and recurrent cardiovascular 
events even after adjustment for conventional risk factors such as hypertension 
and dyslipidaemia (Kotseva et al., 2010). In large scale registries such as The 
Global Registry of Acute Coronary Events (GRACE) and global Reduction of 
Atherothrombosis for Continued Health (REACH) Registry, Can Rapid Risk 
Stratification of Unstable Angina Patients Suppress ADverse Outcomes with 
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Early Implementation of the ACC/AHA Guidelines (CRUSADE), recurrent 
cardiovascular event rates remained higher in diabetes despite optimal 
secondary prevention therapy(Franklin et al., 2004; Koek et al., 2007; Bhatt et al., 
2010). In the Swedish Coronary Angiography Angioplasty Registry (SCAAR), 
recurrent cardiac events occurred in one fourth of the T2DM patients who had 
percutaneous coronary revascularisation (Norhammar et al., 2010). Results from 
the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI-2D) 
study  in T2DM patients who underwent coronary bypass surgery also yielded 
similar results (Rutter and Nesto, 2010). After adjusting for baseline and 
treatment differences in the pooled Thrombolysis In Myocardial Infarction (TIMI) 
trials from 1997 to 2006, 30-day mortality was 78% higher in unstable angina 
(UA) and non ST segment myocardial infarction (NSTEMI) patients with T2DM 
and 40% higher in those with ST elevation myocardial infarction (STEMI). At 1 
year, the excess mortality risk independently attributed to diabetes was 65% and 
22%, respectively for UA/NSTEMI and STEMI (Donahoe JAMA 2007). There is 
less reduction in recurrent cardiovascular events with aggressive coronary 
revascularisation strategies such as percutaneous and surgical revascularisation 
in those with T2DM compared to those without T2DM (Franklin et al., 2004). In 
addition, significantly higher rates of stent thrombosis were seen in patients with 
T2DM who received percutaneous coronary revascularisation treatment, even 
after adjusting for vessel diameter and implanted stent length. In the large 
multicentre EVASTENT registry of largely on-label sirolimus drug eluting stent 
use, the rate of drug-eluting stent thrombosis was 4.3% among T2DM  vs. 3.0% 
in non diabetic patients in those with multivessel disease and 3.2% vs. 1.7% in 
those with single vessel disease at one year follow-up (Machecourt et al., 2007). 
1.1.3 Factors Contributing to CAD in T2DM 
Higher cardiovascular events in T2DM were traditionally attributed to the 
increased prevalence of the cluster of conventional risk factors such as 
hypertension, smoking and dyslipidaemia (Bhatt et al., 2010). However, large 
scale studies have confirmed significantly higher event rates in T2DM and 
coronary artery disease after adjustment for conventional risk factors (Buse et al., 
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2007). The presence of other factors such as visceral obesity and impaired 
endothelial function are associated with higher event rates in patients with T2DM 
and coronary artery disease. Despite improvement of obesity and vascular 
endothelial function by multifactorial lifestyle interventions, cardiovascular 
mortality and non fatal cardiac events remained higher in patients with diabetes 
compared to those without diabetes (Eberly et al., 2003; Griffin et al., 2011). 
Tighter control of hyperglycaemia reduces cardiovascular mortality over many 
years when begun in individuals with short-duration diabetes in United Kingdom 
Prospective Diabetes Study (UKPDS) follow up study (Home, 2008; Gore and 
McGuire, 2009) but not when commenced in individuals with longer duration  of 
T2DM (Gerstein et al., 2008; Patel et al., 2008; Duckworth et al., 2009; Skyler et 
al., 2009). This has led to search for novel risk factors unique to the diabetes 
population (Hayden and Reaven, 2000).Pathophysiology of coronary 
atherosclerosis in T2DM 
1.1.4 Overview of coronary atherosclerosis 
Pathophysiological mechanisms contributing to atherosclerosis are complex and 
inter linked.  The definitions of atherosclerosis in general have changed in parallel 
with an ever expanding knowledge base. In the nineteenth century, one eminent 
pathologist, Virchow, called this condition a local proliferative disease, whilst 
another, Rokitansky, referred to it as recurrent thrombotic disease (Mayerl et al., 
2006). Multiple experimental data in the early 20th century supported the 
significant role played by lipids in atherosclerosis. Late 20th century studies have 
revealed inflammation and genetic propensity to be important in various stages of 
atherosclerosis. Our current knowledge of atherosclerosis encompasses all these 
mechanisms, with inflammation occupying a significant role in the initiation and 
progression of atherosclerotic lesions. 
No single definition of atherosclerosis can explain the nature and mechanism of 
the condition. The definition which I favour is “atherosclerosis is defined as a 
systemic, dysfunctional endothelial, focal or diffuse, stenotic, chronic 
inflammatory, fibro-proliferative, prothrombotic, angiogenic, multifactorial disease 
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of the arterial tree caused by the retention of modified low-density lipoproteins, 
and hemodynamic and oxidative stress” (Hayden and Tyagi, 2004). 
The mechanism of coronary atherosclerosis is well studied. The earlier view of 
atherosclerosis as a localised narrowing of the arteries secondary to lipid 
deposits is being replaced as a widespread vascular inflammatory disorder with 
acute (e.g. acute myocardial infarction), chronic (e.g. chronic stable angina) and 
acute on chronic (e.g. acute myocardial infarction in those with angina pectoris) 
clinical manifestations (Libby, 2002). A focal atherosclerotic lesion in a coronary 
artery is known as an atheromatous plaque, which is in constant flux.  It responds 
to changes internal and external, mainly mediated by the inflammatory, 
vasomotor and lipid environment in the intra and extra plaque milieu. 
1.1.5 Coronary artery: anatomical considerations  
Our knowledge of coronary artery anatomy has changed significantly since the 
days of Virchow. An understanding of the anatomical ultra structure is crucial in 
interpreting the pathophysiology of atherothrombosis. 
A normal coronary artery is made up of:  
i. a thin inner layer, the tunica intima consisting of a single layer of 
endothelial cells  
ii. a thick middle layer, the tunica media, made up of smooth muscle cells 
and elastin rich extra cellular matrix 
iii.  an outer layer, the tunica adventitia, rich in collagen fibrils and with the 
neurovascular bundle with vasa vasorum.  
The endothelial cells form a continuous sheet in the inner most layer of the 
arteries which is non thrombogenic in healthy individuals. It covers the highly 
thrombogenic collagen in the tunica media, preventing exposure to flowing blood 
(Fuster et al., 1992). 
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1.1.6 Initiation and progression of coronary atherosclerosis 
The mechanism of very early atherosclerotic changes remains conjectural. 
However, evidence from autopsy studies and multiple experimental studies has 
provided a unifying theory pointing towards structural and functional changes in 
the endothelial layer as a marker of initiation of atherosclerosis. Damage to 
vascular endothelium in the form of ‘fatty streak’ has been identified in infants as 
early as 21 days old. Fatty streaks are intracellular and extracellular deposits of 
cholesteryl esters and other lipids in the tunica media layer of the artery (Strong, 
1995). Fatty streaks progress to frank atheromatous lesions later in life. 
The growth of an atheromatous lesion does not occur in a linear fashion with an 
inexorably progressive course with age, but in a step wise fashion with periods of 
spurts in growth interspaced with periods of slower progression related to age. 
Such periods of rapid growth of a plaque are precipitated by episodes of plaque 
rupture, sub-total luminal thrombosis and smooth muscle cell proliferation 
(Gutstein and Fuster, 1999). 
1.1.6.1 Fatty streak 
The progression of minor fatty streaks to frank atheromatous lesions is facilitated 
by impairment in the endothelial repair process. The coronary endothelium 
suffers continuous damage from external and systemic factors throughout the life 
span of an individual. When inherent protective mechanisms of the coronary 
endothelium in the form of functional antagonism to injurious products and the 
damage-repair process is overwhelmed, the fatty streak progresses to extensive 
atherosclerotic changes (Chien, 2003). 
In a lipid rich milieu, small lipoprotein molecules in circulating blood tend to enter 
the tunica media layer and reside in the sub endothelial region where they bind to 
proteoglycan molecules of the tunica intima. Lipoprotein particles accumulate 
over a period of time and undergo oxidative modification in the presence of free 
radicals. Low density lipoproteins (LDL) that reside in the sub endothelial region 
undergo modification by oxidation and glycation and become oxidised LDL 
cholesterol which is more atherogenic and immunogenic (Tegos et al., 2001). 
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1.1.6.2 Laminar flow and protection against atherosclerosis  
Atheromatous changes occurring in coronary arteries can be focal or diffuse. 
Early atheromatous lesions in certain anatomical parts of the vascular tree, 
especially at bifurcations and branch points, are more susceptible to progression 
to significant atherosclerotic plaque (Nigro et al., 2011). Rapid changes to shear 
stress and non laminar flow at bifurcation points and tortuous parts of the 
coronary vasculature trigger and maintain damage to endothelial function 
mediated via the nuclear factor kappa B (NFKB) pathway (Tegos et al., 2001; 
Cunningham and Gotlieb, 2005; Berk, 2008; Chiu and Chien, 2011) . 
1.1.6.3 Progression of atheromatous lesion 
Endothelial injury accelerates the progression of coronary atheromatous lesions. 
The damaged endothelial cell initially responds by expressing adhesion 
molecules for leucocytes such as vascular cell adhesion molecule-1 (VCAM- 1) 
and P-selectin as a repair mechanism. However, upon continuous insult by both 
endogenous (high cholesterol) and exogenous (smoking) factors, these adhesion 
molecules are over expressed in coronary endothelium. The circulating 
leucocytes, mainly mononuclear phagocytic cells (MNC), attach to damaged 
endothelium via these molecules (Linton and Fazio, 2003). Once in contact with 
endothelial surface adhesion molecules, the MNC’s undergo morphological and 
functional transformation to tissue macrophages inside the tunica media layer. 
MNC adhesion is mediated by cell membrane receptors and protein molecules 
such as monocyte chemo attractant protein-1 (MCP-1) (Chien, 2003; Boyle, 
2005). 
Once inside the tunica intima layer of vascular tissue, the modified MNC’s 
releases various inflammatory mediators including cytokines, leukotrienes, 
prostenoids and histamine like substances. These act via membrane receptors to 
impair the functional and regenerating capacity of the endothelium (e.g. impaired 
production of nitric oxide). MNC’s that are transformed to macrophages digest the 
lipoproteins to become ‘foam cells’. In the presence of macrophage stimulating 
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factors, these foam cells undergo mitotic cell division and thus constitute 
enlargement of atheromatous plaque (Libby and Theroux, 2005). 
Smooth muscle cells elaborate the matrix structure of the sub endothelial layer by 
synthesis of collagen and proteoglycans (Robbie and Libby, 2001; Libby et al., 
2010). The resultant  initial outward remodelling  preserves the luminal diameter 
of the arteries (Clarkson et al., 1994). Some of these smooth muscle cells secrete 
cytokines and sequester calcium into the atheromatous plaque, thus enabling 
calcific mineralisation of the plaque. When the parallel apoptotic processes of 
macrophages and smooth muscle cells are overwhelmed, growth of plaque 
occurs both abluminally and inside the lumen, thereby resulting in a focal stenotic 
lesion (Bjorkerud and Bjorkerud, 1996; Stoneman and Bennett, 2004). 
1.1.7 Atherosclerotic plaque vulnerability and rupture 
Coronary atherosclerotic plaque morphology has recently been classified into 7 
types based on lipid core, ratio of fibrous tissue to lipid core, fibrous tissue lining 
of the plaque and presence of thrombus (Figure 1.1). This pathological 
classification has put more emphasis on the vulnerability and rupture of the 
plaque (Farb et al., 1996; Virmani et al., 2000). The final common end point in the 
life cycle of a coronary atherosclerotic plaque is often plaque rupture and 
thrombosis (Arai et al., 2010). 
Fibrous tissue forms the cap of the atheromatous lesion. The architecture of the 
fibrous cap is weakened in the presence of matrix degrading enzymes such as 
metalloproteinases and cathepsins, resulting in rupture or erosion of the plaque. 
Programmed cell death of the smooth muscle cells can also result in reduced 
production of collagen and extracellular matrix, thus rendering the plaque 
vulnerable for rupture. Plaque rupture exposes thrombogenic lipids and collagen 
to flowing blood and can result in either occlusive or non occlusive thrombus 
leading to myocardial necrosis (Lafont, 2003). Plaque erosion without overt 
rupture can also occur secondary to similar mechanisms and can result in 
thrombosis. Most plaque erosions do not result in clinically apparent myocardial 
infarction but are responsible for bursts in growth of atheromatous plaques, 
(Fuster et al., 2005; Virmani et al., 2006a). 
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Figure 1.1 Classification of atherosclerotic plaques.  
The boxed areas represent the 7 categories of lesion. Dashed lines were used for 
two categories because there is controversy over the role that each of them plays 
in the initial phase of lesion formation, and both "lesions" can exist without 
progressing to a fibrous cap atheroma (i.e., AHA type IV lesion). The processes 
leading to lesion progression are listed between categories. Lines (solid and 
dotted, the latter representing the least-established processes) depict current 
concepts of how one category may progress to another, with the thickness of the 
line representing the strength of the evidence that these events do occur. From 
Virmani R et al, Arterioscler Thromb Vasc Biol, 2000; 20: 1262 - 1275. 
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Vulnerable plaque is currently defined not as a plaque prone to rupture, but as a 
plaque prone to thrombus formation. There is a strong association of thrombus 
with plaque rupture and plaque erosion (Lafont, 2003). Autopsy studies of 
patients who died suddenly due to cardiac causes have revealed the presence of 
multiple layers of thrombi of different ages, thereby indicating this process is 
continuous and often silent (Lafont, 2003). In addition, recurrent episodes of 
thrombus in vulnerable plaques drive further atherosclerosis via platelet derived 
growth factors and cytokines (Fu et al., 2001). 
The pathophysiological mechanisms in the progression of stable plaques to 
vulnerable plaques can be summarised as: 
i. biomechanical 
ii. biochemical 
The traditional model of Davies et al (Davies and Thomas, 1984) describes the 
plaque prone to rupture as consisting of a large lipid core composed of foam 
cells, apoptotic and necrotic cells, and debris, and which is separated from the 
lumen by a fibrous cap (made up of collagen, proteoglycans, and smooth muscle 
cells) which is actively weakened both by continuous lysis of extra cellular matrix 
and absence of repair. This results in plaque fissuring, often at the shoulder 
region of the plaque, exposing platelet activating substances such as collagen, 
and ultimately leading on to occlusive thrombus formation (Davies and Thomas, 
1984). 
 The eccentric plaques are subjected to more mechanical shear stress and 
rupture at their shoulder region (Garcia-Pavia et al., 2007). A myriad of scientific 
evidence confirms the significant role played by biochemical factors in plaque 
rupture. Cytokines released by macrophages play a central role in plaque rupture 
through extra cellular matrix damage induced by matrix metalloproteinases 
(Libby, 2009; Fishbein, 2010), suppression of collagen synthesis (Libby, 1995) 
and enhanced tissue factor generation (Mach et al., 1997). Plaque erosion due to 
fracture of the fibrous cap and or superficial erosion of the intimal layer with or 
without alterations in the extracellular matrix of the tunica media of coronary 
arteries account for two-thirds of fatal acute myocardial infarctions (AMI) 
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(Sugiyama et al., 2004). Biomechanical and biochemical processes are not 
separate but complementary to each other (Shah, 2003). 
1.1.8 Coronary atherosclerosis in T2DM 
Coronary atherosclerotic changes of some degree are observed in almost all 
patients with T2DM. Every stage in the process of atherosclerosis namely 
initiation, progression and plaque rupture is widespread and accelerated in 
T2DM. A greater atherosclerotic burden is consistently seen in medium sized 
arteries in T2DM, along with microvascular disease (Goraya et al., 2002). 
Atherosclerotic changes are more dynamic from initiation to progression in 
T2DM, resulting in early plaque disruption and thus heralding more frequent 
occlusive thrombotic events resulting in AMI compared to those without diabetes 
(Waller et al., 1980). In addition, mild to moderate sized atherosclerotic plaques 
known as ‘non-flow limiting coronary atherosclerotic lesions’ occur more 
frequently in T2DM and are associated with the majority of the plaque rupture 
events and thrombosis resulting in non ST elevation acute coronary syndrome 
(NSTE-ACS) in T2DM (Goraya et al., 2002). 
In patients with T2DM, the endothelial damage – repair cycle loses its ‘balancing 
act’ earlier than in those without T2DM. In the presence of frequently associated 
cardiovascular risk factors in T2DM such as hypertension, dyslipidaemia and 
obesity, damage to endothelium is more pronounced and the repair mechanisms 
are rapidly exhausted, thereby resulting in early and widespread atheromatous 
disease (Moreno and Fuster, 2004). 
T2DM is associated with small coronary arteries and diffuse irregularity in the 
coronary architecture (Spinetti et al., 2008). This anatomical feature would result 
in non laminar flow and increased LDL permeability due to a high cell turnover 
rate and the widening of the intercellular junction (Figure 1.2). In addition, non 
laminar flow also favours an increased tendency for more monocyte 
accumulation due to NFKB mediated cytokine generation in T2DM compared to 
non diabetic individuals (Chien, 2008). 
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Figure 1.2 Atheroma formation in type 2 diabetes mellitus.  
Endothelial cell apoptosis, reduced generation of nitric oxide (NO), and loss of 
endothelial cell junctions allow infiltration of macrophages and extravasation of 
plasma proteins. Leukocyte adhesion is facilitated by endothelial expression of 
adhesion molecules, aiding monocyte/macrophage infiltration and ultimately foam 
cell generation. Increased protein entrapment in the extracellular matrix, together 
with increased matrix deposition, and reduced degradation result in higher matrix 
volume. Low NO levels promote vascular smooth muscle cell (VSMC) 
proliferation and impede relaxation. Infiltrating macrophages and VSMC further 
increase intima/media (IM) thickness. Secretion of thrombogenic factors 
accelerates platelet adhesion and thrombus formation. From: Spinetti G et al, 
Cardiovasc Res, 2008; 78(2): 265-273.  
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1.1.9 Inflammation in T2DM and CAD - a common soil hypothesis 
An inflammatory hypothesis for CAD and diabetes has been put forward which 
advocates shared molecular mechanisms between inflammatory mediators and 
insulin signalling pathways. Every step in the ‘life cycle’ of an atheromatous 
plaque in T2DM from endothelial dysfunction to plaque rupture and clinical events 
is associated with increased amounts of inflammatory constituents compared to 
those without diabetes (Yan, 2008,  (Meng et al., 2010). Coronary atherectomy 
specimens from patients with T2DM show larger areas of monocyte-macrophage 
infiltration compared to those from patients without diabetes (Figure 1.3) (Moreno 
et al., 2000). 
The presence of low grade inflammation which is characteristic of T2DM favours 
monocyte activation, migration and foam cell formation (Moreno et al., 2000). The 
changes in MNC’s are mediated by chemo attractant cytokines such as 
macrophage colony stimulating factor and interleukin 1(IL-1) which are abundant 
in T2DM compared to those without T2DM. Metabolic abnormalities in T2DM, 
such as higher concentrations of diacylglycerol (DAG) and advanced glycation 
end products (AGE), initiate and further intensify humoral, cellular and subcellular 
responses in coronary arteries that lead to vascular inflammation and 
atherothrombosis (Linton and Fazio, 2003; Zhang et al., 2003). The damaged 
endothelial cell initially responds by expressing adhesion molecules for 
leucocytes such as vascular cell adhesion molecule-1 (VCAM- 1) and P-selectin.  
The circulating leucocytes, mainly mono nuclear phagocytic cells (MNC) attach to 
damaged endothelium. 
The changes in MNC’s are mediated by chemo attractant cytokines such as 
macrophage colony stimulating factor which are augmented in T2DM (Meng et 
al., 2010). There is enhanced retention of macrophages in the sub endothelial 
layer in T2DM and interaction with medial vascular smooth muscle cells (VSMC). 
This vicious cycle increases further MNC accumulation in the tunica media. Both 
the VSMC and MNC show hyper response to various oxidative, immunogenic 
and haemodynamic factors in T2DM and secrete mediators of vascular damage 
such as matrix metalloproteinases and leukotrienes. The recent identification of 
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receptors for advanced glycation end products (RAGE) in monocytes provides 
the missing link between diabetes and hyper response of cytokines on sub-
endothelial macrophages and VSMC’s. Secretary (paracrine) products along with 
local endogenous tissue factors increase activation, proliferation and migration of 
vascular cells resulting in neointimal vascular formation (Yan et al., 2008). 
Changes in the constituents of extracellular matrix of the coronary artery in T2DM 
delay the transfer of accumulated lipoproteins back into the vascular lumen, 
which promotes foam cell formation in the tunica media of patients with T2DM 
(Schmitz and Grandl, 2008; Mooradian, 2009). 
1.1.10 Adventitial neovascularisation in T2DM 
The coronary artery adventitial layer derives the majority of its oxygen by a 
process of diffusion from the intimal layer. The vessel wall thickens due to 
atheroma formation and  leads on to the proliferation of new adventitial vasa 
vasorum into the inner layers of the vessel wall (Fuster et al., 2005). It has been 
identified that T2DM patients have complex morphology of neovascularisation 
including sprouting, and red blood cell and monocyte extravasation with 
macrophage erythrophagocytosis eventually resulting in intraplaque 
haemorrhage (Kockx et al., 2003; Moreno et al., 2006; Orasanu and Plutzky, 
2009). A vicious cycle is set up following intraplaque haemorrhage by recruitment 
of more inflammatory cells and delayed clearance of the oxidation prone iron 
radical (Virmani et al., 2005; Michel et al., 2011). 
1.1.11 Plaque vulnerability in T2DM 
Plaque vulnerability as determined by various stages of plaque disruption is 
higher in T2DM. Increased shear stress in patients with T2DM leads to damage 
of proteoglycans and results in a poorly intact extra cellular matrix. Furthermore, 
the higher levels of cytokines seen in T2DM disturb the interlinking of collagen by 
vascular smooth muscle cells (VSMC) that form a vital link in stability of the 
plaque (Shah, 2003; Hess and Grant, 2011). Greater apoptosis and matrix 
metalloproteinase levels in T2DM result in increased matrix degradation and 
destabilization of the plaques, and trigger thrombus formation (Figure 1.4) 
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(Sayeeda et al., 2007). Intravascular ultrasound (Nicholls et al., 2008), coronary 
computed tomography scanning (Yun et al., 2009) optical coherence tomography 
(Feng et al., 2010) and angioscopic studies (Ueda et al., 2003) have shown a  
higher proportion of plaque rupture events occurring in patients with Acute 
Coronary Syndrome (ACS) and T2DM. Autopsy studies also confirm this, along 
with the presence of excess cellular infiltrates in vulnerable plaques (Figure 1.5) 
(Virmani et al., 2006b). 
1.2 Thrombogenicity in T2DM and CAD 
1.2.1 Blood haemostasis and thrombus formation  
Thrombus formation is the most effective protective mechanism by which 
haemostasis is maintained in a closed, high-pressure circulatory system after 
vascular damage. Haemostasis is Nature’s first and often the most efficient 
response to control bleeding. This process must remain ‘dynamically’ inactive but 
should be activated immediately to minimise extravasation of blood from the 
vasculature following tissue injury. After thrombogenesis is activated, it is critical 
to contain thrombus formation so that it is localised to the site of injury and 
thrombus size is appropriate to the injury (Figure 1.6). Thus, there exists a very 
fine balance between the pathways that initiate thrombus formation and regulate 
or modulate thrombus formation (Furie, 2009). 
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Figure 1.3 Macrophage content in coronary atheroma of type 2 diabetes mellitus.  
Increased percent macrophage area in coronary tissue from patients with 
diabetes mellitus (left) versus tissue from patients without diabetes (right). 
Photomicrographs of coronary atherectomy tissue were immunostained with 
antihuman pan-macrophage antibody. Greater macrophage content is seen in 
coronary tissue from a patient with diabetes mellitus (A) than in coronary tissue 
from a patient without diabetes (B). From Moreno PR, et al. Circulation 2000; 
102: 2180–4. 
 
Figure 1.4 Plaque rupture and thrombosis in type 2 diabetes mellitus.  
In type 2 diabetes mellitus, rupture of fibrous cap (upper left) causes majority of 
fatal coronary thrombosis. Superficial erosion (upper right) occurs in one fifth to 
one quarter of all cases of fatal coronary thrombosis. Diabetic patients are more 
susceptible to superficial erosion as the mechanism of plaque disruption and 
thrombosis. Erosion of a calcium nodule may also cause plaque disruption and 
thrombosis (lower left). In addition, friable micro vessels in the base of 
atherosclerotic plaque may rupture and cause intraplaque haemorrhage. 
Consequent local generation of thrombin may stimulate smooth muscle cell 
proliferation, migration, and collagen synthesis, promoting fibrosis and plaque 
expansion on a subacute basis. Severe intraplaque haemorrhage can also cause 
sudden lesion expansion by mass effect acutely. Modified from Libby et al 
Circulation. 2005;111:3481-3488. 
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Figure 1.5 Atherosclerotic lesions with luminal thrombi.  
Ruptured plaques are shown as thin fibrous cap atheroma lesions with luminal 
thrombi (Th). These lesions usually have an extensive necrotic core (NC) 
containing large numbers of cholesterol crystals and a thin fibrous cap (< 65 μm) 
infiltrated by foamy macrophages and a paucity of T lymphocytes. The fibrous 
cap is thinnest at the site of rupture and consists of a few collagen bundles and 
rare smooth muscle cells. The luminal thrombus is in communication with the 
lipid-rich necrotic core. Erosions occur over lesions rich in smooth muscle cells 
and proteoglycans. Luminal thrombi overlie areas lacking surface endothelium. 
The deep intima of the eroded plaque often shows extracellular lipid pools, but 
necrotic cores are uncommon; when present, the necrotic core does not 
communicate with the luminal thrombus. Inflammatory infiltrate is usually absent, 
but if present, is sparse and consists of macrophages and lymphocytes. Calcified 
nodules are plaques with luminal thrombi showing calcific nodules protruding into 
the lumen through a disrupted thin fibrous cap (FC). There is absence of an 
endothelium at the site of the thrombus, and inflammatory cells (macrophages, T 
lymphocytes) are absent. From Virmani R et al, Arterioscler Thromb Vasc Biol, 
2000; 20: 1262 – 1275. 
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1.2.2 Mechanisms of thrombosis 
At sites of vascular injury, platelets rapidly adhere to the exposed subendothelial 
extracellular matrix, become activated and, together with the coagulation system, 
form a thrombotic plug that seals the lesion (Furie and Furie, 2008). A highly 
specialised and efficient haemostatic system consisting of cellular (platelets) and 
non cellular (coagulation factors) components is responsible for three main 
components of thrombosis, namely: 
i. Initiation of thrombosis 
ii. Propagation of thrombus 
iii. Autolysis of thrombus 
 
1.2.2.1 Initiation of thrombosis 
Endothelial cells play a crucial role in the delicate balance between activation and 
inhibition of the haemostatic system. Under normal circumstances, endothelial 
cells produce and release the two powerful soluble inhibitors of platelet activation, 
nitric oxide and prostacyclin, and express high levels of CD39. The major platelet 
feedback agonists such as ADP are rapidly metabolised (Davi and Patrono, 
2007). Anatomically and functionally intact endothelium is key to deter 
thrombogenesis. Loss of endothelial cells due to injury or plaque rupture exposes 
the subendothelial extracellular matrix, rich in collagen, to flowing blood. This 
activates, in the presence of tissue factor, powerful cell signalling molecules that 
result in platelet adhesion and activation. Circulating independent platelets are 
subjected to a phenomenon called ‘rolling’ to the exposed endothelium which 
results in platelet adhesion. Platelet adhesion to the subendothelial structure 
results in a ‘platelet plug’ that forms the hallmark of the events resulting in 
initiation of thrombosis. Exposed collagen in the subendothelial region, von 
Willebrand Factor (vWF) and glycoprotein Ib (GpIb) play a key role in the initiation 
of thrombus formation (Jennings, 2009). 
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Figure 1.6 Thrombus formation in the vessel wall.  
Collagen and tissue factor associated with the vessel wall provide a haemostatic 
barrier to maintain the high-pressure circulatory system. Collagen (yellow 
arrows), located in the subendothelial matrix beneath the endothelium, is not 
exposed to flowing blood under normal conditions. Tissue factor (blue arrows), 
located in the medial (smooth muscle) and adventitial layers of the vessel wall, 
comes in contact with flowing blood when the vessel is disrupted or punctured. 
Both collagen and thrombin initiate thrombus formation. Collagen is a first line of 
defense, and tissue factor is a second line of defense. From Furie et al. N Engl J 
Med 2008;359:938-49. 
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Platelets contain a surface bound molecule known as glycoprotein VI. This 
interacts with collagen of the exposed vessel wall, vWF and GpIb, resulting in 
adhesion of platelets to the vessel wall injury site. In addition to its role in the 
adherence of platelets to collagen, glycoprotein VI is the major agonist for initial 
platelet activation and granule release. The platelet integrin α2β1 plays a 
supportive but not an essential role in the interaction between platelets and 
collagen (Jurk and Kehrel, 2005). There exists an equally powerful, parallel 
pathway involving tissue factor from the vessel wall and or flowing blood which 
generates thrombin, and results in activation and aggregation of platelets 
(Mackman, 2006; Meerarani et al., 2006). Tissue factor triggers a second 
independent pathway that initiates platelet activation. Tissue factor forms a 
complex with coagulation factor VIIa, the enzymatically active form of factor VII, 
and this tissue factor–factor VIIa complex activates coagulation factor IX, thereby 
initiating an enzymatic and proteolytic cascade that generates thrombin (Steffel et 
al., 2006). Thrombin cleaves protease-activated receptor 1 (PAR 1) on the 
platelet surface and eventually results in activation and aggregation of platelets. 
Thrombin also promotes platelet adhesion to the endothelial surface, via an 
unknown mechanism (Andrews and Berndt, 2004). 
1.2.2.2 Progression of thrombus formation 
Further development of thrombus is mainly mediated by platelets and fibrin. 
There is a continuous activation of platelets influenced by the shear force of 
flowing blood and coagulation factors. Platelet activation is positively reinforced 
by the release of granules and microparticles from already activated platelets. 
The platelet integrin α2bβ3a, when activated, mediates recruitment of platelets to 
the thrombus as well as platelet–platelet interactions. Activation of platelets 
bound to the wall of the injured vessel causes a conformational transition in 
α2bβ3a integrin of the platelet cell membrane that increases its affinity for 
fibrinogen and von Willebrand factor (Lefkovits et al., 1995). At low shear rates, 
fibrinogen is the predominant ligand promoting thrombosis, whereas von 
Willebrand factor plays an important role at higher shear rates. Platelet activation 
releases the contents of platelet alpha granules and dense granules, each of 
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which is critical for thrombus formation (Nesbitt et al., 2009). Proteins in various 
subpopulations are released from alpha granules, whereas ADP and calcium ions 
are released from the dense granules. The release of ADP stimulates platelet 
activation through two ADP receptors, P2Y1 and P2Y12. The role of these 
receptors in platelet function and the pharmacology of drugs directed against 
these receptors are described in detail vide infra. 
Following adhesion, rapid signal transduction leads to platelet activation and 
structural changes including cytoskeletal changes associated with shape change, 
spreading and pseudopodia formation and functional changes such as secretion 
of thrombogenic substances. There is an inside–out activation of integrins that 
support adhesion and aggregation. Activated platelet aggregates thus accelerate 
the coagulation cascade, leading to stabilization of the clot by fibrin and α2bβ3-
dependent platelet surface contraction. Activated platelets also interact with 
circulating leukocytes and facilitate platelet–leukocyte–endothelial cell adhesion 
(Libby, 2009). In addition, platelets promote the interaction of inflammatory 
leukocytes with the vessel wall, thus accelerating the formation of atherosclerotic 
plaques (vide infra). The role of platelets in thrombus formation and leukocyte 
adhesion is illustrated in figure 1.7. 
The next important step in propagation of thrombus is its stabilisation by 
interlinkage of platelets and leucocytes with fibrin polymers. Fibrinogen in its 
soluble form is converted to insoluble fibrin by thrombin and other coagulation 
factors. The insoluble fibrin provides the ultraskeletal framework for the thrombus. 
Fibrinogen binds to activated α2bβ3 integrin on the platelet surface, forming 
bridges responsible for platelet aggregation in haemostasis, and also has 
important adhesive and inflammatory functions through specific interactions with 
other cells (Weisel et al., 1983). The significant mechanical strength or 
viscoelastic property to thrombus is derived from fibrin to fibrin cross linkage and 
overlapping of longitudinal fibrin fibres. By forming a mesh-like structure due to 
cross linking of the individual fibres, cellular elements in blood are trapped in the 
thrombus, resulting in cellular thrombus (Collet et al., 2003a; Weisel, 2005). 
  
23 
Circulating monocytes are attracted towards the organising thrombus. The 
adhesion of leukocytes to platelets is mediated by inflammatory cytokines in 
blood, microparticles shed from activated platelets and high levels of P-selectin 
ligands expressed on the surface of activated platelets. Monocytes release tissue 
factor which augments the coagulation response (Zarbock et al., 2007). Platelet 
monocyte interaction in thrombus is described in detail elsewhere. 
1.2.2.3 Autolysis of thrombus 
Autolysis of the formed thrombus is Nature’s mechanism by which the balance in 
haemostasis is restored by removal of excessive clot formation. This consists of 
an early but weaker thrombus retraction mediated by platelets to be followed by a 
stronger process of fibrinolysis mediated by fibrinolytic enzymes. Thrombus 
retraction is the earliest step in regulation of excessive thrombus formation and 
organisation of the thrombus. This step consists of rearrangement of internal 
actin cytoskeletons in the platelet cell wall and results in platelet contraction. 
Shape changes in platelets during this phase are combined with rearrangement 
of fibrin to platelet and fibrin to fibrin cross linkages. Exact stimuli for initiation of 
this process are still unknown (Carroll et al., 1981). 
Fibrinolysis follows thrombus retraction immediately. The fibrinolytic system 
consists of plasminogen activators which convert plasminogen to plasmin. 
Plasmin converts insoluble fibrin to soluble fibrin degradation products and 
thereby results in thrombolysis. Plasmin activity is mediated by two kinds of 
powerful plasminogen activators, namely tissue plasminogen activator, produced 
in the endothelium, and urokinase-type plasminogen activator produced in the 
liver (Cesarman-Maus and Hajjar, 2005). Tissue plasminogen activator mediates 
intravascular fibrinolysis and urokinase plasminogen activator mediates 
extravascular proteolysis (Medcalf, 2007). 
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Figure 1.7 Vascular cell interactions and adhesion receptors.  
(A) Vascular cell interactions: circulating platelets (a) interact with activated 
endothelial cells (b) or subendothelial matrix (c) to form mural thrombi (d) 
providing a substrate for adhesion of leukocytes (e) which also adhere to 
activated endothelium (f) prior to extravasation through the vessel wall (g). 
(B) Vascular cell adhesion receptors: adhesive interactions in the vasculature 
[(A), a–g] are mediated by specific receptors on platelets, leukocytes, and/or 
endothelial cells, and their ligands in plasma or subendothelial matrix, such as 
fibrinogen, von Willebrand factor, or collagen. The interaction of platelet GPIbα 
(the major ligand-binding subunit of GPIb-IX–V) or GPVI with von Willebrand 
factor or collagen, respectively, initiates activation of the integrin and αIIbβ3. This 
will then bind to von Willebrand factor or fibrinogen and mediate platelet 
aggregation. GPIbα can also mediate platelet–endothelial cell adhesion by 
binding to P-selectin, or P-selectin-bound von Willebrand factor. GPIbα can 
mediate platelet–leukocyte adhesion by binding to the leukocyte integrin, αMβ2 
(Mac-1). The leukocyte receptors PSGL-1 and αMβ2 are involved in leukocyte 
adhesion to endothelium by binding P-selectin or ICAM-1, respectively, on 
endothelial cells, or by binding to P-selectin or GPIbα, respectively, on adhered 
and activated platelets. This network of receptor–counter receptor or ligand 
interactions provides intricate regulation of platelet–leukocyte–endothelial cell 
cross-talk. Andrews RK, Berndt MC. Thromb Res. 2004; 114(5-6): 447-53. 
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Plasminogen activator inhibitor-1 (PAI-1), a serine protease enzyme produced by 
the liver and endothelial cells, binds to the active site of both tissue plasminogen 
activator and urokinase plasminogen activator and neutralizes their activity. 
There is a dynamic equilibrium between tissue plasminogen activator and PAI-1 
on the luminal surfaces of vessels that determines net local fibrinolytic activity. 
Either increased expression of PAI-1, or decreased expression of tissue 
plasminogen activator, or both can lead to decreased fibrinolytic activity and 
predispose to thrombosis (Vaughan, 2005). 
Macrophages which are often seen in formed thrombus are involved in its 
resolution. Platelets and other cellular elements are resorbed by macrophages 
once the fibrinolytic process is completed. However, some of these cellular 
elements engulfed by macrophages undergo calcification and result in giant cell 
formation. Calcification and a layering effect are seen in human coronary arteries 
and are the hallmark of old and recurrent thrombus and are mediated by 
macrophages (Fuster et al., 2005; Medcalf, 2007). 
1.2.3 Platelets in thrombogenesis 
Platelets are derived from megakaryocytes in the bone marrow and are anucleate 
and discoid cells which circulate in blood for 7-10 days. Platelets contribute to 
haemostasis by activation, adhesion and aggregation. Platelets exhibit extreme 
flexibility and change of shape (Jennings, 2009). They are activated by vessel 
wall damage and agonists such as arachidonic acid, collagen, adenosine 
diphosphate (ADP), fibrinogen and epinephrine via trans-membrane receptors 
(outside-in activation). This leads to intraplatelet events mediated by substances 
such as adenyl cyclase and calcium, resulting in conformational changes to 
integrins such as alpha IIb/beta3 (glycoprotein IIb/IIIa receptor). The integrins are 
translocated to the outer membrane from inside the platelets and they form high 
affinity sites for molecules such as fibrinogen (inside-out activation) (Lefkovits et 
al., 1995). This results in binding of fibrinogen and leads on to platelet to platelet 
interaction. Activated platelets are identified by up regulation of cell surface 
markers such as p-selectin, CD63 and CD40 ligands. Platelets also bind to 
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leucocytes via integrin type membrane receptors (Biondi-Zoccai et al., 2003; 
Antoniades et al., 2009; Ferroni et al., 2009).  
Upon activation, platelets respond with: 
i. change of shape from a discoid to a pseudopodial structure 
ii. aggregation with other platelets and other blood-derived cells such as 
monocytes 
iii. release of substances from secretory granules (α-granules), dense 
bodies, and lysosomes 
iv. liberation of arachidonic acid, which is rapidly converted to 
prostaglandins and lipoxygenase (Jennings, 2009) 
The end result of platelet activation is conversion of soluble fibrinogen into 
insoluble fibrin and also activation and recruitment of other platelets. Platelets, 
along with other cells such as erythrocytes and monocytes, are trapped in the 
fibrin mesh formed by fibrin polymerisation. This results in growth and 
stabilisation of thrombus. 
1.2.4 Platelet procoagulant activity 
Once activated, platelets promote thrombogenesis further by interaction with 
other coagulant factors and activation of other resting platelets by paracrine and 
endocrine mechanisms. This eventually will lead on to exponential amplification 
of coagulation cascade (Ilveskero et al., 2001). This inherent property is known 
as platelet procoagulant activity (PPA) and is shown to play a key role in 
thrombogenicity.  
Platelet activation often begins upon attachment of platelets to the damaged 
endothelium and exposed collagen. This process is mediated by vWF and 
glycoprotein Ib (vide supra). This step initiates PPA which comprises of changes 
in platelet membrane architecture, intra cytoplasmic enzyme activation and 
release of powerful procoagulants from the platelets. Interaction between 
circulating coagulation factors and platelets sustain this platelet procoagulant 
state.  
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Activation of factor X and formation of thrombin constitute the most powerful step 
in coagulation cascade. This process requires a catalytic surface on which the 
enzyme complexes can be assembled. This catalytic surface is provided by the 
phospholipids of the activated platelet plasma membrane, which are turned inside 
out and exposed to flowing blood and collagen. This results in the loss of normal 
asymmetric distribution of phospholipids on the inner surface of the platelet and 
formation of a procoagulant surface (Bevers et al., 1991). Activated platelets 
further accelerate coagulation cascade by releasing coagulation factor V and 
thrombin and ultimately results in insoluble fibrin. These exert a positive effect on 
the resting platelets and thus PPA is magnified in whole blood. This 
prothrombotic tendency of the activated platelets is kept in balance by the 
inherent inactivation of coagulation factors V and VIII via an activated protein C 
dependent pathway (Solum, 1999). 
The exact mechanism of PPA remains uncertain. Mechanical factors play a 
significant role in PPA. Firstly, shape change occurs upon activation of the 
platelets as described vide supra. This would expose the circulating coagulation 
factors to the pseudopodia and membrane channels of the platelets. This is 
accompanied by changes in the membrane receptors and ligands like α2β3 in 
activated platelets (Swords et al., 1993). Platelet activation also causes 
mobilisation of intracellular fibrinogen-glycoprotein IIb/IIIa complexes to the 
platelet surface in a secretion-dependent manner. This would facilitate binding of 
fibrinogen and vWF (Sims et al., 1991) and thereby lead on to platelet to platelet 
and platelet to fibrin binding. In addition, the membrane phospholipids contributes 
to the formation of microparticles whose significance is described elsewhere 
(Chapter 1.3.8, page 47).  
PPA can result from biophysical or biochemical mechanisms. Physical shear 
force can increase platelet procoagulant activity. In the presence of high shear 
condition, platelet activation was still demonstrated after blocking vWF and GpIb 
receptors suggesting direct effect of shear stress on the procoagulant activity. 
High shear force has been shown to increase the release of ADP and 
accumulation of cytosolic calcium in activated platelets. This will sustain further 
procoagulant activity and thus will enhance thrombogenesis (Goto et al., 2003; 
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Chen et al., 2010). Thrombin is a powerful substance released by platelets upon 
activation. Thrombin sustains platelet activation by augmenting the release of 
procoagulant factors like calcium and ADP. In addition, upon activation platelets 
contribute to coagulation activity by releasing several compounds, factor V, factor 
XIII, fibrinogen, vWF, calcium ions, and ADP from their alpha granules and dense 
granules (vide supra). These compounds in turn activate the resting platelets and 
thereby sustain and amplify procoagulant tendency of the platelets (Jennings, 
2009). 
Every aspect of PPA is enhanced in patients with T2DM. Excess production of 
cytosolic factors like ADP, thrombin, calcium, thromboxane and fibrinogen were 
noted in diabetic platelets. These prothrombotic substances are released even at 
sub threshold stimuli in T2DM. In addition, the plasma membrane changes are 
more pronounced in diabetic platelets as evidenced by higher levels of 
microparticles and α2β3 integrins on the platelet surface compared to non 
diabetics. These changes were attributed to the reduction in the antiplatelet 
effects of aspirin and clopidogrel in T2DM (Davi et al., 1990; Carr, 2001; 
Angiolillo, 2009). 
1.2.5 Coagulation factors 
Historically, the coagulation cascade is divided into the extrinsic (tissue factor 
mediated) pathway and the intrinsic (factor XII, XI initiated) pathway (Davie et al., 
1991; Gailani and Renne, 2007; Meerarani et al., 2007). Both these pathways 
stimulate a final common pathway which mediates the conversion of prothrombin 
to thrombin and ultimately results in production of insoluble fibrin and thrombus 
(Figure 1.8). The coagulation cascade is tightly regulated by a series of inhibitors. 
Tissue factor pathway inhibitor (TFPI) inhibits coagulation by binding with 
activated factor X, thereby inhibiting the tissue factor- activated factor VII 
complex. Activated protein C and protein S inactivate factor V and factor VIII 
whereas antithrombin III inhibits thrombin (Girard et al., 1990; Esmon, 1992).  
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Figure 1.8 Coagulation cascade.  
F represents factor, “a” represents activated, APC- activated protein C, TFPI 
tissue factor pathway inhibitor, ATIII anti-thrombin III, TF tissue factor. Modified 
from Breitenstein A, et al Circ Journal 2011; 74:3-12. 
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Tissue factor (TF) is a key trans-membrane protein involved in the initiation of 
the coagulation pathway. The name tissue factor is a misnomer as it is derived 
from both vascular tissue sources such as endothelium, vascular smooth muscle 
cells, and fibroblasts (Day et al., 2005) and blood borne cells including platelets 
and monocytes (Giesen et al., 1999; Steffel et al., 2006). TF is a 263-residue 
membrane-bound glycoprotein which is not normally present in or exposed to the 
circulation. The location of TF on plasma membranes of endothelium and smooth 
muscle cells enables the process of coagulation to remain fixed at the site of 
vessel wall injury. The exposure of cell surface TF to plasma leads to the binding 
of factor VII to TF. The complex TF-factor-VII is activated by free factor VIIa and 
or pre-existing TF-factor VIIa complexes. The TF-factor VIIa complex rapidly 
activates factor X and, at a lower rate, factor IX. Activated factor IX, in the 
presence of its co-factor VIII, cleaves further factor X to activated factor Xa. 
Eventually, these processes culminate in the generation of thrombin, which 
converts fibrinogen to fibrin (Butenas et al., 2009). 
Tissue factor pathway inhibitor (TFPI) is a serine protease formed in 
endothelial cells which circulates in inactive form. Upon activation of the 
coagulation cascade, TFPI is activated and inhibits conversion of factor X into 
activated factor X (Xa) of the coagulation cascade by binding to tissue factor-
factor VII complex. It also inhibits the conversion factor IX (Broze et al., 1993; Lu 
et al., 2004). Levels of TFPI correlate to the levels of tissue factor in patients with 
dyslipidaemia (Hansen et al., 2001) and acute coronary syndrome (Falciani et al., 
1998; Hansen et al., 2001; Gori et al., 2002). A rise in TFPI is a marker of 
hyperactivation of the coagulation system (Lwaleed and Bass, 2006) and offers 
some but not full protection against future thrombotic events (Viles-Gonzalez and 
Badimon, 2004).  For example, high levels of tissue factor seen in T2DM are 
insufficient to protect against future thrombotic events (Leurs et al., 1997; 
Badimon et al., 1999). 
von Willebrand factor (vWF) is synthesized and secreted by endothelial cells 
and megakaryocytes. vWF promotes platelet adhesion to the vascular 
subendothelium which is exposed following plaque rupture mediated by platelet 
GPIb receptor. Elevated levels of vWF are an indication of endothelial cell 
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damage, and correlate with cardiovascular risk factors including T2DM and 
dyslipidaemia (Kessler et al., 1998). vWF is the carrier of procoagulant factor VIII 
in circulating blood and plays a crucial role at high shear states. 
vWF plays a crucial part in thrombosis by the following mechanisms: 
i. Binding of vWF to components of the sub endothelium (various forms 
of fibrillar collagen, non-fibrillar collagen, heparin and sulfatide) 
ii. Conformational change of vWF, an essential step in its interaction with 
platelet GPIb receptor 
iii. Initial platelet adhesion through binding of fibrinogen and vWF to 
platelet GPIb 
iv. Transduction of an intraplatelet signal triggering the expression of 
GPIIb/IIIa at the platelet membrane surface 
v. Binding of vWF to GPIIb/IIIa, leading to the spreading of platelets and 
their irreversible adhesion and aggregation (Kessler et al., 1998; 
Reininger et al., 2006) 
Fibrinogen is a polypeptide synthesised by liver which influences 
thrombogenesis, rheology of blood flow, blood viscosity and platelet aggregation. 
Fibrinogen is an acute phase protein and a marker of systemic inflammation. 
Fibrinogen is present in blood in the soluble state at a concentration of 2.0 to 5.0 
g/dl. Each end of a fibrinogen molecule can bind with high affinity to the α2bβ3 
integrin receptor on activated platelets, and thus act as a bridge to link platelets. 
The fibrinogen molecule is made up of alpha, beta and gamma peptide chains, 
figure 1.9 (Weisel, 2004). 
Serum fibrinogen concentration is a well known independent risk factor for 
coronary artery disease and is frequently used as a surrogate marker for 
cardiovascular risk. The relative risk for coronary artery disease in individuals in 
the top compared to the bottom tertile of plasma fibrinogen is 1.8. In a 
longitudinal observational study over 13 years, elevated plasma fibrinogen was 
associated with higher rates of sub clinical cardiovascular disease (Danesh et al., 
1998). 
  
32 
 
Figure 1.9 Schematic diagram of the three pairs of polypeptide chains of 
fibrinogen.  
The Aα, Bβ, and γ chains are represented by bars with lengths proportional to the 
number of amino acid residues in each chain and the N- and C-terminal ends of 
the chains are labelled. The coiled-coil regions are indicated by the diagonally 
striped boxes, while the intra- and interchain disulfide bonds are indicated by 
solid lines. Carbohydrate attachment sites are labelled with CHO, while thrombin 
and major plasmin cleavage sites are indicated by T and P, respectively. From 
Weisel, J Thromb Haemost, 2007;5,116-124. 
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Fibrin is formed by polymerisation of fibrinopeptides. Soluble fibrin is converted 
to insoluble fibrin by thrombin. The fibrin monomers are formed from a molecule 
of fibrinogen in the form of fibrinopeptide A and B which subsequently bind to 
themselves after the exposure of the binding sites within these monomers in the 
presence of factor XIII (Figure 1.10). Staggered arrangement of fibrin monomers 
in this fashion result in protofibrils. Once protofibrils reach sufficient length (600-
800 nm), they begin to elongate laterally by binding to their adjacent fibril units to 
form mesh like fibres (Weisel, 1986; Weisel et al., 1987; Ryan et al., 1999). The 
intermolecular interactions that occur in lateral aggregation are specific, so that 
the fibres have a repeat of 22.5 µ, or about half their molecular length (Cohen et 
al., 1983). The molecular structure and packing in fibrin revealed that fibres are 
par crystalline structures with the molecules precisely aligned in the longitudinal 
direction, but only partly ordered in the lateral direction. The length and lateral 
growth of fibrin is limited by the twisting of individual fibres, which reduces the 
availability of binding sites. Increased thickness of fibrin strands in this way limits 
the growth of fibre, as the energy to stretch these twisted fibres to expose 
additional binding sites exceeds the energy stored in the unbound individual fibrin 
monomers (Wolberg, 2007). 
Fibrin is a viscoelastic polymer, characterised by stiffness (representing its elastic 
properties) and compliance (representing its inelastic properties). Viscoelasticity 
determines the response of the clot to the shear force of flowing blood. A clot with 
a greater inelastic component will deform permanently with stress, while one with 
a greater elastic component will return to its original shape. Detailed physical 
principles behind clot viscoelasticity are still largely unknown (Weisel, 2007). 
1.2.6 Platelet monocyte interaction and thrombosis 
Platelet monocyte interaction forms a crucial link between thrombosis and 
inflammation and is mediated by P-selectin, a membrane glycoprotein contained 
within platelet alpha granules and Weibel-Palade bodies of endothelial cells. 
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Figure 1.10 Schematic diagram of fibrin polymerisation.  
 
Fibrinopeptide A is cleaved from fibrinogen, producing desA fibrin monomers, 
which aggregate via knob-hole interactions to make oligomers. Fibrinopeptide B 
is cleaved primarily from polymeric structures. The oligomers elongate to yield 
protofibrils, which aggregate laterally to make fibres, a process enhanced by 
interactions of the αC domains. Factor XIIIa crosslinks or ligates γ chains more 
rapidly than α chains. Plasmin cleaves the αC domains and Bβ1-42 and then cuts 
across the fibrin in the middle of the coiled coil. At the bottom of the diagram, a 
branch point has been initiated by the divergence of two protofibrils. From Weisel, 
J Thromb Haemost, 2007;5,116-124. 
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P selectin is rapidly translocated to the plasma membrane following cell 
activation. P-selectin interacts with its natural ligand, P-selectin glycoprotein 
ligand-1 (PSGL-1), present on neutrophils and monocytes, thus providing an 
anchoring source for inflammatory cells on activated platelets and endothelial 
cells (McEver et al., 1995). Neutrophil rolling on platelets is mostly mediated by 
platelet P-selectin binding to P-selectin glycoprotein ligand (PSGL)−1 on 
leukocytes.  Blocking one of these molecules with a monoclonal antibody 
completely inhibits neutrophil rolling on platelets. Firm adhesion of leukocytes to 
platelets is facilitated by molecules such as CD11b/CD18 and CD11a/CD18 
(Esmon, 2005). Platelets also activate monocytes via cytokines such as IL-6. 
Activated platelets increase monocyte binding to inflamed endothelium, and thus 
indirectly accelerate progression of atheromatous plaque. Monocytes also 
secrete tissue factor, and thus enhance thrombogenicity (Pamukcu et al., 2011). 
Antiplatelet agents including clopidogrel suppress platelet monocyte interaction 
(Zarbock et al., 2007). 
1.2.7 Blood thrombogenicity in T2DM 
Higher cardiovascular mortality has been attributed to higher thrombogenicity in 
patients with T2DM (Osende et al., 2001; Berry et al., 2007). An inherent 
prothrombotic state has been established by invitro studies in patients with 
T2DM. Blood thrombogenicity in patients with T2DM results from a complex 
interplay of coagulation factors, hyperactive platelets and impaired fibrinolysis. 
Antiplatelet therapy reduces this thrombogenicity in those with T2DM less than in 
those without diabetes (Natarajan et al., 2008a). Hyporesponse to the currently 
available antiplatelet agents may be responsible for excess mortality seen in 
patients with T2DM (Angiolillo, 2009). 
1.2.7.1 Hyperactive platelets in T2DM 
Platelet function is significantly altered, favouring a thrombotic tendency in 
patients with T2DM (Vinik et al., 2001; Natarajan et al., 2008b; Ferroni et al., 
2009).  Platelets of patients with T2DM have been referred to as ‘angry platelets’ 
(Bhatt, 2008) as they constantly remain in a state of hyperactivation. Flow 
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cytometry studies have revealed that a subpopulation of large, hyperactive 
platelets circulates in patients with T2DM, at a level similar to that seen in 
patients who have had an MI but do not have T2DM. This suggests that platelets 
in T2DM respond to sub threshold stimuli and have high potential for aggregation 
(Trovati and Anfossi, 2002). 
Platelet hyperactivity could itself be a marker of diabetes mellitus. Animal studies 
showed enhanced platelet aggregation within a week after onset of diabetes 
(Stratmann and Tschoepe, 2009). Platelet dysfunction in T2DM is due to a 
combination of innate platelet abnormalities such as enhanced aggregation to 
stimulus, excess platelet agonists such as arachidonic acid and reduced platelet 
inhibitory substances like prostaglandin I2 (PGI2) (Sobel and Schneider, 2004). 
Platelets in diabetic subjects have higher surface expression of the glycoprotein 
IIb IIIa receptor in the resting state (Tschoepe et al., 1990). 
Persistent hyperglycaemia enhances platelet activation. Activated platelets 
require glucose to supply energy rich adenosine triphosphate (ATP) for regulation 
of transmembrane function. Glucose entry into the platelet occurs by a gradient 
driven process due to translocation of glucose transporter protein 3 (GLUT-3) 
from alpha granules inside the platelets. This process of translocation is 
enhanced by thrombin (Ferreira et al., 2005). Unlike most human cells, glucose 
entry into platelets is not directly facilitated by insulin. New evidence suggests 
that insulin promotes glucose entry into platelets indirectly by activation of protein 
kinase B (PK-B) in normoglycaemic states (Randriamboavonjy and Fleming, 
2009). Hyperglycaemia results in an increase in the intraplatelet concentration of 
the platelet agonist thromboxane (Davi et al., 1999) and short bursts of 
hyperglycaemia have been associated with platelet hyperactivity (Assert et al., 
2001; Osende et al., 2001). Platelets of patients with T2DM respond to 
hyperglycaemia by translocation of membrane receptors such as protein kinase 
C (PKC) and increase in intracellular calcium, which mediate the enhanced 
activity to platelet agonists (Assert et al., 2001). Hyperglycaemia also increases 
oxidation of LDL, which facilitates calcium entry into platelets.  
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This cytosolic hypercalcaemic state is responsible for enhanced adhesion and 
aggregation of platelets, reduction of intracellular nitrate production and changes 
in anti-aggregatory properties of the platelet membrane (Ferretti et al., 2002). 
Risk factors such as obesity and hypertension independently augment platelet 
hyperactivity irrespective of glycaemic status (Stratmann and Tschoepe, 2009). 
Platelet leucocyte interaction is responsible for propagation and stabilisation of 
thrombus. T2DM is associated with higher platelet monocyte linkage and is 
mediated by P-selectin and cytokines (Elalamy et al., 2008). Leukocyte-platelet 
heterotypic aggregates (involving mainly monocytes) produce procoagulant, 
oxidative, and mitogenic substances  which potentially play a role in capillary 
micro embolism and arterial thrombosis (Kaplar et al., 2001). 
Platelet synthesis is also hyperactive in patients with T2DM. As diabetic platelets 
respond more frequently to sub-threshold stimuli, they soon become exhausted, 
consumed and finally incorporated into thrombus. This relatively excess 
consumption of platelets results in accelerated thrombopoiesis in the bone 
marrow mediated by thrombopoietin and release of ‘fresh’ hyper-reactive 
platelets. The presence of ‘young’ active platelets in T2DM reduces the response 
to antiplatelet agents and augments the response to naturally occurring platelet 
agonists (Watala et al., 1999; Watala et al., 2005). These platelets also exhibit 
altered membrane fluidity which promotes a vicious cycle of hyperactivity and 
sustains the prothrombotic state in T2DM (Papanas et al., 2004). Platelet 
structural and functional alterations seen in T2DM are summarised in Table 1.1. 
1.2.7.2 Coagulation factor activity in T2DM 
Higher thrombogenicity in T2DM is facilitated by coagulant factor activity. Patients 
with T2DM have increased quantities of prothrombotic factors, to the extent that 
T2DM is called a ‘hyper-coagulable’ state (Carr, 2001). In addition to 
conventional screening tests  such as shorter prothrombin and partial 
thromboplastin times (PT and APTT), T2DM is associated with elevated tissue 
factor levels (Meerarani et al., 2007), relative reduction of tissue factor pathway 
inhibitor activity (Lwaleed and Bass, 2006), higher prothrombin activating factor 
and higher thrombin-antithrombin complexes compared to individuals without 
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diabetes (Davì et al., 1992). Increases in the levels of factor VIII, plasma 
fibrinogen and Von Willebrand factor and factor XI found in T2DM favour 
thrombus formation (Ferroni et al., 2004). In T2DM, Tissue factor (TF)  
expression is increased directly by hyperglycaemia (Stegenga et al., 2006), and  
hyperinsulinaemia (Boden et al., 2007) and indirectly by stimulation of receptors 
of advanced glycation end products (RAGE) (Min et al., 1999), nuclear factor 
kappa B (NFkB) and  reactive oxygen species (Herkert et al., 2004). Tissue factor 
pathway inhibitor (TFPI) levels are higher in patients with T2DM and correlates 
with hyperglycaemia and insulin resistance (Leurs et al., 1997; Vambergue et al., 
2001) but functionally these higher levels do not offer protection from excess 
thrombus formation. Experimental administration of more than double the usual 
levels of TFPI reduced platelet dependent thrombogenicity in T2DM, confirming 
that the levels of TFPI seen in T2DM are insufficient to protect against future 
thrombotic events (Badimon et al., 1999). 
Factor VII is a pro-coagulant protein which is elevated in patients with T2DM, in 
pre-diabetes and relatives of patients with T2DM (Heywood et al., 1996; 
Mansfield et al., 1996). There is a strong association between Factor VII levels 
and LDL cholesterol and triglyceride levels, particularly in T2DM (Hoffman et al., 
1992; Zito et al., 2000). von Willebrand factor (vWF) is elevated and correlates 
with other cardiovascular risk factors such as T2DM and dyslipidaemia (Frankel 
et al., 2008; Jax et al., 2009). Recent reports from the Framingham heart study 
have confirmed the association between high levels of vWF and T2DM and 
correlation of vWF and cardiovascular events in patients with T2DM. These 
suggests that vWF may represent a unique risk factor in patients with T2DM and 
coronary artery disease (Frankel et al., 2008). 
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 Increased aggregating responses 
 Decreased responses to anti-aggregating substances 
 Increased membrane viscosity 
 Increased protein tyrosine phosphorylation 
 Increased calpain activity 
 Increased calcium content and reverse mode of sodium/calcium 
exchanger 
 Increased calcium-induced presentation of the thrombospondin receptor 
CD36 
 Reduced L-arginine uptake 
 Reduced endothelial-type nitric oxide synthase activity 
 Enhanced homocysteine ability to reduce nitric oxide availability 
 Trend to leukocyte-platelet heterotypic aggregation 
 Increased expression of adhesive proteins  
 Decrease of nitric oxide availability 
 Protein kinase C translocation to the membrane 
Modified from Trovati et al. Current Diabetes Reports 2002;2:316–322 
Table 1.1 Platelet alterations in type 2 diabetes mellitus.  
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Elevation of fibrinogen levels may provide the link between inflammation, 
thrombosis and T2DM as it is an acute phase protein synthesised in response to 
inflammatory mediators (Takebayashi et al., 2006). Poor glycaemic control is 
associated with high fibrinogen levels which are reversed upon restoration of 
normoglycaemia in T2DM (Emanuele et al., 1998). Multiple epidemiological 
studies such as the  Insulin Resistance Atherosclerosis study (IRAS) and 
Framingham heart study (Kannel et al., 1990) confirm that elevated serum 
fibrinogen is a strong and independent cardiovascular risk factor in T2DM 
(Danesh et al., 1998; Kaptoge et al., 2007; Ang et al., 2008; Bhatt, 2008; 
Guardado-Mendoza et al., 2009). Fibrinogen levels are associated with a higher 
incidence of silent myocardial infarction in patients with T2DM (Guardado-
Mendoza et al., 2009) and hypo-response to antiplatelet agents including 
clopidogrel in patients with T2DM (Ang et al., 2008). Levels of coagulation factors 
such as factor XII and factor XIII were higher in individuals with T2DM both in 
the baseline state and after acute myocardial infarction compared to those 
without T2DM (Miller et al., 1997; Mansfield et al., 2000).  
1.2.7.3 Impaired fibrinolysis in T2DM 
The procoagulant state in DM is further sustained by an imbalance of 
prothrombotic and fibrinolytic mechanisms. In T2DM,  reduced fibrinolysis 
potentiates thrombogenicity and also promotes atherogenesis by extended fibrin 
deposition (Sobel and Schneider, 2004). The fibrinolytic system is less effective 
in T2DM because of abnormalities in clot structure, such as increased side to 
side fibrin polymer chains, making it more resistant to degradation, and elevated 
levels of fibrinolytic inhibitors such as PAI-1 (Aso et al., 2002; Alzahrani and 
Ajjan, 2010). Aggressive management of cardiovascular risk factors including 
dyslipidaemia and hypertension reduces the levels of PAI-1, thereby providing 
one mechanistic link for reduction of thrombotic events with risk factor 
management (Colwell, 2001; Mertens et al., 2008). PAI-1 is consistently elevated 
in the vessel walls of patients with T2DM (Figure 1.11) (Sobel et al., 1998; 
Pandolfi et al., 2001). Genetic polymorphisms, hyperglycaemia and inflammatory 
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cytokines are responsible for high PAI-1 levels seen in patients with T2DM (Jokl 
et al., 1994; Mansfield et al., 1995; Dellas and Loskutoff, 2005; Saely et al., 
2008). Current evidence suggests that increased PAI-1 production is linked not 
only to increased thrombotic events seen in T2DM but also may be important in 
the development of widespread atheroma (Raghunath et al., 1995; Carmeliet et 
al., 1997; Eitzman et al., 2000). 
1.2.8 Microparticles in T2DM 
Microparticles (MPs) are small membrane prothrombotic structures of size 0.02 to 
0.10 µm shed from platelets and endothelial cells. They are released into the 
circulation by exocytosolic budding of plasma membranes of the cells and are 
highly thrombogenic (Horstman and Ahn, 1999; Nieuwland et al., 2007). MP 
levels are consistently higher in T2DM. It is still unclear if an increase in platelet 
MPs serves as an independent marker for future coronary events or is just a 
reflection of platelet hyperactivity in T2DM (Nomura et al., 2008). Interestingly, 
elevated endothelial MP levels were useful in identifying a subpopulation of 
diabetic patients without typical anginal symptoms but with angiographic 
evidence of coronary artery disease. Monocyte derived MP were associated with 
microvascular and macrovascular complications of T2DM. (Omoto et al., 2002; 
Koga et al., 2005). 
1.2.9 Inflammation and thrombosis in T2DM 
Type 2 diabetes mellitus has been associated with chronic low grade 
inflammation. Persistent hyperglycaemia, advanced end glycation products and 
hyperinsulinaemia are associated with greater inflammation. Recent evidence 
has categorically shown a link between inflammation and thrombosis leading on 
to coronary events (Hotamisligil, 2006). As mentioned earlier, it is possible that 
inflammation is the hidden but potent “common soil” for the prothrombotic state in 
T2DM (Stern, 1995; Hess and Grant, 2011). 
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Figure 1.11 Immunohistochemistry of Plasminogen activator inhibitor-1.  
Intensity of immunohistochemical staining for plasminogen activator inhibitor-1 
(PAI-1) from patients without diabetes (A and B) compared with those from 
patients with diabetes (C and D). Intensity and distribution of PAI-1 were 
generally greater in samples from subjects with diabetes than in those 
without. Magnification ×100. From Sobel, Am J Med,2007; 120(9, Supplement 
2), S3-S11. 
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The exact mechanism by which inflammation contributes to thrombogenicity is 
unknown. However, it has been widely accepted that inflammation up-regulates 
procoagulants, and down regulates anticoagulants and fibrinolysis (Figure 1.12) 
(Willerson and Ridker, 2004; Levi and van der Poll, 2010). 
Tumour necrosis factor α (TNFα) levels are higher in T2DM and have been linked 
to insulin resistance and complications of T2DM such as diabetic nephropathy 
and diabetic retinopathy (Mavridis et al., 2008).  Suppression of TNFα either by 
biological antagonists or physical measures such as weight reduction and 
exercise improve glycaemic control in T2DM. It is plausible but yet remains to be 
proven that similar benefits can be achieved in alleviating the  prothrombotic state 
in T2DM by physical or pharmacological modulation of  the TNFα pathway 
(Alexandraki et al., 2006). 
Elevated C reactive protein (CRP) correlates with the increased risk of 
myocardial infarction (Ballantyne et al., 2004). A recent meta-analysis of large 
scale clinical and epidemiological studies confirmed the strong association 
between elevated CRP and cardiovascular events (The Emerging Risk Factors 
Collaboration, 2010). Numerous data exist that high sensitivity CRP (hs-CRP) 
also can predict, independently of conventional risk factors, coronary heart 
disease (CHD) and cardiovascular disease (CVD) mortality in patients with T2DM 
and metabolic syndrome (Ridker et al., 2004). The American Heart Association 
suggested in their guidelines on cardiovascular risk factors that higher levels of 
CRP are a hallmark of T2DM and may warrant preventive therapy for 
cardiovascular events even in patients with pre-diabetes (Sabatine et al., 2007). 
However the Norfolk - EPIC study and a recent meta-analysis have shown that 
the association between T2DM and CRP is weak and is often confounded by 
visceral adiposity (Boekholdt et al., 2006; The Emerging Risk Factors 
Collaboration, 2010). 
In patients with T2DM the levels of IL-6 and IL-8 are significantly higher than 
those without T2DM even after adjustment for confounding factors including 
visceral obesity. Inflammatory mediators, such as interleukin IL-6 increase 
platelet production. As newly released platelets are more thrombogenic 
  
44 
compared to the older ones, IL-6 indirectly increases thrombogenicity (Lim et al., 
2004). Inflammatory mediators induce expression of protease activated receptors 
(PARs) on endothelium of patients with T2DM which in turn increases leukocyte 
adhesion molecules on the cell surface (Dangwal et al., 2011).  
1.2.10 Insulin resistance and thrombogenicity 
Insulin resistance augments the abnormalities of coagulation, including platelet 
aggregation and platelet adhesion in T2DM. Hyperinsulinaemia increases levels 
of thromboxane, von Willebrand factor, factor VIII, tissue plasminogen activator 
and fibrinogen. Levels of plasma insulin, proinsulin, modified lipoproteins and 
cytokines, which are elevated in metabolic syndrome and hyperinsulinaemic 
states, are directly correlated to platelet activating factor inhibitor type 1 (PAI-1) 
(McBane et al., 2010). Insulin has inherent anti-platelet effects in healthy 
volunteers. In vitro and in vivo studies have demonstrated that insulin inhibits 
platelet aggregation in healthy non-obese subjects. However, in obese and T2DM 
subjects with insulin resistance, this anti-aggregating effect of in vitro insulin is 
blunted (Sobel, 1999a; Colwell, 2001; Pandolfi et al., 2001; Randriamboavonjy 
and Fleming, 2009). 
 Platelet dysfunction in T2DM is modulated by insulin resistance at the molecular 
level by: 
i. blunting of the insulin effects on the nitric oxide / cyclic guanosine 
monophosphate (NO/cGMP) system and on platelet aggregation 
(Sobel and Schneider, 2004) 
ii. resistance to the anti-aggregating effects of nitrates and adenosine 
mediated via cGMP and cyclic adenosine monophosphate (cAMP) 
pathway respectively (Trovati et al., 1994; Anfossi et al., 1998) 
iii. increased platelet cytosolic calcium (Watala et al., 2005) 
Restoration of insulin sensitivity by experimental weight loss has restored these 
molecular abnormalities to normal, thereby improving platelet function (Baalbaki 
and Bell, 2007). 
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Figure 1.12 Differences between coagulation in normal versus inflamed 
vasculature.  
Top: The protein C anticoagulant pathway under normal conditions. Vascular 
injury initiates prothrombin (Pro) activation, which results in thrombin (T) 
formation. Prothrombin activation results in formation of factor Va (Va) and factor 
Xa (Xa) complex. Thrombin then binds to thrombomodulin (TM) on the lumen of 
the endothelium, illustrated by the heavy line, and the thrombin-TM complex 
converts protein C (PC) to activated protein C (APC). The APC then binds to 
protein S (S) on cellular surfaces. The APC protein S complex then converts 
factor Va to an inactive complex (Vi), illustrated by the slash through the larger 
part of the two-subunit factor Va molecule. Protein C and APC interact with an 
endothelial cell protein C receptor (EPCR).  
Bottom: The protein C pathway after inflammation. In this model, inflammatory 
mediators lead to the disappearance of thrombomodulin from the endothelial cell 
surface. Endothelial cell leucocyte adhesion molecules, P-selectin or E-selectin, 
are synthesised or expressed on endothelial or platelet surfaces. Tissue factor 
(TF) is expressed on monocytes and binds factor VIIa (VIIa), and this complex 
converts factor X (X) to factor Xa (Xa), which forms complexes with factor Va 
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(Va) to generate thrombin (T) from prothrombin (Pro). Because little APC is 
formed and the little that forms does not function well because of low protein S 
(S), factor Va is not inactivated and prothrombin activation complexes are 
stabilised. From Remick DG, Pathophysiology of sepsis, Am J Pathol. 2007; 
170(5): 1435-44. 
  
 
Figure 1.13 Platelet leukocyte interaction.  
Activated platelets recruit inflammatory cells and amplify vascular inflammation. 
In addition, they induce synthesis of adhesion molecules in endothelium and tilt 
the balance towards thrombogenicity. Inflammatory cytokines are released from 
activated platelets, monocytes and polymorpho nucleated neutrophils (PMN).This 
inflammatory pathways interact with each other and augment the thrombotic 
milieu.  From Esmon, C. T., Br J Heamatology, 2005: 131: 417–430. 
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1.3 Antiplatelet therapy in patients with T2DM and CAD 
Platelets play a central role in thrombosis and antiplatelet agents are the 
cornerstone in prevention of coronary arterial thrombosis in high risk patients. 
Antithrombotic action of antiplatelet agents can be summarised via two major 
mechanisms: 
i. Enzyme inhibition and 
ii. Receptor blockade 
Commonly used antiplatelet agents in patients with CAD and T2DM are aspirin 
and clopidogrel. 
1.3.1 Structure of aspirin 
Aspirin is the most commonly used antiplatelet agent for prevention of 
atherothrombotic events.  Low dose aspirin  (e.g. 75 mg daily) has been used as 
an antiplatelet agent since 1960 (Varon and Spectre, 2009). The routine use of 
aspirin for primary prevention has recently been questioned, but clear cut benefits 
are well established  in secondary prevention trials  (Antithrombotic Trialists 
Collaboration, 2009), (Vane and Botting, 2003; Patrono and Rocca, 2009). 
Aspirin is prepared by chemical synthesis from salicylic acid, by acetylation with 
acetic anhydride and the structure of acetyl salicylic acid, the chemical name for 
aspirin is given below (Figure 1.14) (Vane, 1971). 
1.3.2 Mechanism of action of aspirin 
Aspirin exerts its antithrombotic effect by irreversible inhibition of thromboxane A2 
synthesis in platelets. Upon activation by a variety of stimuli such as vascular 
tissue injury, inflammation and stress, arachidonic acid (a 20 carbon chain fatty 
acid) is liberated from platelet membrane phospholipids by enzymes known as 
phospholipases.  Arachidonic acid is then metabolised by cytosolic prostaglandin 
H synthase (PGH) enzymes, which act by two distinct pathways namely cyclo-
oxygenase (COX) and hydroperoxidase activity. 
 
  
48 
 
Figure 1.14 Structure of aspirin.  
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 The final common products of this reaction are thromboxane A2 (TXA2) by the 
COX pathway and prostaglandin I2 (PGI2) by the hydroperoxidase pathway 
(Patrono et al., 2005). TXA2 induces potent platelet aggregation and 
vasoconstriction, whereas PGI2 inhibits platelet aggregation and induces 
vasodilation. In addition, TXA2 augments the actions of platelet agonists and is 
pro atherogenic and a potent stimulus for vascular smooth muscle cells to 
express adhesion molecules (Vane and Botting, 2003). Aspirin irreversibly 
inhibits  the cyclo-oxygenase enzyme in human platelets (Vane, 1971). Cyclo-
oxygenase enzyme exists in two forms called COX-1 and COX-2. Low dose 
aspirin (30-100mg) selectively and irreversibly inhibits COX-1, and high dose 
aspirin (more than 1000mg) inhibits both COX-1 and COX-2 (Reilly and 
FitzGerald, 1987; Vane, 2000). 
1.3.3 Pharmacokinetics of aspirin 
Aspirin is absorbed mainly from the stomach and duodenum by passive diffusion. 
Plasma levels peak at 30-40 minutes for standard preparations of aspirin 
whereas it may take up to three or four hours for enteric coated preparations. 
Aspirin undergoes hydrolysis in gastrointestinal mucosa and liver, and forms 
salicylic acid (Pedersen and FitzGerald, 1984). Aspirin has a half life of 15–20 
minutes in the circulation but its antiplatelet effects last for the entire lifespan of 
platelets due to the irreversible inhibition of COX-1, allowing the use of a once a 
day regimen for antiplatelet therapy despite the very short half life of the drug 
(Reilly and FitzGerald, 1987; Maree and Fitzgerald, 2004). Platelet function 
recovers after stopping aspirin faster than the predicted 10 days and is due to the 
non-linear relationship between TXA2 biosynthesis and COX-1 inhibition 
(Perneby et al., 2006), (Antithrombotic Trialists Collaboration, 2002). 
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Figure 1.15 Cyclo-oxygenase pathway and aspirin. From Bjorkman DJ, AM J 
Med 1998;105,1,8S-12S. 
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1.3.4 Dosage of aspirin for coronary artery disease 
Aspirin is commonly used at doses 75 mg to 100 mg for primary and secondary 
prevention of cardiovascular diseases as this dosage has maximum antiplatelet 
effect and reduces major cardiac events without excess bleeding risk. Complete 
suppression of COX-1 mediated platelet activity was achieved at doses 50-81 mg 
(Patrono et al., 2005; Lordkipanidzé  et al., 2007; Qayyum et al., 2008). 
Three factors support the use of low dose aspirin in patients with CAD: 
i. saturation of antiplatelet effects of aspirin at low doses 
ii. lack of higher dose related clinical benefits 
iii. dose dependent side effects (Patrono et al., 2008) 
1.3.5 Side effects of aspirin  
The most common side effect of aspirin is gastrointestinal toxicity mediated by 
gastric mucosal erosion. Concomitant use of NSAIDS, Helicobacter pylori 
infection, history of previous gastric ulcer and age more than 70 years increase 
the risk of gastro intestinal side effects of aspirin (Lanas and Scheiman, 2007; 
Yeomans et al., 2009). The estimated excess risk of upper gastrointestinal 
complications attributable to aspirin is around 5 extra cases per 1,000 aspirin 
users per year (Garcia Rodriguez et al., 2001). Meta-analysis by Antithrombotic 
Trialists' Collaboration (ATC) found an odds ratio of 1.6 for major extracranial 
bleeding, i.e. gastric bleeding, in patients taking aspirin (Antithrombotic Trialists 
Collaboration, 2009). 
1.3.6 Aspirin resistance  
There is no consensus on the definition of aspirin resistance. In general terms, 
aspirin resistance is defined as failure to inhibit platelet activation and 
aggregation upon stimuli or ‘platelet hypo responsiveness to aspirin’ (Hankey and 
Eikelboom).  In addition, non-compliance of aspirin is more common (up to 40 %) 
than true aspirin resistance and any laboratory or clinical assessment of aspirin 
resistance should be adjusted for compliance to aspirin therapy (Cotter et al., 
2004; Schwartz et al., 2005). 
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Clinical resistance or ‘real life resistance’ to aspirin is revealed only after the 
individual who is taking aspirin suffers from a major thrombotic event such as 
acute myocardial infarction. Patients with type 2 diabetes mellitus, high platelet 
turnover and chronic kidney disease and those taking non steroidal anti-
inflammatory drugs are at risk of aspirin resistance. Laboratory aspirin resistance 
(also known as biochemical resistance) has recently been studied intensively.  
The reported prevalence of biochemical aspirin resistance ranges widely from 1% 
to 61% (Hankey and Eikelboom, 2006). Three studies followed individuals with 
failure to suppress thromboxane production by aspirin and found they were 2.2 to 
4.3 times at risk of developing cardiovascular events (Dragani et al.; Sciulli et al., 
2006; Santilli et al., 2009). Routine measurement of serum or urinary 
thromboxane  is not practical because of its wide day to day variability secondary 
to the inherent ability of platelets to augment thromboxane production under high 
shear state (Tantry et al., 2009). 
1.3.7 Aspirin and T2DM 
Patients with T2DM have hyperactive platelets and enhanced platelet 
regeneration with biochemical evidence of persistent thromboxane-dependent 
platelet activation (vide supra).  Aspirin at doses of 75mg-100 mg is the 
antiplatelet drug of choice for a secondary prevention strategy in T2DM with a 
history of CVD, whereas direct evidence for the efficacy of low dose aspirin in the 
primary prevention in T2DM is inconclusive (Antithrombotic Trialists 
Collaboration, 2009; De Berardis et al., 2009). It has been argued that patients 
with T2DM may need higher doses of aspirin. In a study by Mortenson et al, 
patients with T2DM and CAD on aspirin 75mg od had higher platelet reactivity as 
measured by two point of care tests (Mortensen, Larsen et al. 2010). Geisler et al 
have shown that T2DM remained a significant risk factor for residual platelet 
reactivity in patients treated with aspirin after adjustment of confounding factors 
and this has been correlated with clinical cardiovascular events (Geisler et al., 
2010). 
In a meta-analysis of more than 45,000 patients with diabetes mellitus, the 
incidence of vascular events was reduced, from 23.5% in the control group to 
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19.3% in the group treated with aspirin, compared to 17.2% to 13.7% in the 
42,000 non diabetic patients. There were 42 vascular events prevented for every 
1000 diabetic patients and 35 events for every 1000 non diabetic patients 
(Antithrombotic Trialists Collaboration, 2002). 
Thromboxane inhibition by low dose aspirin is less in T2DM. Potential 
mechanisms underlying low dose aspirin insensitive thromboxane biosynthesis in 
T2DM include: 
i. reduced cyclo-oxygenase-1 (COX-1) binding capacity of aspirin due to 
glycation of COX-1 (Watala et al., 2005) 
ii. faster recovery of COX-1 activity because of accelerated platelet 
release from bone marrow (DiMinno et al., 1986). 
iii. enhanced platelet COX-2 expression and recovery (Rocca et al., 2012) 
iv. increased production of thromboxane by diabetic platelets (Davi et al., 
1990) 
v. extra platelet sources of thromboxane, uninhibited by aspirin (Santilli et 
al., 2011) 
1.3.8 Pharmacology of clopidogrel 
Clopidogrel is a thienopyridine class antiplatelet agent and acts by inhibition of 
P2Y12 receptors in the membrane of platelets. This is the most widely used and 
well studied medication of this class. Platelet P12Y12 receptor is stimulated by 
adenosine diphosphate (ADP) released by platelet granules. Activation of P2Y12 
receptor augments platelet activity by further secreting more platelet activator 
substances. Clopidogrel is absorbed well in the upper small intestine and enters 
the portal circulation. Clopidogrel is converted to its active metabolite by a group 
of cytochrome P450 enzymes in the liver. The platelets that come in contact with 
the active metabolite of clopidogrel in the portal circulation will be inactivated 
permanently by blocking their P2Y12 receptor. 
Only 15% of the absorbed drug is metabolised by cytochrome P450 (CYP450) 
enzymes in the liver into an active metabolite. About 85% of the drug is 
hydrolyzed by an esterase to create an inactive carboxylic acid derivative. 
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Cytochrome enzymes produce an unstable active metabolite of clopidogrel by a 
two step process (Figure 1.17): 
i. CYP450 oxidizes the thiophene ring of clopidogrel to 2-oxoclopidogrel, 
which will undergo further hydrolysis by CYP450. Oxidation of the 
thiophene ring of clopidogrel by a CYP450 dependent mechanism, 
involving enzymes like CYP3A4, CYP3A5 and CYP2C19, is necessary 
to generate 2-oxo-clopidogrel (Lau et al., 2004) 
ii. The second reaction results in opening of the thiophene ring to form a 
thiol and carboxyl group. This short lived thiol derivative of clopidogrel 
binds with cysteine residues (cys17 and cys270) of the P2Y12 receptor 
of human platelets with high affinity (Ding et al., 2003),(Savi et al., 
2000) and results in permanent irreversible platelet inhibition. 
Clopidogrel by inhibiting platelet activation via P2Y12 receptor blockade prevents 
expression of GP IIb llla receptors and thereby inhibits fibrin mediated platelet 
aggregation. Clopidogrel also inhibits collagen and thrombin induced aggregation 
with human platelets (Patrono et al., 2008). In addition to specific inhibition of the 
effects of ADP, Clopidogrel reduces platelet–leukocyte aggregate formation, and 
the levels of CRP, p-selectin and CD 40L, and the rate of thrombin formation 
(Gurbel et al., 2007). 
Platelet inhibition occurs within 1–2 h after a single loading dose of clopidogrel. 
The maximal level of platelet inhibition (approximately 30%) is achieved within 4–
5 h after a 300 mg dose and is maintained for at least 24 h (Jernberg et al., 
2006). Platelet inhibition decreases to pre-treatment levels one week after the 
drug is discontinued (Wallentin, 2009). Doubling the loading dose to 600mg 
achieves platelet inhibition at 2-3 hours and a further increase in platelet inhibition 
is reported at this dose. Only a limited increase in platelet inhibition occurs at 
doses higher than 600mg (Taubert et al., 2004) (Cuisset et al., 2006; Price et al., 
2006). Antiplatelet response to clopidogrel is highly heterogeneous. Variability in 
clopidogrel response is widely recognised and is associated with higher adverse 
clinical events (vide infra) (Angiolillo et al., 2007a; Vila et al., 2009). 
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Figure 1.16 Structure of clopidogrel  
 
 
Figure 1.17 Metabolism of clopidogrel  
Cytochrome enzymes produce an unstable active metabolite of clopidogrel by a 
two step process: CYP450 oxidizes the thiophene ring of clopidogrel to 2-
oxoclopidogrel, which will undergo further hydrolysis, to generate 2-oxo-
clopidogrel. The second reaction results in opening of the thiophene ring to form 
a thiol and carboxyl group. This short lived thiol derivative of clopidogrel results in 
permanent irreversible platelet inhibition. From Gurbel et al, Thromb Res 2007, 
120: 311 – 321. 
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1.3.9 Clinical studies of clopidogrel in CAD 
The Clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) 
study randomised patients to receive either clopidogrel 75 mg or aspirin 325 mg. 
The study population comprised of patients with a previous history of 
symptomatic atherothrombotic disease or with major risk factors such as diabetes 
mellitus or hypercholesterolaemia. There was a significant reduction in the 
primary endpoint (death, myocardial infarction or stroke) with a relative risk 
reduction of 8.7% (95% confidence interval 0.3% - 16.5%) between clopidogrel 
and aspirin. The overall incidence of haemorrhagic events did not differ between 
treatment groups (CAPRIE steering Committee, 1996) . 
The Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) study 
randomised patients with non-ST-segment elevation acute coronary syndrome to 
receive either clopidogrel (a loading dose, 300 mg orally, followed by 75 mg daily) 
or placebo in addition to standard therapy with aspirin (dose 75-325 mg). After a 
mean follow-up of 9 months, in the group receiving clopidogrel, there was a 
significant reduction in the primary end point including death from cardiovascular 
causes, non-fatal acute myocardial infarction, or stroke (ischaemic and 
haemorrhagic) [all cardiovascular events: OR 0.84, 95% CI 0.77 to 0.93]. There 
was an increase in major bleeding events in the clopidogrel group [OR 1.39, 95% 
CI 1.14 to 1.70]. This study was a landmark study which resulted in widespread 
use of clopidogrel as a dual antiplatelet agent in patients after non ST elevation 
acute coronary syndrome (Yusuf S, 2001). 
The Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, 
Management, and Avoidance trial (CHARISMA, 2006) randomised patients at 
high risk for a cardiovascular event (multiple atherothrombotic risk factors, 
documented coronary disease, or cerebrovascular disease, or symptomatic 
peripheral arterial disease) either to clopidogrel (75 mg daily) plus low dose 
aspirin (75 to 162 mg per day) or to a placebo plus low dose aspirin. There was a 
non significant reduction in the primary end point of myocardial infarction and 
death from cardiovascular causes (OR 0.92, 95% CI 0.81 to 1.04). There was a 
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non significant  increase in major bleeding (OR 0.92, 95% CI 0.81 to 1.04) (Bhatt 
et al., 2006). 
The Clopidogrel as Adjunctive Reperfusion Therapy (CLARITY)–Thrombolysis in 
Myocardial Infarction (TIMI) 28  trial  randomised  patients who underwent 
thrombolysis and aspirin therapy for ST elevation myocardial infarction, to receive 
a 300 mg clopidogrel loading dose, followed by 75 mg daily, or matching placebo 
for 30 days.  The primary composite end point (death, myocardial infarction, and 
infarct related occluded artery flow) was lower in the clopidogrel arm (odds ratio 
0.64, 95%CI 0.53 -0.76). There was no difference in bleeding between the two 
groups. Clopidogrel improved patency of the infarct related artery compared to 
placebo (odds ratio of 1.36, 95%CI 1.18 to 1.57) (Gibson et al., 2008). 
The ClOpidogrel and Metoprolol in Myocardial Infarction Trial (COMMIT) also 
known as the Second Chinese Cardiac Study (CCS -2) is the largest study to test 
the effectiveness of aspirin and clopidogrel. Patients with suspected acute 
myocardial infarction were randomised to receive aspirin and clopidogrel 75 mg 
each daily or aspirin and placebo for four weeks or until hospital discharge. The 
clopidogrel group had a 9% (95%CI 3-14%) relative risk reduction in the 
composite end point of death, reinfarction, and stroke (p=0.002; odds ratio 0.91, 
0.86 to 0.97). There were no excess major bleeding events or cerebral 
haemorrhage in the clopidogrel group (COMMIT (ClOpidogrel and Metoprolol in 
Myocardial Infarction Trial) collaborative group, 2005). 
The Clopidogrel and Aspirin Optimal Dose Usage to Reduce Recurrent 
Events−Seventh Organization to Assess Strategies in Ischemic Syndromes 
(CURRENT–OASIS 7) trial was a complex design and showed that there was no 
difference in the primary outcome (cardiovascular death, myocardial infarction 
and stroke) in patients assigned to double dose clopidogrel (150mg) as 
compared to standard dose clopidogrel (75mg) (hazard ratio, 0.94; 95% CI 0.83 
to 1.06). Major bleeding occurred at similar rates in both the groups and 150mg 
of clopidogrel was associated with a significant reduction in stent thrombosis 
(CURRENT-OASIS7 Investigators, 2010).  
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Trial Population Study treatments Sample 
size 
Mean 
study 
duration 
Primary 
composite 
outcome 
Primary outcome: 
clopidogrel vs. 
comparator 
Primary outcome: 
clopidogrel vs. 
comparator ( 
diabetes subset) 
CURE USA or 
NSTEMI 
ASA + clopidogrel vs. ASA + 
placebo 
12,562 9 months CV 
death/MI/stroke 
HR 0.80; 95% CI 
0.72–0.90 
HR 0.85; 95% CI 
not reported 
CAPRIE Recent 
stroke, MI, 
or PAD 
ASA vs. clopidogrel 19,185 1.9 years Vascular death/ 
MI/stroke 
HR 0.91; 95% CI 
0.84–0.98 
HR 0.87; 95% CI 
0.76–0.99 
CHARISMA CVD or 
multiple 
CVD risk 
factors 
Clopidogrel + low dose ASA vs. 
placebo + low dose ASA 
15,603 28 months CV 
death/MI/stroke 
HR 0.93; 95% CI 
0.83–1.05 
HR 1.2; 95% CI 
0.91–1.59 
PCI-CURE NSTEMI ASA + pre treatment with 
clopidogrel followed by long term 
therapy vs. ASA + no pre treatment 
and short-term therapy with 
clopidogrel  
2658 9 months CV 
death/MI/urgent 
revascularisation 
HR 0.70; 95% CI 
0.50–0.97 
HR 0.77; 95% CI 
0.48–1.22 
CREDO Elective 
PCI 
Clopidogrel loading dose pre-PCI + 
long term therapy post PCI vs. 
placebo  
2116 12 months CV 
death/MI/stroke 
HR 0.73; 95% CI 
0.56–0.96 
HR 0.89; 95% CI 
0.54–1.47 
CURRENT-
OASIS 7 
ACS 
undergoing 
PCI 
Increased dose clopidogrel vs. 
standard clopidogrel plus high dose 
ASA vs. Low dose ASA 
25,086 30 days CV 
death/MI/stroke 
HR 0.94; 95% CI 
0.83–1.06 
HR 0.86; 95% CI 
not reported 
COMMIT Suspected 
ACS 
Aspirin and clopidogrel Vs aspirin 
alone 
45,852 4 weeks CV 
death/MI/stroke 
HR 0.91; 95%CI 
0.86-0.97 
Not reported 
Table 1.2 Clinical trials on aspirin and clopidogrel use in patients with coronary artery disease.  
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1.3.10 Dosage of clopidogrel 
Clopidogrel achieves better platelet inhibition after a loading dose of 300mg or 
higher followed by a daily dose of 75mg or above compared to aspirin (Steinhubl 
et al., 2002). Dosage regimes of clopidogrel differ based on the timing of 
percutaneous intervention and clinical indications. 
1.3.10.1 Loading dose of clopidogrel 
Current guidelines recommend loading dose of clopidogrel as follows: 
i. In patients who are undergoing elective PCI, a dose of 300mg is 
advised, to be administered at least 24 hours before PCI 
ii. In patients who have acute coronary syndrome, a loading dose of 
600mg is advised 
iii. In patients who are undergoing non elective PCI and have never had 
clopidogrel (clopidogrel naïve), a loading dose of 600 mg is advised. If 
the patients are already preloaded with 300mg of clopidogrel, a further 
dose of 300mg is recommended 
iv. In patients who are undergoing elective PCI, a loading dose of 600mg 
can be considered when glycoprotein IIb IIIa inhibitor usage is either 
contraindicated or to be avoided 
v. Doses higher than 600 mg are not currently recommended (Bassand et 
al., 2007; Hamm, 2011; Hamm et al., 2011; Patrono et al., 2011; 
Wenger, 2012) 
1.3.10.2 Maintenance dose of clopidogrel: 
Clopidogrel 75 mg once daily achieves optimal platelet inhibition in 5 days when 
administered without a loading dose  (Wenger, 2012), (Hamm, 2011). Therefore, 
daily dose of clopidogrel 75 mg od is advised for maintenance therapy. 
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1.3.11 Side effects of clopidogrel 
Clopidogrel was well tolerated in clinical trials and serious side effects at loading 
doses of 300mg or maintenance doses of 75 mg are rare in clinical practice. The 
most serious adverse drug reactions occurred in less than 1% and were 
gastrointestinal haemorrhage, haemorrhagic ulcer and haemothorax. Common, 
non serious side effects of clopidogrel include diarrhoea, dyspepsia, abdominal 
pain and epistaxis. 
The incidence of major or minor bleeding with clopidogrel was 2.5% and was 
similar to aspirin in the CAPRIE study (CAPRIE steering Committee, 1996). 
However, there were more bleeding events in the clopidogrel combined with 
aspirin group compared to aspirin alone (1.6% vs. 1.0%) in CURE study (Yusuf 
S, 2001).  Contemporary evidence from a large scale registry warns that bleeding 
complications in patients on dual antiplatelet therapy after acute MI are 3.7%, 
twice the risk of bleeding compared to aspirin alone (Sorensen et al., 2009). 
Thrombotic thrombocytopenic purpura (TTP), a severe multisystem thrombotic 
microangiopathy, occurs secondary to clopidogrel therapy in 1 in 100,000 
patients. 
Dyspeptic symptoms were more frequent in clopidogrel therapy in CAPRIE study 
(27.1%) but resulted in discontinuation of the drug in very few cases (3.2%) 
(CAPRIE steering Committee, 1996). Gastrointestinal haemorrhage requiring 
hospitalisation was less frequent with clopidogrel compared to aspirin in 
CHARISMA trial (2.0% vs. 2.7%) (Berger et al., 2010). 
1.3.12 Variability of clopidogrel response 
Clopidogrel has a significant variability in its antiplatelet effects across a wider 
range of subjects. The variability is attributable to patient related clinical factors, 
pharmacokinetic mechanisms and genetic variability. Table 1.3 lists major 
mechanisms behind the heterogeneous response of clopidogrel. (O’Donoghue 
and Wiviott, 2006; Holmes et al., 2010). 
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Clinical factors 
 Failure to prescribe/poor compliance 
 Under dosing 
 Poor absorption 
 Drug–drug interactions involving intestinal P-glycoprotein  
 Drug–drug interactions involving CYP3A4 
 Acute coronary syndrome 
 Diabetes mellitus/insulin resistance 
 Elevated body mass index 
Pharmacokinetic factors 
 Accelerated platelet turnover 
 Reduced CYP3A metabolic activity 
 Increased ADP exposure 
 Up-regulation of the P2Y12 , P2Y1 and P2Y–independent pathways 
Genetic factors 
 Polymorphisms of Cytochrome P450 enzymes 
 Polymorphisms of GPIa, P2Y12, GPIIb/IIIa receptors 
(Adopted from Angiollilo DJ, et al; J Am Coll Cardiol 2007; 49, 1505-16) 
Table 1.3 Mechanisms of clopidogrel response variability.  
 
  
62 
1.3.13 Pharmacogenomics of clopidogrel 
The response to clopidogrel is  influenced by pharmacokinetic variables such as 
intestinal absorption and metabolic activation in the liver, both of which are 
affected by genetic polymorphisms (Giusti and Abbate, 2010). Three types of 
genetic polymorphisms are of clinical interest in patients taking clopidogrel, 
namely, CYP2 series, CYP3 series and ABC series polymorphisms (Figure 1.18a 
and 1.18b). Genetic variation of these cytochrome 450 enzymes have been 
associated with variability in clopidogrel response and this has resulted in a 
special warning issued by the FDA regarding low or poor response to clopidogrel 
(Holmes et al., 2010). CYP2C19 polymorphism involving CYP450 enzyme was 
present in 28.6% individuals who had a significantly increased risk of 
cardiovascular death (hazard ratio 1.84) and stent thrombosis (hazard ratio 2.81) 
(Mega et al., 2010). 
1.3.14 Clopidogrel and T2DM 
Evidence supports the superiority of clopidogrel compared to aspirin in patients 
with diabetes mellitus. The Clopidogrel versus Aspirin in Patients at Risk of 
Ischemic Events (CAPRIE) trial included 4,000 patients with T2DM. The primary 
endpoint (combined incidence of vascular death, MI, or ischemic stroke) occurred 
less in the clopidogrel group compared to the aspirin group (15.6% vs. 17.7%) 
(Bhatt et al., 2002). This has been confirmed by a sub group analysis of 
CHARISMA trial (Bhatt et al., 2007). In the Clopidogrel in Unstable Angina to 
Prevent Recurrent Events (CURE) study, a sub group analysis of patients with 
T2DM showed that addition of clopidogrel to aspirin therapy resulted in fewer 
cardiovascular events (14.2% vs. 16.7%). In a smaller randomised control study, 
(The PLavix Use for Treatment Of Diabetes (PLUTO-Diabetes) Trial), 
combination therapy with aspirin and clopidogrel has resulted in greater 
suppression of biomarkers of platelet activation compared to aspirin alone 
(Serebruany et al., 2008). 
Nevertheless, clinical benefits of clopidogrel are lower in T2DM compared to 
those without diabetes (Angiolillo, 2009).  The variability of clopidogrel response 
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is more pronounced in T2DM (Angiolillo et al., 2007a). Lower response to 
standard dose of clopidogrel therapy (75 mg once daily), also known as 
‘clopidogrel resistance’, a term widely used but not yet clearly defined, is more 
common in patients with T2DM compared to those without (Angiolillo et al., 
2007b). In a recent study by El Ghannundi et al, impaired response to clopidogrel 
in T2DM was an independent marker of cardiac mortality after adjusting for 
confounding factors (El Ghannudi et al., 2011). 
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Figure 1.18a Pharmacogenomics of clopidogrel intestinal absorption.  
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Figure 1.18b Pharmacogenomics of clopidogrel.  
Pharmacogenomics of clopidogrel intestinal absorption of the prodrug clopidogrel 
is limited by an intestinal efflux pump P-glycoprotein coded by the ABCB1 gene. 
The majority of the prodrug is metabolised into inactive metabolites by ubiquitous 
esterases. The minority is bioactivated by various cytochrome P450 (CYP) 
isoforms into active metabolites. These metabolites irreversibly antagonise the 
adenosine diphosphate (ADP) receptor (coded by the P2RY12 gene), which in 
turn inactivates the fibrinogen receptor (the glycoprotein GPIIb IIIa receptor 
coded by the ITGB3 gene) involved in platelet aggregation. From Simon et al, N 
Engl J Med 2009; 360:363-37 
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Chapter 2 Hypothesis and aims 
2.1 Study 1: ACS study 
2.1.1 Hypothesis 
Blood thrombogenicity is higher in patients with type 2 diabetes mellitus 
(T2DM) after non ST-elevation acute coronary syndrome (NSTE-ACS) 
despite currently recommended therapy with dual antiplatelet agents, 
aspirin and clopidogrel. 
2.1.2 Aims 
i. To quantify platelet dependent thrombus in patients 7-10 days after 
NSTE-ACS (two groups: T2DM and non DM) 
ii. To study the association between platelet dependent thrombus and  
a. on treatment platelet reactivity upon stimulation with platelet 
agonists 
b. inflammation 
c. metabolic factors 
d. platelet activation markers 
iii. To evaluate viscoelastic properties  of thrombus after NSTE-ACS 
iv. Clinical relevance of platelet dependent thrombus in T2DM after NSTE-
ACS 
a. to evaluate the association between coronary atheroma burden 
and platelet dependent thrombus 
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2.2 Study2: Stable CAD study 
2.2.1 Hypothesis 
Dual antiplatelet therapy with aspirin and clopidogrel reduces blood 
thrombogenicity compared to aspirin monotherapy in patients with type 2 
diabetes mellitus (T2DM) and stable coronary artery disease (CAD).  
2.2.2 Aims 
i. To quantify platelet dependent thrombus in patients with T2DM and 
stable CAD after treatment with aspirin and clopidogrel 
ii. To study the association of platelet dependent thrombus in patients 
with T2DM and stable CAD to 
a. on treatment platelet reactivity upon stimulation with platelet 
agonists 
b. inflammation 
c. metabolic factors 
d. platelet activation markers 
iii. To evaluate viscoelastic properties of thrombus in patients with T2DM 
and stable CAD 
iv. To assess the  ultrastructural changes to thrombus  after initiation of 
dual antiplatelet therapy   
v. To evaluate the relationship between platelet reactivity measured by  
“point of care” platelet function assays and platelet dependent  
thrombus 
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Chapter 3 Methods 
3.1 General methods 
3.1.1 Patient selection 
I conducted two hypothesis led clinical studies, namely study 1 ACS study 
(observational cohort study) and study 2 stable CAD study (randomised, double 
blind, placebo controlled study). 
3.1.1.1 Study 1 ACS study 
Patients who had non ST elevation acute coronary syndrome (NSTE-ACS) with 
elevated serum cardiac troponin levels were studied one week following their 
index coronary event. Patients with type 2 diabetes mellitus (T2DM) and those 
without T2DM, who were treated with secondary prevention therapy according to 
current international society guidelines (including aspirin 75mg once daily and 
clopidogrel 75mg once daily), underwent blood thrombogenicity studies including 
the ex-vivo Badimon chamber. The period of study was between June 2008 and 
May 2011. 
i. Patient selection 
Eligibility Criteria 
a. Inclusion Criteria 
1. T2DM and NSTE-ACS as defined below: 
T2DM: Diagnosed according to the WHO criteria 
(whqlibdoc.who.int/publications/2006/9241594934_eng.pdf, 
accessed on 01st August 2013), and on treatment 
NSTE-ACS: Patients admitted to hospital with cardiac chest pain 
and who had electrocardiographic evidence of ST segment 
depression and / or T wave inversion accompanied by elevated 
serum cardiac troponin levels, measured 12 hours after the onset 
of symptoms 
2. Aged between 18 and 75 years 
3. Provided written informed consent for participation in the trial prior 
to any study-specific procedures or requirements 
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4. Patients who had aspirin 300 mg  and clopidogrel 300 mg loading 
doses 
5. Patients who had maintenance doses of aspirin 75 mg and 
clopidogrel 75 mg 
6. Patients with angiographic evidence of coronary artery disease, 
with at least one major vessel having more than 50% stenosis 
7. Patients who were treated with a beta blocker (or a rate limiting 
calcium channel blocker if beta blockade was contraindicated), 
angiotensin converting enzyme inhibitor (or an angiotensin 
receptor blocker) and a hydroxy methyl co-enzyme A reductase 
inhibitor (statin) 
b. Exclusion Criteria 
1. Patients with ST elevation acute coronary syndrome 
2. Patients who were on anti thrombotic agents other than aspirin 
and clopidogrel e.g. warfarin, prasugrel 
3. Current smokers (as smoking could increase clopidogrel 
responsiveness) 
4. Malignancy (currently diagnosed or under evaluation, as it could 
increase the prothrombotic state and bleeding risk) 
5. Haematological disorders (anaemia, malignancy, bleeding 
disorders) 
6. Use of corticosteroids or non steroidal anti-inflammatory drugs as 
they could increase bleeding risks 
7. Chronic liver disease (cirrhosis, malignancy and patients with 
abnormal liver function tests, as clopidogrel bioavailability will be 
unpredictable) 
8. End stage renal disease on dialysis as clopidogrel can be 
removed from the blood by haemodialysis 
9. Patients who were waiting for urgent coronary artery bypass 
surgery, as they were considered clinically unstable 
10. Patients with unstable atrial and ventricular rhythms 
11. Ongoing septic illness 
  
70 
12. Patients who were taking aspirin at doses other than 75 mg once 
daily 
13. Use of glycoprotein IIb/IIIa inhibitors within the previous 5 days 
14. Heparin within the previous 48 hours 
15. Patients with NYHA class III or IV symptoms 
16. Patients who are unable to consent 
17. Patients who had unstable blood glucose levels and were at high 
risk of fasting hypoglycaemia 
18. Intercurrent gastrointestinal illness as drug absorption may be 
unpredictable 
19. Serum cardiac troponin rise secondary to causes other than 
NSTE-ACS, such as cardiac failure, pulmonary embolism and 
sepsis 
20. Use of other investigational study drugs within 1 year prior to 
study entry 
21. Patients who are already taking part in another investigational 
clinical trial 
22. Poor venous access 
 
 
ii. Screening and recruitment 
All participants were recruited from the cardiology departments of the 
Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle 
upon Tyne. Potential participants were identified by review of inpatient 
hospital records and eligibility was confirmed after obtaining permission 
from the responsible clinicians.  Details of the study were discussed 
with eligible in-patients and a patient information sheet was provided.  
After a 24 hour “cooling off” period, written informed consent was 
obtained. I arranged them a single visit to the Clinical Research 
Facility, Royal Victoria Infirmary, Newcastle upon Tyne for the study 
specific procedures including Badimon chamber experiment 7 to 10 
days after their index cardiac event. The study was approved by 
Regional Ethics Committee, Sunderland. No financial reimbursements 
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were offered to the participants. The study was conducted according to 
general principles of clinical research as per Helsinki declaration, and 
the patient’s right to refuse to participate in the study without giving 
reasons was respected. 
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Assessed for eligibility (n=271)
Total participants (n=90)
Completed study (n=90)
Analysis (n=80)
T2DM (n=40) Non T2DM, Controls (n=40) 
Enrollment
Excluded (n=181)
 Not meeting inclusion criteria 
(n=121)
 Declined to participate (n=41)
 Recurrent ischaemia (n=15)
 Others (n=4)
Poor thrombus formation (n=8)
Non-compliance to medications (n=2)
 
Figure 3.1 Flow chart for Study 1 – ACS study.  
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3.1.1.2 Study 2: stable CAD study 
Patients who had type 2 diabetes mellitus (T2DM) and stable, established 
coronary artery disease (CAD) were recruited. This was a randomised, double-
blind, 1:1 placebo-controlled, parallel design study, comparing efficacy of 
clopidogrel versus placebo in reduction of thrombogenicity in patients with type 2 
diabetes mellitus and coronary artery disease, who were already taking aspirin 
75mg daily. The objective of this study was to compare the effect of clopidogrel 
and placebo on platelet dependent thrombosis in patients with T2DM and CAD. 
Briefly, eligible patients with T2DM and stable CAD were studied on day 1 to 
assess baseline thrombogenicity.  They were randomised to either clopidogrel 
75mg once daily or matching placebo for 7 days and studied again on eighth day. 
All patients were on their routine medications as per standard practice. 
i. Patient selection 
Eligibility Criteria 
a. Inclusion Criteria 
1. Patients with T2DM and CAD as defined below 
T2DM: Diagnosed according to the WHO criteria, and on 
treatment, as in Study 1 
CAD: Presence of any one of the following: history of angina and 
positive exercise tolerance test, history of (enzyme and/or Q 
wave) positive myocardial infarction, angiographic evidence 
(>50% stenosis of one vessel) or prior history of percutaneous or 
surgical coronary revascularisation 
2. Patients aged between 18 and 75 years 
3. Patients who were taking aspirin 75 mg once daily 
4. Patients who could provide written informed consent for 
participation in the trial prior to any study-specific procedures or 
requirements 
b. Exclusion Criteria 
1. Contraindications to clopidogrel, as per Summary of Product 
Characteristics (www.medicines.org.uk/emc/medicine/9483/SPC, 
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accessed May 5th 2013) such as history of hypersensitivity and 
major bleeding 
2. Current smokers 
3. Malignancy (currently diagnosed or under evaluation) 
4. Haematological disorders (anaemia, malignancy, bleeding 
disorders) 
5. Women of child-bearing potential as clopidogrel is contraindicated 
in pregnancy 
6. Use of corticosteroids or non steroidal anti-inflammatory drugs as 
it could increase bleeding risks 
7. Chronic liver disease (cirrhosis, malignancy and patients with 
abnormal liver function tests, as clopidogrel bio-availability will be 
unpredictable) 
8. End stage renal disease on dialysis as clopidogrel can be 
removed from the blood by haemodialysis 
9. Patients who were already on clopidogrel for standard clinical 
indications e.g. stroke and coronary stent insertion 
10. Patients who were taking aspirin at doses other than 75 mg once 
daily 
11. Patients who were taking other antithrombotic agents like 
dipyridamole, warfarin and low molecular weight heparin 
12. Unable to consent 
13. Use of other investigational study drugs within 1 year prior to 
study entry 
 
ii. Screening and recruitment 
All participants were recruited from the Newcastle Diabetes Centre, 
Diabetes clinics in general practice of Tyneside PCTs and cardiology 
outpatient clinics and day case unit of the Newcastle upon Tyne 
Hospitals NHS Foundation Trust, Newcastle upon Tyne. Potential 
participants were identified by me and eligibility was verified from 
information documented in the case records. The patient information 
sheet and consent form were posted to eligible patients with a letter of 
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invitation at least 1 week prior to their planned outpatient appointment 
or cardiac day case procedure. Eligible patients then were approached 
in person at a suitable time point during this visit and I provided 
detailed verbal information regarding the study and answered any 
questions. Patients who provided written consent were given a further 
minimum of 24 hours to reflect on their agreement to participate in the 
study. The study was approved by Regional Ethics Committee, 
Sunderland. Participants voluntarily agreed to take part in the studies 
and no financial reimbursements were offered to them.  
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Assessed for eligibility (n=149)
Enrollment
Randomised (n=90)
Allocation
Follow-Up
Analysis
Excluded (n=59)
 Not meeting inclusion criteria 
(n=49)
 Declined to participate (n=5)
 Other reasons (n=5)
Allocated Clopidogrel (n=45)
 Received allocated intervention (n=45)
 Did not receive allocated intervention (n=0)
Allocated to placebo (n=45)
 Received allocated intervention (n=45)
 Did not receive allocated intervention (n=0)
Lost to follow up (n=0)
Discontinued intervention (n=1)
Lost to follow up (n=0)
Discontinued intervention (n=0)
Analysed (n=42)
 Excluded from analysis due to poor 
thrombus formation (n=2)
Analysed (n=43)
 Excluded from analysis due to poor 
thrombus formation (n=2)
 
Figure 3.2 Flow chart for Study 2 – CAD study.  
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3.1.2 Study specific procedures undertaken by participants 
3.1.2.1 Study 1: ACS study 
Participants of ACS study attended their early morning appointment, (usually 
between 8 am to 9 am) at Clinical Research Facility, Royal Victoria Infirmary, 
Newcastle upon Tyne Hospitals NHS foundation trust for the study after 12 hour 
fasting. I checked their compliance with medications by pill counting and 
confirmed their eligibility prior to the study. Participant’s demographic data were 
entered in a clinical research report form. A well validated Rose angina 
questionnaire (Heyden et al., 1971; Haywood et al., 1998; Graff-Iversen et al., 
2008) was completed by the patient. I recorded height, weight, heart rate, blood 
pressure, waist and hip circumference prior to the Badimon chamber study (vide 
infra). 
An 18G cannula was inserted in the forearm. The first 2 ml blood was discarded 
to avoid platelets activated by venepuncture. Ten ml blood was then collected for 
serum separation and then the Badimon chamber experiment was conducted. 
Effluent blood sample (5 ml) was collected for serum separation. Venous blood (5 
ml) was collected from the antecubital vein at the end of the chamber study using 
the same cannula for platelet function assays and biomarker studies. The 
cannula was then removed. Participants were discharged from the Clinical 
Research Facility after consuming breakfast. 
3.1.2.2 Study 2 CAD study 
Participants attended two morning appointments (usually between 8 am and 10 
am), one week apart at Clinical Research Facility, having fasted overnight  and 
delayed taking their usual medications till the chamber studies were completed. 
At visit 1 (baseline visit), I reconfirmed their eligibility and understanding of the 
study specific procedure. The random number (randomisation procedure 
explained vide infra) assigned to the patient (sequential numbering beginning 
from 501) was checked independently by two members of the staff at Clinical 
Research Facility. Participants’ demographic data including height, weight, waist 
and hip circumference, heart rate and blood pressure were recorded. Participants 
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completed the Rose angina questionnaire on visit 1 and their up-to-date routine 
prescription was checked. 
Badimon chamber experiment was performed as described above during visit 1 
and haematology, clinical biochemistry, serum and plasma samples were 
collected as described for ACS study. The bottle containing the investigational 
medicinal product (IMP), i.e. either clopidogrel 75 mg or placebo was rechecked 
to match the randomisation number assigned to the participant. Instructions were 
given to the patient to take one capsule a day starting on the day of visit 1. We 
provided spare capsules for compliance check with pill counting and to be used in 
the event of spillage or damage to the IMP. A wallet sized card with information 
regarding the IMP, emergency contact details of myself and principal investigator, 
randomisation number and sponsors of the study was provided. Participants were 
given breakfast and then were observed to swallow their IMP with at least 100ml 
water. Participants were then discharged from Clinical Research Facility. The 
above investigations were repeated on study day 8, after 7 daily doses of IMP. 
Adverse events were documented and compliance was checked by pill counting. 
3.1.3 Demographic data 
Demographic data was collected during patients visit to Clinical Research Facility 
for ACS study and during their first visit for stable CAD study. Data were collected 
in a clinical research proforma and stored electronically in a password operated 
computer in the premises. Participant’s age was calculated as total number of 
completed years on the day of chamber study. Weight and height were measured 
with light clothing and without shoes, using calibrated and certified scales.  BMI 
was calculated as body weight (kg) divided by height squared (m2). Waist 
circumference (cm) was measured at the midpoint between the lower rib margin 
and the iliac crest. Hip circumference (cm) was measured at the level of the 
widest circumference over the greater trochanters. Waist hip ratio (WHR) was 
computed as waist circumference divided by hip circumference. I measured heart 
rate and blood pressure in the reclining position after 5 minutes of rest. The left 
arm was used for blood pressure measurements. 
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Patient was identified by case records review.
Patient was met in the wards while being an 
inpatient.
If eligible and willing, consent form was 
obtained.
Study day visit: Consent form was checked; 
Chamber study and bloods were done.
 
Figure 3.3 Participant Pathway for study 1 – ACS study.  
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Patient was identified by case records review.
Letter was sent if suitable for screening visit.
Patient was met at clinic/daycase unit/ward 
to discuss the study. 
If eligible and willing, consent form was 
obtained. 
Reply slip proforma was given.
After sequential randomization, visit dates 
were arranged.
Visit 1: Consent form was checked again, 
Chamber study and blood IMP was dispensed. 
Wallet information card was given.
Visit 2: IMP container was collected after pill 
check, AE check, Chamber study was done.
Patients were monitored 1 week for adverse 
events (AE).
 
Figure 3.4 Participant Pathway for study 2 – CAD study.  
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3.1.4 General biochemistry and haematology 
3.1.4.1 General Biochemistry 
Patient’s blood samples were analysed at nationally accredited clinical 
biochemistry laboratory at Royal Victoria Infirmary, Newcastle upon Tyne 
Hospitals NHS Foundation Trust, Newcastle upon Tyne (www.cpa-uk.co.uk, CPA 
0925).  Samples were identified by study numbers only, so that all staff were 
blinded to the patient’s details. For the stable CAD study (double blinded RCT), 
statistical analysis was performed only after unblinding. 
The following tests were performed by standard routine laboratory methods: 
i. Serum creatinine µmol/L 
ii. Blood urea mmol/L 
iii. Serum high sensitivity C reactive protein, mg/dl 
iv. Lipid profile (fasting) including total cholesterol, LDL cholesterol, 
triglycerides and HDL cholesterol, mmol/L 
v. Fasting plasma glucose, mmol/L 
vi. HbA1c (DCCT aligned),% 
vii. Troponin I (for ACS study only), mg/dl 
3.1.4.2 General Haematology 
Patients’ blood samples were analysed at the nationally accredited general 
haematology and coagulation laboratories at Royal Victoria Infirmary, Newcastle 
upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne (www.cpa-
uk.co.uk, CPA 0926). Blood samples were collected at patients’ only visit for the 
ACS study and on both visits for the stable CAD study. Samples were collected 
and processed according to local laboratory protocols. I preferred citrate tubes 
over heparinised tubes, as citrate preserves labile coagulation factors V and VII, 
thus ensuring better reproducibility of coagulation parameters including 
fibrinogen. Plasma fibrinogen was measured using von Clauss quantitative 
method, by measuring the time taken for clot formation after mixing with excess 
thrombin to plasma (Clauss, 1957). Clauss fibrinogen assay is “the most reliable 
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method for use in clinical laboratories” and has been standardised according to 
the guidelines of British Society of Haematology (Mackie et al., 2003). Quality 
control and quality assurance were performed according to the local laboratory 
protocols. 
Following haematology tests were performed by standard methods: 
i. Red blood cell count, 1012/L 
ii. Haematocrit, % 
iii. Haemoglobin, g/L 
iv. Platelet count, 109/L 
v. Plasma fibrinogen (Clauss) g/L 
vi. Prothrombin time, sec 
vii. Activated partial thromboplastin time, sec 
3.1.5 Preparation of investigational medicinal product 
For the double blinded RCT study (Stable CAD study) we used clopidogrel 
(Plavix®, Sanofi-Aventis) and placebo. Clopidogrel was defined as the “active” 
investigational medicinal product (IMP) and placebo was defined as “comparator” 
IMP. Both the IMP’s were prepared as “look alike” to ensure blinding in 
accordance with the specifications approved by Medicine Health Regulatory 
Authority (MHRA), UK. 
Tablets of clopidogrel bisulphate 75 mg (Plavix®, Sanofi-Aventis) were over-
capsulated with a brownish orange coloured capsule at the pharmacy production 
unit at Royal Victoria Infirmary, Newcastle upon Tyne (MHRA Unit IMP license 
number 17736). Methyl cellulose was used as a filler to avoid movement of the 
clopidogrel tablet inside the capsule. Another set of capsules are filled with 
methylcellulose alone and labelled as placebo IMP. Both clopidogrel and placebo 
capsules looked alike and had similar weight. 
In order to ensure uniform disintegration and gastrointestinal absorption, I 
conducted drug disintegration experiments in the Pharmacy production unit for 
both the capsules using special product testing equipment. The solution used 
was acidified to mimic the gastric milieu and a mechanical stirrer was used to 
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mimic gastric peristaltic movements. I conducted experiments for four time 
periods, namely 5 min, 10 min, 15 min and 30 min to document capsule 
disintegration and dissolution of methylcellulose. At 15 minutes, there was 
complete dissolution of the capsule. At 30 minutes, both the capsule and 
clopidogrel tablet dissolved completely. These experiments were repeated 3 
times, with the same results. The experiments were supervised and certified by 
the Pharmacy Production unit, Royal Victoria Infirmary, Newcastle upon Tyne. 
The Production unit then prepared and labelled both the IMP’s (clopidogrel and 
placebo). I was blinded to randomisation code and the pharmacy department 
placed 8 of the individual IMP’s in the medication container labelled with study ID. 
I chose to use 8 capsules for the following reasons: i) pill counting to monitor 
compliance ii) spare IMP to be used if patients lost any capsules and iii) the 
volume of the container would allow maximum of 8  capsules only. 
3.1.6 Randomisation and blinding 
The randomisation schedule was generated by an independent team at 
Newcastle Clinical Trials Unit (NCTU, Newcastle upon Tyne) using the web-
based service at http://www.randomization.com. The master copy of the codes 
was held at NCTU in a sealed envelope to facilitate unblinding at the end of the 
study. Two sets of sequentially numbered 100 code break envelopes were also 
prepared, to be held by the Pharmacy Clinical Trials and Medicines Information, 
Royal Victoria Infirmary and the Newcastle Clinical Trials Unit. This was done to 
facilitate urgent unblinding in case of a clinical emergency (in which case, 
pharmacy unit assumed responsibility for unblinding) or for unblinded reporting of 
suspected serious adverse reaction (SUSARs), in which case NCTU assumed 
responsibility for unblinding. Fortunately there were no SUSAR’s and there was 
no need for emergency unblinding during the study. 
A randomly permuted block system with variable block size was used to allocate 
patients to clopidogrel or placebo (2x2 block size but I was blinded to the block 
size). Randomisation on a 1:1 ratio was generated for 50 participants in each arm 
of the study to allow a 10% drop out rate. The randomisation schedule comprised 
a list of sequential study numbers (Patient Study Number: 501 to 600), and the 
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random treatment allocation to Clopidogrel or placebo. The open randomisation 
schedule was provided to the production unit at Newcastle upon Tyne Hospitals 
NHS Foundation Trust, who assembled and labelled study drug according to the 
“Patient Study Number” and “treatment allocation”.  
3.1.7 Pharmacovigilance and data monitoring 
An adverse event (AE) was defined as any untoward medical occurrence which 
does not necessarily have a causal relationship with the treatment. “Treatment” 
included all investigational agents administered during the course of the study. 
Medical conditions/diseases present before starting study treatment were only 
considered adverse events if they worsened after starting study treatment. During 
the study two AE’s occurred: 
i. deterioration of glycaemic control 
ii. self terminating minor gingival bleeding 
Both were reported to the authorities and the study safety committee has decided 
that no further action was necessary. 
As per the delegation log set for this study, I was responsible for monitoring and 
reporting adverse events. Any serious adverse event was deemed to be recorded 
throughout the duration of the trial until 5 days after cessation of study drug. Non-
serious adverse reactions were monitored and recorded throughout duration of 
trial until 5 days after cessation of study drug either clopidogrel or placebo.  
Participants were provided with a wallet sized contact card to enable them to 
contact an appropriate member of the research team if they experienced any 
further events after the final visit. I was delegated with the task of informing the 
MHRA and main REC of all SUSARs occurring during the study. A study data 
monitoring committee and adverse event monitoring committee oversaw the 
safety of the study. 
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3.1.8 Statistical methods 
Statistical analyses were performed using SPSS version 17.0 (SPSS Inc, NY, 
USA) and Stata version 12 (StataCorp LP, TX, USA) with the help of a senior 
statistician. Study 1 ACS study was an observational study and the dependent 
variable in all analyses presented was high shear and low shear thrombus.  The 
key independent variable was type 2 diabetes mellitus. In addition to a crude 
hypothesis test, I performed analyses adjusting for the effects of age, sex, body 
mass index, waist-hip ratio, basic laboratory tests (including lipids and measures 
of glycaemic control), and indicators for three modalities of treatment for diabetes 
(diet, oral agents, insulin). Also due to the highly skewed distribution of the 
outcome variable, analysis was repeated with log-transformation. An analysis 
including fibrinogen was carried out, not to “control” for its effects, but to 
determine to what extent the effect of diabetes on thrombus levels is mediated 
through increased fibrinogen levels. 
Study 2 was a randomized study, and the two study groups were compared on all 
study variables.  For continuous variables, means and standard deviations were 
calculated, and student t test was used to measure statistical significance and 
Cohen’s d was calculated to evaluate the size of group differences.  For 
dichotomous variables, the percentage in each group was measured and chi-
square estimates were used to calculate the statistical significance.  I also 
examined the Pearson correlations of each of the variables with the thrombus 
measure outcomes to identify any variables which might need to be controlled 
for. 
In the second study, because of the 2X2 block randomisation design, no potential 
confounding variables were identified; therefore the effect of the intervention on 
thrombus formation was studied without inclusion of covariates in the analysis. I 
estimated mixed effects models with high shear and low shear thrombus as the 
dependent variables. The independent variables were indicators for study group, 
time (baseline vs. post treatment) and the interaction between group and time.  
The effect of the intervention on thrombus formation is represented by the group 
X time interaction term (The coefficient of this term estimates the average 
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difference between groups of the pre-post treatment difference in outcome).  A 
random effect at the individual patient level was included to account for the 
nesting of observations within patients. A p value of less than 0.05 with two tailed 
measurement was considered statistically significant. 
For correlation analysis, Pearson’s method and linear regression analysis were 
employed for normal data and Spearman’s method and non linear regression 
analysis method were employed for non-normal data. Graphpad prism version 6 
(Graphpad software, CA, USA) was used to analyse the data prior to constructing 
graphs. 
Using data from our previous study (Natarajan et al., 2008a), in order to detect a 
20% reduction in thrombus area (I predicted a 10% higher amount in ACS 
patients) between the groups, with 80% power, we estimated recruitment of 45 
patients with T2DM and 45 controls. For study 2 (stable CAD patients), in order to 
detect a 20% difference in reduction in thrombus from baseline between the two 
groups, (i.e. 20% reduction in active group versus 0% reduction in placebo group, 
alpha = 0.05 and a 2 tailed test) with 80% power, I estimated a sample size of 90 
(45 patients on placebo and 45 patients on clopidogrel), each supplying data on 
two occasions (baseline and follow up visits). 
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3.1.9 Permission from regulatory authorities 
1. Study 1 ACS study: 
i. Main Research Ethics Committee (North East), Sunderland Reference 
number: 08.H0904.4 
ii. Research and development department, NUTH NHS Foundation trust, 
Newcastle Upon Tyne, Reference number 3639b 
2. Study 2 Stable CAD study 
i. Main Research Ethics Committee (North East), Sunderland Reference 
number: 08.H0904.6 
ii. Medicines and Health Regulatory Authority, London. Eudract number: 
2006-003745-16; MHRA number: 31088/0006/001-0001 
iii. Research and development department, NUTH NHS Foundation trust, 
Newcastle Upon Tyne, Reference number 3639a 
3. Clinical trial registries 
i. Clinical trials.org: ACS study Ref: www.clinicaltrials.gov, NCT00728286  
ii. Clinical trials.org: Stable CAD study www.clinicaltrials.gov, 
NCT00728156 
iii. UKCRN: Portfolio study ACS study number www.ukcrn.org.uk, 7338 
iv. UKCRN: Portfolio study Stable CAD study number www.ukcrn.org.uk. 
5159 
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3.2 Special methods 
3.2.1 Badimon chamber 
3.2.1.1 Principles of the Badimon chamber 
The Badimon chamber mimics rheological conditions that favour coronary 
thrombosis using a deep arterial injury model. The perfusion chamber has been 
designed to “retain the cylindrical shape typical of the vasculature, to be flexible 
enough to accept a variety of biologic and prosthetic materials, and to simulate a 
broad range of physiologic flow conditions” in either an ex vivo or in vitro 
perfusion system (Badimon et al., 1987). The Badimon chamber used in my 
study is an ex vivo model which mimics: 
i. the flow conditions of normal arteries and arteries with moderate 
stenosis  
ii. deep arterial injury (Napoli et al., 2006) 
This well validated chamber has been in use for over fifteen years and recently 
re-validated for consistency and reproducibility in a cohort of 24 healthy 
volunteers (Lucking et al., 2010)  
Generation of platelet dependent thrombus (PDT) by Badimon chamber involves 
the basic physiological principles of arterial thrombosis in coronary vasculature 
namely, 
i. collagen mediated  
ii. shear induced platelet activation.  
I used freshly slaughtered pig’s aorta as a source of collagen in Badimon 
chamber experiments. The thin endothelium was surgically dissected and the 
tunica media, which is rich in collagen, was exposed to flowing blood. The 
second principle involved in Badimon chamber experiments is shear mediated 
platelet activation. Platelet activation occurs at high shear conditions present in 
the coronary circulation at the site of luminal narrowing produced by 
atheromatous plaques. The laminar flow of blood is disrupted and the shear rate 
of flowing blood increases at these sites. Thrombus generation in Badimon 
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chamber is favoured by the laws of physics governing Newtonian motion of 
particles in moving fluid, as reduction of luminal diameter increases the velocity of 
flowing blood in the chamber. In addition, the disruption of the laminar flow results 
in redistribution of platelets in a moving column of blood. Platelets are being 
pushed towards the periphery from the centre. This enables contact activation of 
the platelets with the tunica media and to one another (Ahlqvist, 2001). 
3.2.1.2 Standardisation of the Badimon chamber 
A series of experiments were carried out in our reference laboratory at Mount 
Sinai Medical School, New York, USA to assess the extent of thrombus 
generation at varying shear forces and duration of blood flow through the 
Badimon chamber. Iridium 111 labelled platelets were used to assess platelet 
dependent thrombus burden at  
i. time intervals from 1 minute to 20 minutes 
ii. flow rates at 5 to 20 ml/minute (blood velocity of 2.65 to 42.3 cm/sec) 
iii. shear rates from 106 per sec to 3380 per sec (Badimon et al., 1986) 
Thrombus formation increased steeply from 1 to 5 minutes but reached a plateau 
after 10 minutes.  Thrombus generation increased when flow rates increased 
from 5 ml/minute to 10 ml/minute but not at higher rates. The response of 
thrombus generation to changes in shear rates was studied both by radio labelled 
platelets and by image analysis. At low shear states (e.g. 100-200 s-1, Reynolds 
number 30), fibrin rich thrombus was formed, whilst at high shear rates (1500-
3000 s-1, Reynolds number 60) platelet rich thrombus was formed. Overall 
quantitative assessment of thrombus (platelet and fibrin content combined) 
showed less thrombus at low shear states compared to high shear state. I 
standardised my Badimon chamber experiments to obtain adequate amount of 
thrombus (at least three fourths of the aorta substrate covered in thrombus) but 
using the lowest possible volume of blood. I used chambers with inner diameter 
of 1.0 mm (high shear chamber) and inner diameter of 2.0 mm (low shear 
chamber) to generate Reynolds number 60 (measure of non laminar flow), shear 
rate of 1920 per sec and Reynolds number 30 and shear rate of 500 per sec 
respectively. I generated a flow rate of 10 ml/min for 5 minutes (total of 50 mgs of 
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blood). 18 G cannula (inner diameter 1.2 mm, maximum flow rates 90-100 
ml/min) and Tygon tube (number 14.0, inner diameter 1.6 mm) were used in all 
subjects to maintain the same shear force in the Chamber. The same peristaltic 
pump (Masterflex® pump, Thermo-Fisher Scientific Inc, MA, USA) was used in all 
the experiments at a fixed flow rate of 10 ml/min. Quality control of the set up was 
checked at fixed time intervals (vide infra in quality control section). 
3.2.1.3 Set up for Badimon chamber experiment 
The assembly unit of the Badimon chamber consists of  
i. one low shear plexi glass chamber 
ii. two high shear plexi glass chambers 
iii. three plexi glass over chambers with a screw to secure the substrate 
inside the chambers respectively 
iv. four plastic connectors 
v. a plexiglass container designed to accommodate the chambers 
connected in line with one another 
Each of the chambers contain two split individual units, called the upper lid unit 
and lower core unit and are placed one over the other. The lower core unit has 
cylindrical channels carved out in the rectangular plexiglass blocks with a 
dimension of 1.0 mmX25.0 mm (high shear) and 2.0 mmX25.0 mm (low shear) 
respectively. The upper lid unit contains a rectangular plexiglass unit with a 
central projection of thickness 1.0 mm and 2.0 mm respectively. 
Substrate for thrombus formation (i.e. porcine aorta) is held in place by the 
pressure of the upper lid on to the lower core. The over chamber with a screw 
holds together the upper and lower unit with the substrate sandwiched in 
between (Badimon et al., 1986). The channels of the chamber are connected by 
plastic connectors with matching diameters. For my study I arranged the 
chambers in the following order, proximal to distal, low shear unit  first high 
shear unit  second high shear unit. This whole assembly was kept as a unit 
inside a plexiglass container and placed in a circulating water bath maintained at 
37 degrees Celsius (Figure 3.5). 
  
91 
 
 
 
Figure 3.5 Set up of the Badimon chamber.  
 
Blood from patients’ antecubital fossa is allowed to flow through the Badimon 
chamber with aorta substrate via tygon tubing. The chamber was kept in a 
circulating water bath and was connected to a peristaltic pump at flow rate of 
10ml/min. The three units of the chamber were connected in the order as low 
shear, high shear 1 and high shear 2 and thrombus was obtained at uniform flow 
conditions without any sluggish flow. High shear chamber has an inner diameter 
of 1.0 mm and generates shear rate of 1920 s-1 and Reynolds number of 60. Low 
shear chamber has an inner diameter of 2.0 mm and generates a shear rate of 
500 s-1 and Reynolds number 30. The effluent blood was discarded except for 
few ml to perform biochemical analysis. 
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Aortas of untreated and freshly slaughtered pigs were purchased from a local 
abattoir. The thin endothelial layer was stripped off to expose the underlying 
collagen rich tunica media. The aortas were then surgically dissected into pieces 
of 15X35 mm size. Excess tunica adventitia layer was gently trimmed to 
accommodate the aorta inside the chamber. The aortas were inspected to rule 
out presence of any flaps or damage to the inner layers using 5X magnification 
glass. They were then immediately submerged and stored in 0.01M phosphate 
buffer solution at minus 80° Celsius.  Aortas were slowly thawed overnight at 2-8 
degrees and brought to room temperature slowly just before the chamber studies. 
The aortas were visualised with a 2.5X magnifier glass and examined for any 
flaps or damage to media layer. Only aortas without dissection artefacts were 
selected to be used in the chamber. The rest of the aorta pieces were disposed 
according to our local research facility and laboratory guidelines. The flow 
chamber unit was constructed as a tubular channel with upper hemisphere 
covered by aorta tissue with exposed tunica media and lower hemisphere by the 
plexiglass groove in the lower core unit. Segments of aorta are fed in to the top 
core of the chamber unit and approximated with bottom core cylindrical unit. The 
outer chamber was used to hold the halves in place, using a screw on its top.  
This enables the flowing blood in the channel to come in contact with the 
exposed tunica media of the porcine aorta. 
The chamber was maintained in a water bath at 37 °C.  Using 14.0 Tygon® 
tubing (Cole Palmer, IL, USA), the output of the chamber was connected to a 
peristaltic pump (Masterflex, model 7013) which regulated flow at a rate of 10ml 
per minute. Initially, to flush and prime the system, 0.01M phosphate buffer 
solution (PBS) was drawn through the system. Then, native (non-anticoagulated) 
blood was allowed to flow from the ante cubital venous cannula into the perfusion 
chamber for exactly 5 minutes. The effluent blood was collected during the 3rd 
minute, into plain and 3.2N sodium citrate tubes. After 5 min, PBS was again 
drawn through the chamber for 30 seconds under identical flow conditions to 
remove unattached cells and blood overlying the formed thrombus on the 
substrate. The changes from buffer to blood and vice versa were achieved 
manually by a three-way valve without stasis in the chamber. 
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3.2.1.4 Connectors of Badimon chamber 
Connectors used in the Badimon chamber have satisfied the following principles: 
i. Non thrombogenic 
ii. Able to generate and sustain the expected shear rates of (200-300 per 
sec and 1900-2000 per sec) 
iii. Fit tightly in to the peristaltic pump. 
I used Tygon® tubing (Cole Palmer, IL, USA) which satisfies all these conditions. 
Venous cannula inserted to patients forearm was connected via a three way tap 
(Alaris®,MFX2280E, Cardinal Health Inc, Rolle, Switzerland ) to the low shear 
chamber. 
3.2.1.5 Phosphate buffer solution 
0.01 M Phosphate buffer solution (PBS) was prepared from commercially 
available RNAse and DNAse free PBS concentrate in powder form (Cole-Palmer 
inc, MA, USA). I reconstituted the powder to prepare fresh 0.01M solution using 
deionised water. 
3.2.1.6 Histopathology methods 
Aorta tissue with thrombus was carefully removed from the chamber units, to 
avoid any dislodgement of fresh thrombus. Individual aorta segments were then 
preserved in 10% buffered formalin. After 72 hours of fixing in formalin, the aorta 
segments (one low shear and two high shears) are sectioned into eight pieces 
each approximately of 1mm width (Natarajan et al., 2008a). The segments are 
labelled as follows and placed in separate histocassettes: 
i. Low shear chamber unit : A1,A2,A3,A4,B1,B2,B3,B4 
ii. High shear chamber unit 1: C1,C2,C3,C4,D1,D2,D3,D4 
iii. High shear chamber unit 2: E1,E2,E3,E4,F1,F2,F3,F4 
The aorta samples were then embedded in liquefied wax. The tissue blocks in 
wax were sectioned to 0.4 µm width sections using microtome and stained using 
modified Masson trichrome stain (method vide infra) and placed in a glass slide. 
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Sectioning and staining procedures were carried out in Cellular Pathology 
department, Royal Victoria Infirmary. 
3.2.1.7 Staining of the thrombus 
The thrombus in the aorta was stained with Masson trichrome method, a three 
colour staining procedure. After staining, the thrombus with fibrin appears red, the 
elastin of the aorta substrate appears green and the aortic smooth muscle 
appears pink. The original Masson trichrome staining was first described in 1929 
(Bancroft JD and M, 2002). The technique was modified to enhance the thrombus 
over the aorta and also to clearly demonstrate the plane of cleavage between the 
thrombus and tunica media of the aorta substrate. This modification has been 
validated by Thrombosis Research Laboratory at Mount Sinai Hospital, New York 
(Osende et al., 2001).  
Step by step method of the staining is given below. Briefly, the slides were 
serially rinsed in xylene and alcohol of varying strengths. They were then stained 
with Weigert’s haematoxylin solution to stain the cellular nuclei and then Ponceau 
red to stain fibrin. After staining with Light Green to stain elastin fibres, the slides 
were quickly rinsed through alcohol of varying strengths and xylene. The 
specimens were then air dried and cover slip was mounted. 
3.2.1.8 Image acquisition 
The slides were viewed using a high precision light microscope (Leica DM 2000, 
Leica Microsystems, Wetzler, Germany). The microscope was calibrated 
according to manufacturer’s standards and cleaned and inspected for the 
integrity of the components with the help of a senior technician twice a year. A 
standard template image was inspected every six months and matched to ensure 
correct optimal illumination and precision. The thrombus images (10X 
magnification) were identified (pink to red) on the top of the raised section of the 
tunica media of the aorta tissue (green). A digital camera with a very high 
definition resolution of 1360X1024 (KY-F1030, JVC, Japan) was used to capture 
the images electronically. This camera was connected using an IEEE1396 
electronic link and an inbuilt TWAIN driver. This allowed the images to be 
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digitised without losing precision, using special software (What You See Is What 
You Get software (WYSIWYG) ®, JVC, Japan). 
3.2.1.9 Thrombus area measurement 
Image analysis of the thrombus image was carried out using the specialist 
software, Image-Pro Plus®, Version 4.0 (Media cybernetics Inc, MD, USA), 
calibrated using the standard micron calibration scale supplied by the 
manufacturer. Acquired images in .jpeg format were opened using this software. 
Brightness and contrast of the images were standardised using an “automated 
best fit algorithm” of the software. This enhanced the contrast of the thrombus 
portion of the image. The thrombus was identified as ‘the area of interest’. Using 
the tool ‘irregular area of interest (AOI)’ in the software, the thrombus was 
carefully traced with the help of a cursor. The thrombus aorta interface was 
delineated and utmost care has been taken not to include the tunica media of 
aorta as an area of interest and to correctly identify the plane of cleavage 
between the thrombus and the underlying aorta. Once the area of interest has 
been distinguished from the rest of the aorta tissue, the thrombus area has been 
measured using the dark object identification algorithm. Briefly, the thrombus in 
the delineated section of the image appeared darker than the plain light 
background image and was counted as multiple individual dark objects. The area 
of the thrombus was quantified as the sum area of the multiple individual dark 
objects. The thrombus areas of each of the 24 sections of aorta (8Xlow shear and 
16Xhigh shear) were counted. The mean thrombus area was obtained for low 
shear and high shear sections of the thrombus and expressed as µ2 per 
millimetre aorta surface area (µ2/mm). 
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Modified Mason trichrome staining 
1. Mix 150 ml of Weigart’s haematoxylin solutions A and B. 
2. Take the slides serially to solutions of XyleneX2, 99% alcoholX2, 95% 
alcohol and 75% alcohol. 
3. Leave in Weigart’s solution (A and B) for 10 minutes. 
4. Run in tap water. 
5. Dip in acid alcohol and then run in tap water. 
6. Dip in Scotts tap water and then run in tap water. 
7. Dip in 2% Poncaeu Red in acetic acid for 10 minutes. 
8. Wash in distilled water. 
9. Leave in 2% light green for 40 seconds. 
10. Dip in distilled water and then 2% acetic acid 
11. Run in tap water and dehydrate quickly, 70% alcohol, 95% alcohol, 99% 
alcoholX2, XyleneX2. 
12. Put in slide holder and paste cover slip. 
13. Blot with tissue and arrange the slides with cover slip. 
 
Figure 3.6 Stepwise protocol for modified Mason trichrome staining.  
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The images were checked for quality control (vide infra) by two observers, myself 
and the senior experienced investigator Prof Azfar Zaman. We excluded the 
sections of aorta deemed unsuitable for analysis as follows: 
i. Sections with flaps: may lead to  sluggish flow and over estimation of 
the thrombus 
ii. Sections which were damaged by tissue microtome: may 
underestimate the thrombus 
iii. Sections with dye artefacts and cover slip artefacts 
iv. Sections with very negligible thrombus (less than 500 µ2/mm), wash 
artefact 
v. Sections with red cell thrombi (appears orange in colour), indicative of 
sluggish flow in the chamber 
We excluded 3.75% of the thrombus images from final analysis (162/4320 
images). 
3.2.1.10 Quality control 
I performed assessment of the circuit using 0.01M phosphate buffer solution. 
Every day before the chamber study, I checked the integrity of the circuit by 
priming with the solution at 10 ml/min (standard laminar flow) and 150 ml/min 
(high shear, non laminar flow). 
I performed quality control of the chamber study once every four months using 30 
g of coffee powder mixed with 50 ml of 4% cream and 50 ml of water (1:1) to 
mimic the flow conditions of viscous blood. Deposition of the coffee powder 
particles was examined during uniform flow and shear conditions under 
magnifying glass (X4) and the presence of coffee powder in places other than the 
central three fourths of aorta was considered non uniform flow. Thirdly, a control 
study with a volunteer (myself) was performed once a year, in exact similar 
conditions to the patient study. Thrombus area in three studies was not 
statistically different (mean thrombus area µ2/mm, 9218, 8878, 9881). 
I standardised and performed quality control exercises during image analysis. 
Two independent observers (myself and Dr Azfar Zaman) analysed 10% images 
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chosen at random. Images were labelled with dummy numbers by a third 
observer, to ensure blinding. The inter-observer co-efficient of variation of 
thrombus area was 5.8 %. I also quantified thrombus area in these same images 
on three occasions on three consecutive days, with an intra-observer coefficient 
of variation of 4.5 %. To ensure uniformity of measurements, I measured 
thrombus area of these standard images every four months and the variability 
was 3.6% (range 0.4 to 5.0). I also performed duplicate thrombus area 
measurement for each set of aortas. Four sections were randomly chosen from 
each set of images (four sections out of 24, from every Badimon chamber 
assessment). The median co-efficient of variation was 1.6 percent (for 4230 
images, range of variability was 0.4 to 3.2). In addition, another two independent 
but in-experienced observers (Prof Sally Marshall and Dr Kath White) have 
analysed the 24 images with a co-efficient of variation of 9.6% Besides, I used 
two different versions of Image Pro-Plus software (version 4.0 and version 7.0) 
held in two different computers to assess inter software variability and the 
coefficient of variation was 4.9 %. 
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3.2.2 Ultrastructural assessment of thrombus using Scanning electron 
microscopy (SEM) 
3.2.2.1 Introduction 
Ultrastructure assessment of thrombus includes studying the architecture of 
cellular component (platelet) and fibrinous component (fibrin fibres) of the formed 
thrombus. Weisel et al have first documented fibrin fibre arrangement of 
thrombus using electron microscopy as early as 1981(Weisel et al., 1981). 
Badimon et al have shown thrombus structure in a small cohort of patients who 
were given iridium labelled platelets (Badimon et al., 1987). Not much progress 
has been made in quantitative electron microscopic assessment of thrombus due 
to difficulties in sample preparation and time consuming and error prone 
quantitative assessment methods (Collet et al., 2005). Current techniques 
therefore focus mainly on fibrin structure derived from platelet poor plasma rather 
than whole blood. Use of semi automated image analysis software                      
(e.g. J software, http://rsbweb.nih.gov/ij) has given new impetus in quantitative 
assessment of whole blood thrombus. However, the quantitative assessment of 
thrombus from SEM images is still not yet formally standardised and remains in 
its infancy. 
3.2.2.2 Operational characteristics of SEM 
Electron microscopy (EM) uses a “beam of energetic electrons to examine 
objects on a very fine scale”. EM was developed due to the limitations of light 
microscopes, which cannot generate images of higher magnification than 1000X. 
Scanning electron microscopy (SEM) uses the principles of signal generation 
when high voltage electron beams are focussed on a smaller area on the surface 
of the solid biological sample. The signals that derive from electron sample 
interactions reveal information about the sample including external morphology, 
components of the sample, crystalline structure and orientation of individual 
subunits of the sample. The electron beam receiver collects data over a selected 
area of the surface of the sample, and a 2-dimensional image is generated that 
displays spatial variations in these properties. Areas ranging from 1 cm to 5 
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microns in width can be imaged using conventional SEM techniques 
(magnification ranging from 20X to approximately 30,000X, spatial resolution of 
50 to 100 nm). 
Components of SEM include i) electron optical column with a source to produce 
electrons and  electromagnetic coils to control and modify the beam ii) vacuum 
systems within a chamber which “holds” vacuum to minimise artefacts and iii) 
signal detection and display unit which consists of detectors that collect the signal 
and electronics to produce an image from the signal. 
The physics behind the image acquisition and analysis is beyond the scope of 
this thesis. Briefly, accelerated electrons in an SEM carry significant amounts of 
kinetic energy, and when the incident electrons hit and decelerate at the surface 
of the sample, this energy is dissipated as a variety of signals. These signals 
mainly include secondary electrons which are refracted and reflected back to the 
detector. SEM generates powerful electric and magnetic fields for separating 
trajectories of backscattered electrons and secondary electrons generated from a 
specimen. A backscatter electron detector covers the trajectory of the 
backscattered electrons. Since secondary electrons and backscattered electrons 
can be detected efficiently in a separate fashion at a low accelerating voltage and 
the detector is strategically placed to avoid the pathway of the primary electron 
beam, backscattered and secondary electron images of high resolution can be 
obtained. 
Transmission EM (TEM) is another high resolution EM and can be used to image 
very smaller objects and magnify up to 450,000X. I decided to use SEM rather 
than TEM for the following reasons: 
i. SEM is better suited to study surface  of the thrombus formed in 
Badimon chamber as TEM may focus on a very minute area of the 
thrombus 
ii. thrombus preparation on a very thin slice of aorta for TEM will be 
technically challenging 
iii. fibrin to fibre interactions are best studied using SEM 
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iv. cross sectional imaging of thrombus by TEM will be very time  
consuming and less likely to yield more information than what is 
already known 
3.2.2.3 My study protocol 
Detailed step by step process has been explained below. With the help of the 
senior operators at Electron Microscopy services, Newcastle University, I 
performed a series of pilot images acquisition. For better reproducibility and 
speed of processing, I standardised the pilot image at approximately 60X 
magnification using an 8 kilo Voltage electron beam and the sample kept at 6mm 
distance from the electron gun. For high power I chose 3,200X magnification and 
for ultra high power, 15,000X magnification as standard for this study. I chose to 
analyse 20 random patient samples (10 in each group) on both visits. The 
samples were identified by the study identification numbers, chosen randomly by 
an independent member of our team and I was kept blinded to the choice of 
therapy of the patients during the analysis. There was no published literature 
available on SEM analysis of thrombus on which to base a power calculation. I 
chose 20 as my sample size as I estimated image analysis of at least 8 patients 
per treatment group per visit accounting for at least 20% sample artefacts. Each 
patient had three aorta specimens, one from low shear and two from high shear 
and therefore I anticipated a minimum of 48 individual thrombus specimens can 
be used for analysis for each group. Thrombus laden aorta samples from the 
Badimon chambers were fixed in 2% glutaraldehyde. A sample of 1mm width is 
taken from each chamber (1Xlow shear and 2Xhigh shear) at the median point of 
the aorta. After 72 hours of fixing, the thrombus specimen was serially treated 
with varied concentration of ethyl alcohol. After critical point drying, the samples 
were mounted using silver adhesive. It was then gold coated in a specialised 
chamber and the samples were loaded to SEM. Standard pilot images were 
taken at 60X magnification. Six images were taken at high power 3.2X103 
magnification and further six images were taken at 15X103 magnification. The 
areas of interest were identified  using a validated random grid model using 2X3 
squares (Silvain et al., 2011). At least 80 fibrin fibres and 200 individual platelets 
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were analysed per sample per visit for diameter analysis. Total numbers of fibres 
were counted in a square grid model with area of 36 µ2. All the images were 
analysed by me completely blinded to treatment allocation. 
The images were analysed using Image ProPlus® software 4.0.1 (Media 
Cybernetics Inc, MD, USA). I first focussed on the standard pilot image (60X 
magnification) and identified platelet rich areas and fibrin areas using a simple 
grid analysis model and calculated proportional content of each of them. This did 
not provide the absolute value of platelet or fibrin content of thrombus but 
percentage area occupied by each of the components. Internal validation was 
performed and intra-observer’s COV (GV) was 11.5% and inter-observer’s COV 
(GV vs KW) was 16.5% for platelet-fibrin content of thrombus. 
I then proceeded with high power images of 3.2X103 magnification and focussed 
on two distinct structures, platelets (disc shaped) and fibrin (filament shaped) 
Platelets in the sample were identified by the following validated structural 
features, Figure 3.7 (Williams Hematology, 8th edition, McGraw Hill, New York, 
USA): 
i. disc shaped structure 
ii. presence of pseudopodia 
iii. presence of filaments 
iv. presence of exosomal globular structures (exocytosis of golgi 
apparatus and granules) 
v. presence of clumping 
Fibrin fibres were identified by the following validated features, figure 3.8: 
i. long filamentous architecture 
ii. presence of interlinkage between filaments 
iii. attachment to platelets 
iv. twisting of filaments 
v. entrapment of platelets 
The “hub and spokes” or “neps” model is routinely used in commercial cotton 
industry to identify the quality of individual cotton fibres and standardisation of the 
quality of the cotton yield. Entanglement of cotton fibres known as “neps” is 
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equivalent of the “hub and spokes” arrangement of fibrin fibres seen in the 
thrombus. Presence of fewer “neps” is deemed as a pre-requisite for premium 
quality of yield and thus used in pricing of wholesale cotton and forms a part of 
essential benchmark tool and a specific cotton industry standard known as 
Uster® statistics (www.ars.usda.gov/main/docs.htm?docid=5260&page=10, 
www.uster.com/en/service/uster-statistics accessed on 23rd Aug 2013). I 
elaborated this concept of “neps” and hypothesised that the presence of higher 
number of “hub and spokes” would limit the energy to be used in individual fibrin 
fibre polymerisation and thus make them more susceptible for autolysis. I visited 
cotton standardisation laboratories in Liverpool, UK and Coimbatore, India and 
the “hub and spokes” model of thrombus assessment was created following the 
discussion with the senior laboratory technicians. 
Dendrite identification algorithm of Image Proplus version 4.0.1 was used to 
study the fibrin to fibrin interlinkage. This semi automated software selects the 
presence of fibrin filaments in the thrombus and can be used to count the 
numbers and measure the size of individual fibres. More specifically, the dendrite 
function algorithm identifies fibrin-fibrin interlinkage in a predefined area of 
thrombus with multiple fibrin fibres. The “hub and spokes model” was overlapped 
with the image to study individual fibrin to fibrin interaction. “Hub” was defined as 
presence of three or more individual fibrin fibres intersecting each other at three 
different angles with at least 20 degrees in between. Those with angles less than 
20 are defined as parallel fibrin fibres. This model was introduced to study the 
compactness of the thrombus. Individual fibrin fibres were known as spokes. In 
addition, as the thrombus was heterogeneous in any given field in SEM, I 
measured clusters of hub and spokes per square micron of the field, providing a 
quantitative assessment of compactness of the thrombus. For quality control, 
every fourth sample was re-analysed and if the differences in fibrin diameter or 
platelet diameter were more than 10%, analysis was performed for the third time 
and the results of the third analysis was included in the analysis. 
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Figure 3.7 Electron microscopy appearance of platelets.  
Electron microscopy appearance of platelets in various stages of activation was 
seen at magnification of 13,300 times and at 8kV energy. Platelets were 
characterised by the presence of pseudopodia at the middle of the figure which 
was seen as an “end on” appearance. The presence of granules was seen as 
small projections on the surface of the platelets. The platelets were seen here at 
various stages of changes in shape. The fibrin filaments are seen bridging the 
adjacent platelets there by resulting in a platelet clump. 
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Figure 3.8 Electron microscopy appearance of fibrin fibres.  
 
Fibrin fibres were viewed at 3,400 times magnification by scanning electron 
microscopy. Fibrin fibres were arranged in longitudinal pleated structure with 
trapped RBC’s and platelets. The presence of hub and spoke appearance was 
also seen in this section with lateral fibrin fibre interlinkages. 
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3.2.2.4 Step by step study protocol 
SEM analysis of the thrombus consisted of three distinct stages, sample 
preparation, image acquisition and image analysis. My protocol is given below. 
i. Sample preparation 
1. After Badimon chamber study has finished, carefully detach the 
chambers 
2. Dissect 1 mm width of aorta laden with thrombus at the median 
point, using a precision blade/scalpel. Take care not to disturb 
freshly formed thrombus. Repeat for the two other chambers, so 
that three specimens will be obtained (one low shear, 2Xhigh 
shear). Fix immediately in 2% glutaraldehyde in Sorensons 
phosphate buffer 
3. Preserve the specimen at 5°C for at least 72 hours. Take the fixed 
thrombus sample and rinse twice for 15 minutes using 0.01M 
phosphate buffer solution 
4. Proceed to step by step dehydration using various strengths of 
alcohol as follows: (gradual increase in ethanol concentration to 
minimise artefacts) 
a) 25% ethanol for 30 minutes 
b) 50% ethanol for 30 minutes 
c) 75% ethanol for 30 minutes 
d) 100% ethanol one hour 
e) 100% ethanol for one hour 
5. Perform critical point drying using Baltec critical point dryer.  Once 
dried, samples are mounted on an aluminium stub with sample 
number written on the bottom surface. Use Achesons silver 
Electrodag as an adhesive on the adventitial side of the aorta 
6. Using Poloron SEM coating unit, with argon vapour, colloid gold 
was spray coated (up to 15 nm thickness) on the surface of the 
thrombus 
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ii. Image acquisition 
1. Load six gold coated samples in the aluminium stubs in the SEM 
tray 
2. Open the door and load one tray in to the holder 
3. Adjust the electron detector 
4. Turn on SEM machine to generate vacuum 
5. Adjust the green flicker from tungsten filament to be a sharp image 
6. Turn on image detector and the sample will appear in the screen 
7. Use the recommended settings to get a magnification of 60-72X 
times as a basal image 
8. Acquire the image to the folder in the PC using Olympus software 
9. This image is the pilot image and check patients ID number 
10. Divide the sample to 6 squares as a major grid. One image to be 
obtained from each major grid 
11. Re focus to the square of interest, start with left top square 
12. Divide the grid to 4 squares as high power grid. Choose one square 
at random and focus at 3,200 to 3,600X magnification. Fine tune 
the image to get better contrast. Acquire and store in the PC as in 
step 8 
13. Divide the high power image as a 4 square ultra power grid. 
Choose one square at random and focus at approximately 15,000X 
magnification. Fine tune the image and acquire the image. Store in 
PC as in step 8 
14. Return to low power at 60-70X magnification and move to next 
square in pilot grid, bottom left corner. Repeat steps as above 
15. Repeat image acquisition for middle top, middle bottom, right top 
and right bottom squares. There should be one high power and one 
ultra power image for each major square in the pilot grid 
16. In total each sample will have six high power (X3200 times 
magnification) and six ultra high power (X15000 magnification). 
There will be six samples for each patients (3 from visit 1 and 3 
from visit 2) generating 36 samples for each patient 
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Figure 3.9 Image acquisition in SEM – Major Grid   
The sample is divided into 6 squares as a major grid. One square is chosen and 
divided into four high power grids (squares). One square was chosen at random 
for high power image (3200 to 3600 times magnification) per one major grid of 
the pilot image. Similar steps were repeated for ultra power image (15000 times 
magnification) per one major grid of pilot image. Solid arrow indicates the area of 
interest in the pilot image of high power grid. 
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17. Once completed, back up the images in the portable hard drive 
18. Turn down filament, and leave SEM under vacuum 
iii. SEM image analysis 
1. Open image Proplus and SEM image 
2. Open pilot image (usually called as LP1 image). 
3. Open measure  Calibration  Spatial  Select SEM pilot  
Select 
4. Open Process  Grid mask  GV1 grid  Apply 
5. Count the stars in the dark areas (or fibrin rich thrombus) and total 
number dots. Calculate the percentage 
6. Proceed to open HP1 
7. Classify the image as fibrin rich or platelet rich image 
8. If PLATELET RICH, Open process  GV2grid  Select lines  
Apply 
9. Choose 4 random squares 
10. Calibrate the scale 
11. Count number of cells and record the diameter of the cells. Use 
open L rule 
12. If FIBRIN RICH, Open process  GV2grid  Select lines  Apply 
13. Choose 4 random squares 
14. Select using a rectangular square 
15. Open measure and count size 
16. Select measurements--called dendrites- and click OK 
17. Select automatic bright objects, 8 hole filler, accumulate counts 
18. Select count 
19. Select view -statistics - and total number of cells and valid counts 
(last two lines) 
20. Select view and look for measurement data then select sort 
descending-and count hub numbers (those with over 30 spokes aka 
dendrites) 
21. Select measure and cluster and note down cluster values 
22. Copy data in Microsoft Excel sheet (four values: All, spokes, hub, 
cluster) 
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23. Repeat for three more squares 
24. Follow similar procedure for all HP images 
25. Proceed to open UP1 image 
26. Open process  GV3Grid  Select lines  Apply 
27. Choose 1 random square from 4 
28. Count number of vertical and horizontal fibres 
29. Calibrate  Spatial calibration  New 
30. Choose Unit  µm  Calibrate the scale 
31. Click  Measure  Calliper  Single line image  calibrate 
32. Before measuring, check with reference line and measure its 
thickness 
33. Use clip board function and store as note pad 
34. Convert note pad files using .csv function to Microsoft Excel format 
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3.2.3 Assessment of viscoelasticity by Thromboelastography® (TEG) and 
Platelet Mapping™ 
3.2.3.1 Principles and technique 
Thromboelastography is a point of care technique which measures the 
viscoelastic property of whole blood. It provides a global measurement of 
haemostatic system function and can be used to identify defects in thrombus 
formation and auto lysis. TEG® is used to assess bleeding tendency and to 
monitor blood and blood product replacement after major cardiac and 
hepatobiliary surgery. TEG® provides a dynamic and real time assessment of the 
elastic property of the thrombus (Reikvam et al., 2009). 
The TEG® consists of two mechanical parts: a heated (37 °C) oscillating cuvette 
or cup, and a stationary pin which is suspended in the centre of the cup and 
connected to a torsion wire (Figure 3.10). Blood is placed in the cuvette and, 
whilst the sample remains liquid as unclotted blood, the motion of the cuvette 
does not affect the pin. However, when thrombus starts to form, the fibrin strands 
"couple" the motion of the cup to the central pin. The viscoelastic force of the 
blood is thus transmitted via the pin to the torsion wire. The cup is rotated in an 
oscillating fashion, 4.45 degrees every 10 seconds both clockwise and 
anticlockwise. As fibrin and platelet aggregates interlink, they connect the inside 
of the cup with the metal pin, transferring the energy used to move the cup to the 
central pin. The torsion wire, connected to the pin, measures this kinetic energy 
as viscoelastic strength of the thrombus over time, and converts the data to a 
digital form which is displayed as a graph. TEG® also evaluates clot lysis or 
retraction by measuring the decrease in the strength of the thrombus, causing the 
amplitude (A) of the TEG® tracing to decline from its maximum strength (MA). By 
measuring the tensile strength of the thrombus continuously, TEG® results reflect 
dynamic whole blood thrombosis including platelet aggregation, platelet to fibrin 
interaction and fibrin polymerization. However, TEG® also measures the velocity 
at which the thrombus forms known as clot kinetics (Figure 3.10). 
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Figure 3.10 Thromboelastography  
The top panel shows the transmission of the torque to the inner central pin. The 
elastic force is recorded digitally and displayed as a graph. The bottom panel 
shows a 4 channel TEG® with reagents mixed to the cuvette.  
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TEG® measurements are derived from a graph and various parameters are 
explained in the table below. Thrombus initiation begins with activation of the 
enzymatic cascade and ends with formation of fibrin polymers (R time). This R 
value reflects fibrinogen levels in blood. TEG® also measures the speed at which 
the thrombus forms (K time) and is calculated from the graph as the time taken 
for amplitude of the clot to increase from 2 mm to 20 mm. Maximum amplitude of 
the thrombus (MA) provides a measure of overall structural interactions of 
platelets interlaced with fibrin polymers is measured as the distance between 
both the diverging limbs of the graph on either side of the y-axis. TEG® 
measurements include α angle, which represents the slope between R and K 
values of the graph and this represents the fibrin to fibrin interlinkage. Early 
autolysis, which is secondary to thrombus retraction, is mainly contributed by 
rearrangement of fibrin to fibrin linkage. Autolysis is measured by percentage of 
lysis at 30 minutes and one hour respectively (CL30 and CL60) and the rate of 
loss of thrombus strength as measured by lysis parameter (L mm/min).                
L parameter is calculated using a complex first derivative integral calculus 
equation by continuously measuring loss of maximum amplitude in mm per 
minute. 
Platelet Mapping™ is an advancement of TEG® technique and it is used to 
measure the platelet suppressant effect of individual antiplatelet agents such as 
aspirin, clopidogrel and glycoprotein IIb IIIa inhibitor. Heparin was used in Platelet 
Mapping™ to neutralise the effect of thrombin, and enabled us to measure the 
effects of particular platelet agonists such as arachidonic acid and ADP. 
Commercially available activator F (labelled A-P1) was used to stimulate 
conversion of fibrinogen to fibrin and activation of Factor XIIIA to crosslink the 
fibrin network, thereby bypassing the effect of heparin. In addition, platelet 
agonists, ADP (2 µM) and arachidonic acid (1 mM) were used to study the effect 
of clopidogrel and aspirin respectively in individual cuvettes. Then TEG® data 
was collected over 60 minutes. Platelet inhibitory effect of clopidogrel and aspirin 
were calculated by measuring maximum amplitude using the formula: 
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Percentage maximum amplitude reduction, MA reduction  
 = 100 – ( ([MAAA or ADP – MAactivator]/[MAthrombin – MAactivator])x100 ) 
There are published data to validate the above formula by using 
i) heparinase-coated cups in patients on heparin therapy 
ii) non citrated blood (Zmuda et al., 2000; Wasowicz et al., 2008) 
In addition to standard TEG® parameters, changes in the viscoelstic strength 
were depicted as a real time graph known as V curve. This quantifies the 
velocity of both generation and autolysis of thrombus based on either the 
changes in amplitude (A) or the elastic modulus (G) of the elastic force over 
time. Since clot development occurs in series of steps strongly influenced by 
inherent thrombin activity, the speed at which thrombus gains or loses its elastic 
force in the stage of thrombogenesis is directly proportional to the speed of 
thrombin generation. Thus, by measuring the velocity changes in TEG®, 
thrombin generation can be quantified indirectly. These values are represented 
as V curve parameters and are not yet published in diabetic individuals. (Rivard 
et al., 2005). 
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Figure 3.11 TEG® Platelet Mapping™ tracings  
The tracings are derived from the changes in viscoelastic force of the thrombus 
from three cuvettes upon activation by kaolin (MA thrombin), ADP or arachidonic 
acid (MA ADP) and Activator F (MA Activator). Individual platelet inhibitory 
values are calculated using the formula, percentage maximum amplitude 
reduction, MA reduction = 100 – «([MAAA or ADP – MAactivator]/[MAthrombin – 
MAactivator])x100». The higher the reduction in MA, better is the antiplatelet 
response of clopidogrel. 
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Name of the 
parameter 
Definition Clinical relevance Normal 
values 
R time, in min Time from the beginning of the TEG® trace 
until amplitude of 2 mm is reached.  
This measures the time taken from the placement of 
the blood sample in the cuvette to the initial fibrin 
formation 
2-8  
K time, in min Time from the end of R until a fixed level of 
thrombus strength is reached i.e. amplitude 
of the trace is 20 mm. 
This measures the time taken to form a firm thrombus, 
corresponds to fibrinogen levels 
1-3  
α- angle (thrombus 
formation rate) 
The angle formed from the horizontal to a 
point on the trace until amplitude is 20 mm 
This measures the rate of fibrin polymerisation and 
fibrin to platelet interaction, thereby assesses the 
speed of thrombus formation 
55-78 
MA, maximum 
amplitude, mm 
Measures the maximum distance between 
the two arms of the graph at their peak 
amplitude 
This measures maximum viscoelastic strength of the 
thrombus. This has been the most studied and 
consistent measurement among all the TEG® indices. 
MA is influenced by fibrinogen and platelet fibrin 
interaction. Using the modification of TEG® assay in 
Platelet Mapping™ assay individual effects of aspirin 
51-69 
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Name of the 
parameter 
Definition Clinical relevance Normal 
values 
and clopidogrel are studied. 
G, dynes/cm2 Measure of the shear elastic force of the 
thrombus, G= (5000A)/(100-A)/1000, A is the 
amplitude of the continual tracing till MA, at 
which point G parameter measurement will 
stop.  
G parameter measures the elastic force and a small 
increase in A will reflect an exponential increase in G. 
These values are indicative of firmness of the 
thrombus. 
4,600 – 
10,900 
CI, clot index Dimensionless parameter calculated by the 
formula, CI = - (0.1227)R + (0.0092)K + 
(0.1655)MA – (0.041)α - 5.0220. 
Overall measure of thrombus strength and it is a 
composite measure and a dimensionless index. CI 
measures the combined effect of fibrinogen and 
platelets on thrombus 
-3 to 3 
LY30 Measures the area under the curve 30 min 
after MA has been achieved 
Indicative of thrombus retraction at 30 minutes, 
signifies early autolysis. 
0-8 
LY60 Measures the area under the curve 60 min 
after MA has been achieved 
Indicative of thrombus retraction at 60 minutes. 0-15 
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Name of the 
parameter 
Definition Clinical relevance Normal 
values 
L parameter, 
mm/min 
This is a thrombus lysis parameter, 
calculated as the average reduction in 
amplitude per unit of time. This is the first 
derivative calculus measurement of thrombus 
strength and is calculated for 90 minutes in 
standard TEG® tracings. 
This represents the changes in viscoelastic property 
due to ongoing clot retraction or autolysis.  
30-60 
Table 3.1 Thromboelastography measurements.  
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Based on the V curve graph and using the area under the curve, the following 
parameters are calculated. L parameter, the composite measure of autolysis has 
been described before. Maximum rate of thrombus generation, (MRTG, mm/min) 
measures the maximum velocity at which viscoelastic strength develops within a 
developing thrombus clot. Time to maximum rate of thrombus generation 
(TMRTG, in seconds) measures the time taken for the initiation of thrombus 
formation (i.e. lag time) plus the time it takes for the thrombus to reach its 
maximum strength. Total thrombus generated (TG, mm/min) was measured 
indirectly as a derived parameter from the area under the curve (AUC). It is 
derived purely on the total elastic force of thrombus generated. Once thrombus is 
formed, it undergoes autolysis. Time to maximum rate of clot lysis (TMRL, in 
seconds) measures the time from the start of the coagulation process until the 
maximum rate of thrombus lysis is achieved. This reflects clot stability and 
persistence of the thrombus. Maximum rate of lysis (MRL, mm/min) is a thrombus 
autolysis parameter which represents the maximum rate of clot breakdown. The 
standard V curve graph is shown in Figure 3.12. 
3.2.3.2 My study protocol 
My step by step study protocol, as per manufacturer’s guidelines is given below 
(Hemoscope, CA, USA). Briefly, citrated and heparinised bloods were collected 
from the patient and 340-360 µl of blood was placed in each cuvette labelled as 
Kaolin, F, ADP and AA respectively. After addition of calcium chloride (for Kaolin 
sample) or heparinise activator (Reagent F, AP1), respective agonists either ADP 
or arachidonic acid were added. TEG® was allowed to run for up to 90 minutes 
and the data was collected and displayed graphically and electronically 
incorporating individual parameters. A total of 100 patients completed the study 
(due to delays in installation of the machine and supply chain of the distributors, 
not all patients were able to complete the sub study). Patients were identified only 
by their study numbers and the data was stored anonymously in the dedicated 
computer attached to TEG® machine. 
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Figure 3.12 V curve as displayed in TEG® 
See legend below 
 
 
Figure 3.13 V curve parameters, raw data of Thromboelastography®.  
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The strength of the thrombus as it forms and undergoes autolysis is represented 
in a graphical format in both the top panel (graph displayed in TEG®) and the 
bottom panel shows the real time graph of changes in elastic strength of the 
thrombus . Thrombus formation is dictated by thrombin generation and thus the 
thrombin can be quantified indirectly by measuring thrombus kinetics. 
 
MRTG (Maximum rate of thrombus generation) – This parameter reflects the rate 
at which viscoelastic strength develops during thrombogenesis. 
TG (Thrombus generated) – This parameter is derived from the positive area 
under the curve (AUC) and represents the total amount of viscoelastic strength 
generated during thrombogenesis. It is directly proportional to the amount of 
thrombin generated during thrombus generation. 
MRL (Maximum rate of lysis) – This parameter represents the maximum rate of 
thrombus autolysis. 
TMRL (Time to the maximum rate of lysis) – This is the time from the start of the 
study till the maximum rate of thrombus lysis is achieved. This parameter reflects 
the stability of the thrombus. 
L (Lysis parameter) – This gives the composite measure of autolysis or clot 
retraction. 
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Figure 3.14 Schematic diagram of the four channels of the Thromboelastography 
(TEG).  
 
• Activator F (labelled A-P1, measured in channel 2) – No platelet agonist added. 
MA results from fibrin contribution only. Results are referred to as MAP1 or MA-
FIBRIN. 
• ADP (labelled ADP-P2) and Activator F (in channel 3) – ADP activates non-
inhibited P2Y12 and GPIIb IIIa receptors. Addition of ADP gives an assessment 
of P2Y12 receptor inhibiting agent clopidogrel. Activator F is added to catalyse 
the conversion of fibrinogen to fibrin and to add Factor XIIIa. MA results from 
non-inhibited platelets and fibrin. Results are referred to as MAP2 or MA-ADP. 
• AA (labelled AA-P3) and Activator F (Channel 4) – Arachidonic acid stimulation 
gives an assessment of the effect of aspirin. Activator F is added to catalyse the 
conversion of fibrinogen to fibrin and then arachidonic acid is added. The MA 
results from non-inhibited platelets and fibrin. Results are referred to as MAP3 or 
MA-AA. 
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3.2.3.3 Quality control for TEG® Platelet Mapping™ 
I performed electronic quality control every day before starting the test. This 
ensured equilibrium of the central pin and torsion wire related to baseline surface. 
This was recorded and stored digitally. Once every week, I performed quality 
control using the control sample provided by the manufacturer. This was 
repeated prior to start of each new batch of reagents, and for every 30 studies 
performed (which ever being earlier). The results were stored digitally and plotted 
in a graph. In addition, I assessed reproducibility using 8 volunteers’ samples. 
The coefficient of variation of MA thrombin was 3.7%. I operated the TEG® 
machine for all my study samples and received assistance in quality control and 
monitoring from the Coagulation services unit, Freeman Hospital, Newcastle 
upon Tyne. 
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My study protocol: 
1. Load the plain disposable cups & pins into the TEG® analysers.  
2. The lyophilised vials containing activator F(A), adenosine 
diphosphate (ADP) and arachidonic acid (AA) are taken out from storage 
at 6 degrees Celsius and gently brought to room temperature.  
3. From the cannula after the Badimon chamber study is over, blood is 
directly filled in to a sodium citrate tube (1.75 ml of blood into the tube 
containing 0.25 ml of sodium citrate) and 2 ml to lithium heparin tube (100 
units). 
4. Pipette out 1 mL blood into the kaolin vial (supplied by 
Haemoscope) at 30 min after drawing blood gently by letting it run down 
the side of the vial until it reaches the 1mL graduation mark. Re-stopper 
the vial. Mix by gentle inversion five times. Do not shake the sample. 
5. Transfer 340 μl blood from the kaolin vial (provided) into a cuvette 
in CHANNEL 1. 
6. Add 20 μl 0.2M of calcium chloride (supplied by the manufacturer). 
7. Immediately slide the carrier up and move the lever to Test position. 
8. Click on the Start button in the software main toolbar to begin 
sample run. 
9. Add 1ml of distilled water (supplied by manufacturer) each to the 
aliquot vials containing reagents A-P1, ADP-P2 and AAP3. Gently mix it by 
rolling between the hands. Avoid foam formation. 
10. Pipette 10 μL of prepared A-P1 into each plain cup. 
11. Add 10 μL of ADP-P2 into plain cup (for ADP assay) in CHANNEL3. 
12. Add 10 μL of AA-P3 into plain cup (for AA assay) in CHANNEL 4. 
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13. Pipette 360 μL of heparinised whole blood into A-P1 cup in 
CHANNEL 2. Pipette sample up and down three times in cup to mix. Slide 
the carrier up, move the lever to test and click start button. 
14. Pipette 360 μL of heparinised whole blood into ADP-P2 cup in 
CHANNEL 3. Pipette sample up and down three times in the cup to mix.  
15. Pipette 360 μL of heparinised whole blood into AA-P3 cup in 
CHANNEL 4. Pipette sample up and down three times in the cup to mix. 
Slide the carrier up, move the lever to test and click start button. 
16. The TEG® machine will start showing graphs from four of the 
channels in four different colours.  
17. Recording will automatically stop once the graph lines reach a 
steady state. It usually takes up to 90 minutes for plain kaolin added 
sample and 60 minutes for other channels. Once the study is completed, 
obtain a print out of the tracings.  
18. The results are digitally stored in the computer attached to the 
TEG® machine. 
19. After the study is over, obtain percentage inhibition. Select the Multi 
button located in the software Main toolbar to select tracings for 
computation. 
20. For the ADP assay, select the three samples with A (A-P1), ADP 
(ADP-P2), and kaolin (K) sample types. Select the Done button located in 
the software main toolbar. For the AA assay, select the three samples with 
A (A-P1), AA (AA-P3), and kaolin (K) sample types.  
21. Select the Done button located in the software Main toolbar. The 
percentage inhibition will be displayed in the screen. 
 
Table 3.2 Study protocol for Thromboelastography® (TEG) and Platelet 
Mapping™.  
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3.2.4 Measurement of Optical aggregation by VerifyNow® assay 
3.2.4.1 Physical principles of VerifyNow® 
VerifyNow® (Accumetrics, CA, USA) is a point of care platelet function assay 
which measures platelet aggregation employing the principles of optical 
aggregation and turbimetry. VerifyNow® is a microprocessor-controlled,  
cartridge-based, software driven  automated assay that measures the antiplatelet 
effect of aspirin, P2Y12 antagonists and glycoprotein IIb IIIa antagonists in whole 
blood. The results are displayed in a digitised format. 
VerifyNow® uses turbimetric principles to measure platelet aggregation in 
response to various agonists such as ADP, prostacyclin E1 and thrombin 
receptor activating peptide (TRAP). It uses similar principles employed in “gold 
standard” light transmission aggregometry (LTA). The VerifyNow® System 
consists of a cartridge with four wells containing various agonists of platelet 
aggregation. After adding whole blood to the wells, using a light source and an 
optical sensor with the cartridge placed in between, platelet induced aggregation 
is measured as decrease in light transmittance. The assay device contains a 
lyophilised preparation of human fibrinogen coated beads and a platelet agonist, 
either arachidonic acid or adenosine diphosphate (ADP). Light scattering will 
occur depending on the ability of platelet glycoprotein IIb IIIa receptors to bind to 
fibrinogen coated beads. The effective platelet inhibition with antiplatelet therapy 
is measured by the changes in light transmittance using arbitrary (dimensionless) 
units.  The greater the effect of antiplatelet therapy there will be more platelet 
inhibition. This will lead on to less platelet aggregation and less light 
transmittance and thereby will record lower reactive units. 
I used different types of cartridges to measure aspirin induced platelet 
suppression and clopidogrel induced platelet suppression respectively. 
Cartridges were purchased from the manufacturer and the whole assay has been 
performed according to the manufacturer’s instruction. Due to unforeseen 
problems with the distributors and supply chain of the cartridges, the assay was 
performed for half of ACS study participants but all of the stable CAD study 
participants. 
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In one channel of the assay cartridge, prostaglandin E1 (PGE1) (22 nM) is 
incorporated with ADP (20 μM). The values measured are reported by the device 
as P2Y12 reactive units – activated (PRUz).  In a separate channel iso-thrombin 
receptor activating peptide (iso-TRAP) is used as an agonist to measure platelet 
aggregation independent of the effects of P2Y12 receptors; this value is regarded 
as baseline or PRUb. The VerifyNow® P2Y12 assay reports the results as P2Y12 
Reaction Units (“PRUz”), “% Inhibition” and “baseline PRUb”. Percentage 
inhibition due to clopidogrel (P2Y12 antagonist), “% Inhibition” is calculated as (1-
PRUz/PRUb) X100. If clopidogrel has produced significant platelet suppression, 
the PRUz values will be lower and the percentage inhibition will be higher. There 
is no universal agreement on the cut off used to measure platelet inhibition. I 
have chosen PRUz of 240 as a cut off and percentage inhibition of less than 40% 
as a cut off for high on treatment platelet hyperactivity to clopidogrel (“hypo 
responders”) based on a landmark paper (Marcucci et al., 2009). Patients with 
ARU ≥495 were classified as high on treatment platelet reactivity to aspirin 
(“hyporesponders”) (Paniccia et al., 2007). 
3.2.4.2 Performance of VerifyNow® assay 
Blood was collected in sodium citrate tubes (0.105M, 3.2% sodium citrate + citric 
acid, pH 5.2, Catalogue number 367691, BD Vacutainer®) and gently mixed by 
inverting 5 times. After leaving the sample static for 30 minutes, the cartridges 
were taken out of the sealed pouch and inserted into the well. The citrated blood 
tube was inverted gently again 5 times and fixed to the needle inside the 
cartridge. The assay device assembly was closed with a cover. Platelet 
aggregation usually proceeded for 3 to 6 minutes and the results were displayed 
as respective units (PRU or ARU). My detailed study protocol was given below. 
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Figure 3.15 Verify Now® assay principles.  
 
The cartridge used in VerifyNow® assay consists of fibrinogen coated beads in 
the four chambers at its bottom (top picture). Blood drawn from the patient mixes 
with these beads and produces aggregation stimulated by a specific agonists like 
ADP or arachidonic acid. The amount of platelet bead aggregation depends on 
the level of residual antiplatelet activity and will result in differential light 
transmittance. The emitted light is read by a sensor and the results will be 
displayed as a dimensionless unit (e.g. ARU, PRU). 
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My study protocol: 
1. After performing electronic QC, enter patients study ID in the device and 
press OK. 
2. Draw 2ml of blood into two 3.2% (0.105M) citrated plasma glass tubes 
(BD vacutainer, Oxford, UK) after the Badimon chamber experiments are over. 
3. Mix the blood gently by turning upside down five times. 
4. At 30 minutes, open the aspirin assay device (cartridge) from the pack. 
Check purple colour indicator for product quality control. If there is any 
decolourisation, discard the assay device.  
5. Handle aspirin device from the top taking care not to touch the sensor 
portion at the bottom. Insert the device firmly into the column. 
6. Remove the needle cover by single outward motion. This will avoid 
needle injuries. 
7. Mix the blood sample gently 5 times and then insert the tube upside 
down into the well where the needle is located. 
8. Close the cover of the assay device to make it lightproof. 
9. After 180 seconds, results will be displayed as ARU. 
10. Remove aspirin assay device and discard in a sharps container. 
11. Remove P2Y12 assay device (cartridge) from the pouch taking care not 
to touch the bottom panel. 
12. Check for the purple colour to ensure quality control. If there is any 
decolourisation, discard the device. 
13. Handle P2Y12 device from the top taking care not to touch the sensor 
portion at the bottom. Insert the device firmly inserted to the column. 
14. Remove the needle cover by single outward motion. Mix the blood 
  
130 
sample gently 5 times and then insert the tube upside down into the well where 
the needle is located. 
15. Close the cover of the assay device to make it lightproof. 
16. At 360 seconds, results will be displayed as PRUz, PRUb and 
percentage inhibition. 
17. Note the results and record them in a folder named as ‘accumetrics only’. 
18. Remove the assay device with vacutainer tube and discard it in a sharps 
box. 
19. Clean the surface with 70% alcohol wipes and close the cover. Switch off 
the device. 
Table 3.3 Study protocol for VerifyNow® assay.  
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3.2.4.3 Quality control 
VerifyNow® incorporates its own manufacturer specified quality control. An 
automatic error message would be displayed as “attention” with a diagnostic 
code, if the results fall outside the wider range for ARU or PRU. I performed an 
electronic quality control (EQC) every day using the standard assay device 
supplied by the manufacturer. I performed a wet quality control assay (supplied 
by the manufacturer) for both aspirin and clopidogrel cartridges once a month 
and at every time a new batch of assay devices was used. In addition, I tested 
reproducibility annually using 10 healthy volunteers measured twice on the same 
day. The coefficient of variation of ARU was 3.7% and for PRUz 4.2% and the 
results of ARU were (median, IQR) 602, 624-596 and PRUz were 324, 306- 342. 
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3.2.5 Electrical impedance analysis of thrombus using Multiplate® 
impedance aggregometry 
3.2.5.1 Physical principles 
The Multiplate® whole blood aggregometer evaluates platelet aggregation by 
measuring the changes in impedance of whole blood during the process of 
thrombogenesis. The Multiplate® assay uses the original principles of whole 
blood impedance platelet aggregometry (IPA) introduced in 1980 by Cardinal 
and Flower (Francis, 1987). Even though the earlier devices have been widely 
used in coagulation laboratories, the reproducibility was affected by the short life 
of the electrodes and presence of residual thrombus after each test. The 
Multiplate® device overcomes these problems by using individual disposable 
test cells with integrated electrodes and use of twin electrodes. 
Blood is a very good conductor of electricity in its fluid state. When electricity is 
passed across the blood via metal electrodes, the electrical resistance is almost 
negligible when it is in fluid state. However, when thrombus forms, platelets tend 
to form a sheet over the electrodes and produce resistance to the flow of 
electrons from cathode to anode plates. When more thrombus is formed, the 
electrical impedance increases proportionately to the platelet aggregation. A 
change in electrical impedance which is a reflection of platelet aggregation is 
measured as a continuous variable over time (Figures 3.15 and 3.16). The 
maximum increase in electrical impedance thus reflects platelet activity and can 
be plotted as a graph. When a specified quantity of platelet agonist is added to 
the whole blood of patients taking antiplatelet agents, the changes in impedance 
will reflect residual platelet reactivity and can be used to assess the response of 
these agents. 
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Figure 3.16 Multiplate® impedance assay.  
Schematic diagram of the cartridges and platelet aggregation inside the cuvette is 
presented here. When electricity is passed across the blood via metal electrodes, 
the electrical resistance is almost negligible when it is in fluid state. However, 
when thrombus forms, platelets tend to form a sheet over the electrodes and 
produce resistance to the flow of electrons from cathode to anode plates. When 
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more thrombus is formed, the electrical impedance increases proportionately to 
the platelet aggregation. A change in electrical impedance which is a reflection of 
platelet aggregation is measured as a continuous variable over time. The 
maximum increase in electrical impedance thus reflects platelet activity and 
displayed as a graph. 
 
 
 
Figure 3.17 Platelet function tests performed by Multiplate® aggregometry.  
Schematic diagram showing various platelet function tests performed by 
Multiplate® aggregometry is presented here. Most commonly used test, ADPtest 
measures platelet inhibition of P2Y12 antagonists such as clopidogrel. ASPItest 
measures the activity of aspirin using arachidonic acid as a stimulus. COLtest 
measures the platelet inhibitory effects of either of the agents upon stimulation 
with collagen. TRAPtest measures the platelet reactivity upon stimulation by 
thrombin receptor activating peptide. 
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3.2.5.2 Multiplate® assay procedure 
Whole blood impedance aggregometry was carried out using the novel 
Multiplate® analyser (Dynabyte medical, Munich, Germany) according to 
manufacturer’s guidelines. Twenty eight patients from stable CAD study 
underwent assessment as a pilot study. Whole blood sample collected from 
patients in hirudin tubes was first incubated to 37 °C in a cuvette supplied by the 
manufacturer called the ‘test cell’. Each disposable test cell has a pipette intake, 
a cup portion with the dual electrode sensor unit protruding into the blood which 
is stirred by a teflon coated magnet at 800 rpm and a jack portion which connects 
the test cell to the device via an electronic cable and records the electrical 
impedance between the sensor wires. The dual sensor units consist of silver-
coated, highly conductive copper sensor wires of 0.3 mm diameter and 3.2 mm 
length. When thrombus begins to form, platelets become attached to the metal 
electrodes of the sensor unit, leading to a change in the electrical conductivity (or 
impedance), which is continuously recorded. The study was continued for 6 
minutes till steady state electrical impedance was reached. Results are displayed 
as a graph in arbitrary units namely: 
i) platelet aggregation (AU, maximal aggregation) 
ii) velocity of aggregation (slope of the curve) 
iii) area under curve (AUC) 
Of these three parameters, I chose to use maximal aggregation (AU) as it was 
the most reproducible parameter and has been studied in clinical context (Sibbing 
et al., 2010b; Kim et al., 2011). The Multiplate® analyser has five test cells, thus 
enabling us to study the effect of five different platelet agonists. 
Step by step study method is described below. Briefly, 154 mmol/l sodium 
chloride solution (300 μL) was pre-heated to 37 °C and pipetted into the test cells 
and 300 μL of blood sample anticoagulated with hirudin, was added to achieve a 
1:1 dilution. After 3 min incubation and stirring using a magnetic stirrer at 37 °C, 
20 μL of the agonist solution (e.g. ADP, arachidonic acid, collagen or thrombin 
receptor activating peptide) was added. The results were displayed as a graph 
with dual lines each representing a single pair of electrodes and displayed as two 
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aggregation curves, serving as an internal control. I used duplicate 
measurements as my internal quality control as recommended by the 
manufacturer. If the area under the curve (AUC) differed by >20% for the two 
curves and or their correlation coefficient was <0.98, the study results were 
discarded and the whole process was repeated. The mean value from the graphs 
was displayed as ‘aggregation units’ (AU). Whole blood samples of 1.2 ml from 
each patient were used to study the effects of four agonists, namely arachidonic 
acid, ADP, collagen and thrombin. 
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My study protocol 
1. Draw 2ml of blood in hirudin vacutainer supplied by the manufacturer. 
2. Gently mix the blood and leave it to stand. 
3. Start the study 35 minutes after blood collection. 
4. In the meantime, switch on the Multiplate® analyser. It will take 20 
minutes to warm up. 
5. Perform electronic quality control every day. Follow the commands 
“Multi Plate"  "Electronic Control"  "Electronic monitoring”   “Run”. 
The values should match the controls in all the five channels. 
6. Enter patient ID and select tests, ADPtest, ASPtest, Coltest, TRAPtest.  
7. Bring the lyophilised vials of the reagents ADP, ASP, Col and thrombin 
to room temperature. 
8. Mix each with 1 ml of distilled water supplied by the manufacturer. 
Gently swirl for thorough mixing. 
9. Divide the reagents to small aliquot tubes each 100 µl and label them 
with name and date. AA, ADP and thrombin mixture is stored at -20 deg C 
and collagen mixture is stored at 5-6 deg C. All the reagents are labelled with 
an expiry date, one week from the date of preparation. 
10. Insert four test cells into the machine and connect them to the sensor 
cable firmly. 
11. Using autopippete (or change to manual) put 300 µl of blood from 
hirudin tube.  
12. Add 300 µl 154 mmol/l saline. 
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13. For ADP test, add 20 µl of the reconstituted ADP reagent (5 µM of 
ADP). 
14. Allow 3 minutes of incubation. 
15. Add 20 µl of activator to the test cell. 
16. The reaction starts and platelet aggregation will be displayed as a 
graph with two lines. 
17. The test will run for 6 minutes and final results are printed out. 
18. For ASP (aspirin), TRAP (Thrombin) and Coll(collagen) reagents, 
repeat steps 11 to 16 in respective channels with a different test cell. 
19. Once the test is completed, remove the test cells after disconnecting 
the cables and dispose them in the sharps disposal container. 
20. If the COV between the recorded curves is more than 2% or there was 
>20% difference in AUC readings, discard the results and repeat again. The 
repeat recording was taken for analysis. 
Table 3.4 Study protocol for Multiplate® impedance aggregometry.  
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3.2.6 Biomarker assay in serum and plasma samples 
3.2.6.1 Sample collection and storage 
Serum and plasma samples for special biomarker assays were collected at the 
end of Badimon chamber study from venous cannula and effluent blood from the 
chamber. 
Following biomarkers were assayed on the stored samples 
i. Soluble P selectin 
ii. Soluble CD40 ligand 
iii. Interferon gamma (IFNγ) 
iv. Interleukin 1 
v. Interleukin 6 
vi. Tumour necrosis factor alpha (TNF α) 
vii. Plasminogen activating factor inhibitor 1 (PAI-1) 
 
 
For all samples other than PAI-1, the following methods of collection and storage 
were used. 
i. Serum samples (pre chamber venous sample) 
Venous blood (5ml) was collected from the antecubital vein at the end 
of the chamber study using the same cannula in plain glass test tubes. 
The sample was allowed to settle for 10 minutes and serum was 
separated and stored in two aliquots of 1 ml each after centrifuging the 
sample at 1550g (3000 rpm) for 10 minutes. The samples were stored 
at  minus 80 degrees and were thawed just before the analysis 
ii. Activated serum samples (post chamber activated blood) 
Blood samples were collected from the effluent of the post chamber. 
Effluent blood from the chamber was traditionally discarded. However, I 
hypothesised that the effluent blood consists of coagulation markers 
secondary to shear and collagen activated platelets and is more likely 
representative of the blood in the local milieus than the standard 
venous blood.  The difference in levels of blood cytokines in flowing 
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and effluent blood is likely to reflect the cytokines used in the 
organising thrombus. Samples were collected exactly between 3rd and 
5th minute of Badimon chamber experiment and were stored in a 
similar fashion to pre chamber-standard venous samples 
For assessment of plasma PAI-1 levels, I used 3.2 N sodium citrate tubes 
(Grainer-bio one, GmbH) instead of plain glass tubes and used same collection 
and storage methods as above. 
3.2.6.2 Measurement of P selectin 
P selectin was measured in serum samples according to manufacturer’s 
instructions (R&D systems, Abington, UK, Human sPselectin/P62, SBBE6). 
Quality control for P selectin was performed using the standards supplied by the 
manufacturer.  I used 4 parameter logistic curve fitting method (Masterplex 
software, Hitachi Solutions America, Ltd., CA, USA) to derive soluble P selectin 
values from optical density values. Studies were done with duplicates and 
samples from normal controls to ensure assay precision. In addition, using 30 
volunteer samples analysed on two separate plates randomly chosen, the mean 
inter plate variability was 3.6%. Eight volunteer samples collected on three 
occasions on three different days were analysed, giving a day-to-day coefficient 
of variability of 2.4%. 
3.2.6.3 Measurement of soluble CD40 ligand 
Soluble CD40 ligand was measured in serum samples according to 
manufacturer’s instructions (R&D systems, Abington, UK, Human sCD40L, 
DCDL40 and quality control kit lot number 1242552-54). I used 4 parameter 
logistic curve fitting method (Masterplex software, Hitachi Solutions America, 
Ltd.CA, USA) to derive soluble CD40L values from optical density values. Studies 
were done with duplicates and samples from normal controls to ensure assay 
precision. Quality control for CD40 ligand was performed using the standards 
supplied by the manufacturer. Standard values matched with my assay values in 
all the plates. I also tested 30 volunteer samples and the mean inter plate 
variability was 5.4% as paired samples. Eight samples were repeated on three 
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different days and the results had a coefficient of variability of 8.6% for day to 
fluctuations. Patient samples were studied in duplicates to improve accuracy. 
3.2.6.4 Measurement of Plasminogen activator inhibitor -1 (PAI-1) 
I performed PAI -1 antigen ELISA assay on plasma samples using Technozym® 
PAI-1 antigen ELISA kit, TC12075, Technoclone GmbH, Vienna, Austria as per 
manufacturer’s instructions. All samples were collected between 08.00 am and 
10.00 am to minimise variations in PAI-1 due to circadian rhythm.  I did my 
experiments in the nationally accredited coagulation laboratory at Freeman 
Hospital, Newcastle upon Tyne under the supervision of the chief technician and 
my protocol was tested with standard samples to ensure reproducibility. 30 
volunteer samples were assayed with a mean COV of 2.3%. 
3.2.6.5 3.2.6.5Measurement of serum cytokines 
I used a novel multi array platform with electro-chemiluminescence (Meso Scale 
Devices, Gaithersburg, MD, USA). Electro-chemiluminescence (ECL) is a well 
studied alternative to conventional ELISA colorimetric methods. It is highly 
sensitive but unaffected by residual serum factors or plasma proteins in the test 
cell matrices. (Blackburn et al., 1991; Swanson et al., 1999; Yuan et al., 2003; 
Horninger et al., 2005; Chowdhury et al., 2009; Rhyne et al., 2009; Thway et al., 
2010). Background signals are minimised in ECL because the stimulation 
mechanism (electricity) is decoupled from the signal (light) which also improves 
its detection range (Deaver, 1995). N-hydroxy-succimide biotin and ruthenium are 
used to generate chemiluminescence upon stimulation by electrodes. In addition, 
use of multiplex technology enables the analysis of large panels from small 
volume samples (Toedter et al., 2008; Fu et al., 2010). The intricate details of this 
assay are beyond the scope of this thesis. 
MSD platform used in this study was a 96-well plate-based assay that 
incorporated electro-chemiluminescence as the basis for detection. Following the 
capture of the cytokine by the spotted antibody, labelled detection antibodies 
were bound to the cytokines in a sandwich manner. The detection antibodies 
were attached to electro-chemiluminescent labels that emitted light when 
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electrochemically stimulated via carbon-coated electrodes in the bottom of the 
array wells. A detection buffer was added prior to the reading of the assay to 
enhance the electrochemical signal. The resulting signal was read using a photo 
detector in a charge-coupled device (sector reader) available in Institute of 
Cellular Medicine, Newcastle University. Duplicates were run as 1:1 and the 
reproducibility of the results was excellent with a COV of 2.1% in 30 volunteer 
samples tested in all the six plates. Eight volunteer samples were repeated on 
three different days and the results showed a COV of 3.8%. 
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3.2.7 Quantification of coronary atheroma using Gensini scoring system 
3.2.7.1 Gensini score 
Coronary atheroma is routinely quantified using diagnostic clinical angiography in 
clinical practice. I aimed to study the association between atheroma burden and 
blood thrombogenicity after an acute coronary event. In order to assess coronary 
atheroma burden, various scoring systems based on luminal stenosis in 
epicardial coronary arteries as visualised by angiography have been devised. I 
chose the Gensini scoring system to quantify coronary atheroma as it is time 
tested, easy to score manually and well validated (Austen et al., 1975; Falciani et 
al., 1998; Blanco-Colio et al., 2007). Coronary angiographic images of patients 
who were included in the ACS study were reviewed and Gensini scores were 
assigned to each patient (Figure 3.18). 
3.2.7.2 Calculation of Gensini score 
Diagnostic coronary angiographic images of both the left and right coronary 
arteries were retrieved from the archives for each patient, and each segment was 
systematically examined. A score was assigned based on the degree of luminal 
obstruction, which included both concentric and eccentric lesions. Points were 
assigned starting at 25% occlusion, with values doubled for each increasing level 
of occlusion. The point assignment was based on the angiographic estimate of 
percentage occlusion. The score for each segment was then multiplied by a 
weighting factor, which reflected the relative importance of that particular 
coronary segment. The Gensini score is the summative value of the scores of the 
individual coronary segments. 
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Gensini score = SUM [(points for each segment) X (weighting factor)] 
I devised modified Gensini score by giving equal points to each segment with 
lesions. 
Modified Gensini score = Total Number of segments with more than 25% 
occlusive lesions. 
Ten randomly selected angiograms were assessed for both inter and intra 
observer variability. Inter-observer co-efficient of variability was 12.4% and intra-
observer CV by myself was 1.8%. 
 
 
Level Percent Occlusion Points 
0 None 0 
1 25% 1 
2 50% 2 
3 75% 4 
4 90% 8 
5 99% 16 
6 100% 32 
Table 3.5 Gensini Score points 
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Coronary 
Artery 
Artery Weighting 
Factor 
right proximal 1 
 mid 1 
 distal 1 
Left main 5 
 LAD proximal 2.5 
 LAD mid 1.5 
 primary diagonal 1 
 secondary diagonal 0.5 
 apical 1 
 circumflex proximal 2.5 
 circumflex distal 1 
 obtuse marginal 1 
 posterolateral 0.5 
left or right posterior descending 1 
Table 3.6 Gensini score weighting factor.  
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Figure 3.18 Gensini scoring system for coronary atheroma.  
Coronary arterial tree is sub divided in to various segments as proximal, mid and 
distal part of the artery. Weightings are given according to the amount of 
myocardium supplied by that segment of the artery.  Any segment with luminal 
narrowing more than 25% is taken as significant stenosis. After multiplying with 
the weightage factor, a segmental score is assigned. Summation of individual 
segmental scores will give the final Gensini score. 
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Chapter 4 Results and discussion 
4.1 Platelet dependent thrombosis in T2DM 
4.1.1 Results – Platelet dependent thrombosis in ACS study 
For this observational cohort study, I screened 271 patients who were admitted 
with a diagnosis of NSTE-ACS between 2008 and 2011. I invited 90 eligible 
patients to take part in the study and 80 patients (40 T2DM and 40 non DM 
controls) who were treated as per current AHA/ESC guidelines including aspirin 
75mg od and clopidogrel 75mg od for one week, have completed the Badimon 
chamber experiments (Figure 3.1). Details of patient selection and patient’s 
journey through the study protocol were explained in chapter 2: General methods 
section. 
Baseline data is shown in Table 4.1. Baseline characteristics showed no 
statistical differences between the groups despite numerically higher values of 
blood pressure and serum creatinine in those with T2DM. By virtue of their 
selection, T2DM had higher HbA1c, plasma glucose, serum triglyceride levels 
and BMI. There was a higher prevalence of treated hypertension and 
dyslipidaemia among those with T2DM reflecting their metabolic syndrome 
phenotype. LDL cholesterol levels were lower in T2DM compared to those 
without DM. 
Patients with T2DM had higher thrombus compared to those without T2DM, total 
thrombus area from high shear chamber was (in µ2 per mm, mean±SD) 
20,414±12,344 vs. Non DM 14,933±8,415 p=0.023, 95% CI of the difference 
between the two groups was 811 – 10674 (Table 4.2, Figure 4.1, Figure 4.2a). In 
view of the skewed nature of the data, I log transformed the values (Figure 4.2b) 
for statistical analysis. Higher thrombus was also seen in low shear chamber (µ2 
per mm, mean±SD, 11313±4526 vs. 8755±3492, p=0.006). Fibrinogen was 
higher in T2DM and had a significant correlation to thrombus (r=0.283, p=0.013) 
which was lost when multiple regression analysis was performed. 
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Figure 4.1 Thrombus images from ACS study  
Thrombus was higher in T2DM in both high and low shear states. Thrombus 
images were stained with modified Mason trichrome stain. Platelet dependent 
thrombus was stained in red (solid white arrows) and tunica media was stained 
with green and pinkish hue (solid black arrows). Thrombus was seen adherent to 
the tunica media which was exposed to the flowing blood in the Badimon 
chamber
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 T2DM (n=40) Non T2DM 
(n=40) 
P value 
Demographic data Mean±SD or %(n) 
Age, years 63.8±12.2 62.2±11.4 0.553 
Male gender, % (n) 67.5 (27) 90.0 (36) 0.027 
Body mass index, kg/m2 33±8.3 30±5.0 0.029 
Waist to hip ratio 1.0±0.05 1.0±0.05 0.422 
Systolic BP, mmHg 130±18.9 125±19.7 0.212 
Diastolic BP, mm Hg 73±11.6 69±8.0 0.137 
Risk profile: %(n) 
History of hypertension 77.5 (31) 45.0 (18) 0.003 
History of dyslipidaemia 90.0 (36) 42.5 (17) 0.001 
History of chronic kidney disease 27.5 (11) 15.0 (6) 0.172 
History of acute myocardial infarction 27.5 (11) 12.5 (5) 0.094 
Medications: %,(n) 
B blockers 82.5 (33) 97.5 (39) 0.057 
Calcium channel blockers 37.5 (15) 17.5 (7) 0.055 
Laboratory data: mean±SD 
HbA1c, % 7.5±1.5 5.8±1.4  
Random plasma glucose, mmol/l 11.2±6.8 6.3±1.7  
Fasting plasma glucose, mmol/l 7.8±3.1 5.2±0.8  
Haemoglobin, g/dl 13.2±1.8 14.0±1.3 0.027 
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 T2DM (n=40) Non T2DM 
(n=40) 
P value 
Platelets, x1000/mm3 254±89.9 246±68.2 0.685 
Fibrinogen, g/l 4.2±0.8 3.5±1.4 0.012 
S Creatinine, µmol/l 111±65.0 104±28.3 0.560 
HsCRP, mg/l 10.9±9.7 3.6±3.2 0.001 
Total cholesterol, mmol/l 3.4±1.0 3.8±0.9 0.135 
LDLc, mmol/l 1.6±0.6 1.9±0.9 0.023 
HDLc, mmol/l 1.0±0.3 1.1±0.4 0.301 
Triglyceride, mmol/l 1.9±1.2 1.5±0.6 0.048 
Troponin I, µg/l 6.9±10.2 7.0±12.7 0.974 
Table 4.1 Baseline characteristics for ACS study.  
 
Mean thrombus 
area, µ2/mm, 
Mean±SD 
T2DM (n=40) Non T2DM(N=40) P value 
High shear chamber 20414±12344 14933±8415 0.023 
Low shear chamber 11313±4526 8755±3492 0.006 
Table 4.2 Thrombus area for ACS study.  
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Figure 4.2 a Thrombus area study 1 (ACS patients).  
 
Figure 4.2 b Log transformed values.  
Mean area of thrombus, measured in 2/mm. T2DM = Type 2 diabetes mellitus. 
Patients with T2DM had higher thrombus after NSTE-ACS despite current 
optimal secondary prevention therapy. Total thrombus area in T2DM [(µ2/ mm, 
mean±SD,) 20,414±12,344 vs. Non DM 14,933±8,415 p=0.023, 95%CI of the 
mean difference was 811 – 10674]. In view of the skewed nature of the data, we 
log transformed the values before analysing and Figure 4.2b represents bar chart 
with log transformed values. 
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4.1.2  Discussion – Platelet dependent thrombosis in ACS study 
Patients with T2DM have more thrombotic events and poorer prognosis 
compared to those without T2DM despite current aggressive secondary 
prevention therapy both in NSTE-ACS setting and stable CAD setting. Current 
international society guidelines (AHA/ACC/EHA) recommend similar secondary 
prevention therapies to these high risk patients compared to those without T2DM 
(Anderson et al., 2007; Fraker et al., 2007; Wright et al., 2011). 
The findings from ACS study are important as  
i. This is the largest cohort of patients studied after NSTE-ACS using the 
Badimon chamber 
ii. Participants were on all recommended secondary prevention therapy and 
were chosen based on a strict eligibility criteria to minimise confounding 
variables 
iii. Data provides a focus for studies of mechanisms underlying the 
observational data of higher recurrent thrombotic event rates in T2DM 
following NSTE-ACS (Cho et al., 2002),(Lee et al., 2004; Bhatt, 2008) 
My findings argue against the current identical recommendations for secondary 
prevention therapy in patients with and without T2DM, and suggest that either a 
more targeted and or more aggressive approach to antithrombotic treatment is 
required in T2DM patients after NSTE-ACS. Studies have confirmed higher 
recurrent thrombotic event rates in T2DM following NSTE-ACS, despite optimal 
secondary prevention therapy but the underlying mechanisms are not clearly 
defined (Bartnik et al., 2005; Donahoe et al., 2007). In trials of more potent 
antiplatelet therapies, the outcomes in patients with diabetes and acute coronary 
syndromes have not improved to levels seen in those without T2DM: in trials of 
newer antiplatelet agents ticagrelor and prasugrel, The Study of Platelet Inhibition 
and Patient Outcomes (PLATO)  and Trial to Assess Improvement in Therapeutic 
Outcomes by Optimizing Platelet Inhibition with Prasugrel–Thrombolysis in 
Myocardial Infarction (TRITON–TIMI), the active arm still had a one year mortality 
of 7.2% and 12.2%, respectively, in patients with diabetes. This suggests that in 
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T2DM we may need to target therapy beyond platelets (Wiviott et al., 2008a; 
James et al., 2010). 
The failure of more potent antiplatelet drugs, and tight glycaemic, lipid and blood 
pressure control in T2DM to reduce vascular event rates to levels seen in the 
non-diabetic population is testament to the need for ongoing studies specifically 
in this patient population (Sobel, 2007; Balasubramaniam et al., 2012).  The 
recently presented trial on intensive weight reduction and risk factor control in 
T2DM did not reduce cardiovascular events(The Look Ahead Research Group, 
2013). Prothrombotic tendency of those with T2DM has been supported by 
studies on individual platelet and coagulation factor abnormalities but their 
contribution to increased thrombus has been speculative (Carr, 2001; Grant, 
2007; Tufano et al., 2011; Vazzana et al., 2012). 
My findings suggest that persistently raised blood thrombogenicity (“vulnerable 
blood”) after discharge from hospital following NSTE-ACS is an important 
contributory factor for recurrent events in T2DM and a focus for targeted therapy 
given the failure of glycaemic and risk factor control to reduce macrovascular 
events in the diabetic population (Skyler et al., 2009). Patients with T2DM had 
higher levels of fibrinogen, a consistent finding reported previously (Kannel et al., 
1990; McBane et al., 2010; Zhao et al., 2011) and this association was lost when 
regression analysis was performed.  My findings were from a smaller cohort and 
the association between fibrinogen and whole blood thrombus in T2DM is yet to 
be shown in a large cohort. I studied the effects of a prototype P2Y12 antagonist 
clopidogrel. Nevertheless, even in trials of more potent oral antiplatelet agents 
(prasugrel and ticagrelor), patients with T2DM had a 20% increased risk of 
recurrent cardiac events in the first year after the index coronary event, 
suggesting that more potent antiplatelet agents may not completely neutralise the 
higher thrombus burden in T2DM (Wiviott et al., 2008b; James et al., 2010). 
Overall, there is very little published data on PDT in the diabetic population with 
ACS and in that aspect my findings are new and so should be confirmed by 
another large scale study. The finding of greater thrombus in T2DM may not be 
entirely surprising as many of the published studies on surrogate haematological 
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markers such as  P selectin, tissue factor and thromboxane have suggested the 
possibility of  greater whole blood thrombus in this high risk population(Lim et al., 
2004; Mason et al., 2005; Meerarani et al., 2007; Stellos et al., 2010; Badimon et 
al., 2011). It is possible that hyperglycaemia could have been the major factor 
responsible for high thrombus burden in T2DM but only a few studies have 
shown that improvement in glucose control reduces the markers of 
thrombogenicity (Becker et al., 2003; Lemkes et al., 2010; Neubauer et al., 2010). 
A small study from Badimon et al showed good correlation with glycaemic control 
and reduction in platelet dependent thrombosis (Osende et al., 2001). 
Persistence of high thrombogenicity in T2DM could be due to either the relative 
lack of efficacy on “hyperactive platelets” with current antiplatelet therapy or the 
presence of powerful non-platelet mediated factors (e.g. fibrinogen, 
inflammation). Nevertheless, my findings are supported by a significant 
proportion of the literature which argues that current secondary prevention 
therapies for patients with T2DM after ACS are sub optimal (Cayla et al.; 
Angiolillo et al., 2008b; Fuster and Farkouh, 2008). 
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4.1.3 Results – Platelet dependent thrombosis in CAD study 
The stable CAD study was a double blinded placebo controlled randomised 
control study. Of 149 patients assessed for eligibility, 90 were found eligible and 
completed the study (Figure 3.2). Details of patient selection were explained in 
general methods section. 
Differences in baseline data between the clopidogrel and placebo group were not 
statistically different despite lower BMI and higher number of insulin treated 
individuals in the clopidogrel group (Table 4.3). Duration of T2DM was not 
statistically higher in patients who had clopidogrel (10 years vs. 7 years). Two 
thirds of patients in both the groups received metformin and one fifth of the 
patients received insulin as a part of glucose lowering treatment. For my study, 
T2DM was managed by clinicians with special interest in diabetes and I have not 
influenced their choice of therapies. Mean HbA1c was 7.5% (DCCT aligned) and 
mean fasting blood glucose was 8.0 mmol/l. 
Thrombus measurements at baseline (visit 1) and 1 week after 75mg od 
clopidogrel therapy (visit 2) are shown in Table 4.4, Figure 4.3a and Figure 4.3b. 
At baseline, both clopidogrel and placebo groups had similar thrombus area in 
high shear chamber (thrombus area in µ2/mm, mean±SD, 13978±5502 vs. 
13959±7038 p = 0.988).  In patients who had clopidogrel therapy, the thrombus 
area reduced from (thrombus area in µ2/mm, mean±SD) 13978±5502 to 
11192±3764 (mean change in the thrombus area 3035 µ2/mm, 95% confidence 
interval 1437-  4633, p<0.0005). Thrombus area remained unchanged in placebo 
group (13959±7038 vs. 14208±6780, p=0.519, Figure 4.4).  Similar findings were 
seen in low shear chamber. No major bleeding events were noted during the 
study period and two patients in clopidogrel group and one patient in placebo 
group reported minor bleeding from gums. 
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In a post hoc analysis combining both the studies, the thrombus area was 
greatest in  patients with ACS and T2DM  and lowest in patients with stable CAD 
and T2DM who had aspirin and clopidogrel therapy (µ2/mm, mean±SD 
24414±12344 vs. 11192±3764, p=0.001). Mean thrombus area of non diabetic 
ACS patients was not different to that of diabetic patients with stable CAD and 
treated with aspirin only (µ2/mm, mean±SD, 14933±8415 vs. 14208±6780, 
p=0.742) (Table 4.5, Figure 4.5). 
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Figure 4.3 a and b Thrombus images from stable CAD study.  
Thrombus was reduced after clopidogrel therapy in both the high and low shear 
states. Thrombus remained unchanged in placebo group.  
Thrombus images were stained with modified Mason Trichrome stain (vide 
supra). Platelet dependent thrombus was stained in red (solid white arrow) and 
tunica media was stained with green and pinkish hue (solid black arrow). 
Thrombus was seen adherent to the tunica media which was exposed to the 
flowing blood in the Badimon chamber. 
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 Clopidogrel + 
aspirin (n=45) 
Placebo + 
aspirin 
(n=45) 
P value 
Demographic data: Means or %(n) 
Age, years 65±8.1 64±7.2 0.546 
Male gender, % (n) 82.2 (37) 84.4 (38) 0.777 
Body mass index, kg/m2 31.8±4.8 33.2±6.3 0.260 
Waist to hip ratio 1.0±0.1 1.0±0.1 0.139 
Systolic BP, mmHg 143±18.4 139±20.7 0.257 
Diastolic BP, mmHg 77±10.2 78±9.3 0.897 
Duration of diabetes, years 10±7.0 7±4.3 0.712 
Risk profile: %(n) 
Angina 68.9 (31) 64.4 (29) 0.655 
Previous MI 40.0 (18) 42.2 (19) 0.830 
PCI 28.9 (13) 28.9 (13) 1.000 
CABG 28.9 (9) 20.0 (9) 0.327 
Chronic kidney disease 11.1 (5) 22.2 (10) 0.157 
Medications: %,(n) 
Sulphonylurea 26.7 (12) 26.7 (12) 1.000 
Metformin 64.4 (29) 64.4 (29) 1.000 
Insulin 24.4 (11) 20.0 (9) 0.800 
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 Clopidogrel + 
aspirin (n=45) 
Placebo + 
aspirin 
(n=45) 
P value 
Laboratory data: mean±SD 
Haemoglobin,  g/dl 13.6±1.4 13.7±1.3 0.817 
Platelets X1000 cells/ mm3 227±55.5 225±56.6 0.880 
Fibrinogen, g/ml 3.4±0.6 3.4±0.8 0.560 
HbA1c, % 7.5±1.2 7.5±1.1 0.957 
Fasting plasma glucose, 
mmol/l 
7.9±2.6 8.3±2.4 0.947 
eGFR,  ml/min/1.73m2 72±20.6 76±19.4 0.332 
Total cholesterol, mmol/l 3.4±1.0 3.8±0.9 0.542 
LDLc, mmol/l 1.9±0.7 1.9±0.7 0.910 
HDLc, mmol/l 1.1±0.3 1.1±0.3 0.847 
Triglyceride, mmol/l 1.6±0.8 1.8±1.0 0.269 
HsCRP, mg/l 4.4±4.5 3.4±3.6 0.293 
Table 4.3 Baseline characteristics for study 2 (stable CAD patients).  
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 Aspirin+Clopidogrel Aspirin+Placebo 
Mean±SD µ2/mm  Visit 1 
(baseline) 
Visit 2 P value Visit 1 
(baseline) 
Visit 2 P value 
Thrombus in high 
shear chamber 
13978±5502 11192±3764 0.001 13959±7038 14208±6780 0.519 
Thrombus in low 
shear chamber 
8426±4080 6561±2925 0.001 7317±2906 6990±2482 0.443 
Table 4.4 Thrombus area in patient with stable CAD study.  
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Figure 4.4  High shear thrombus area of patients in stable CAD study.  
High shear thrombus area measurements in patients with T2DM and stable CAD 
are shown at baseline and one week after therapy with aspirin+clopidogrel vs. 
aspirin+placebo. In clopidogrel group, thrombus area (2/mm, mean±SD), 
reduced from 13978±5501 to 11192±3764 whereas it remain unchanged in 
placebo group from 13959±7038 to 14208±6780, p<0.0005. Mean difference in 
thrombus area of clopidogrel group was (µ2/mm) 3035 with 95% confidence 
interval was between 1437 and  4633. 
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Thrombus area, µ2/mm Mean Std. deviation 
ACS and T2DM (n=40) 20414 12344 
ACS and Non DM (n=40) 14933 8415 
T2DM with stable CAD on 
aspirin (n=45) 
14208 6780 
T2DM with stable CAD on 
aspirin and clopidogrel (n=45) 
11192 3764 
Table 4.5 Thrombus area of the combined study population.  
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Figure 4.5 Thrombus area of combined study population.  
ACS and T2DM had highest thrombus and patients with stable CAD and T2DM 
who had aspirin and clopidogrel therapy had the lowest thrombus (µ2/mm, 
mean±SD 20414±12344 vs. 11192±3764). Thrombus area of non diabetic ACS 
patients was not different to that of patients with stable CAD and treated with 
aspirin only (µ2/mm, mean±SD, 14933±8415 vs. 14208±6780). One way ANOVA: 
F statistic 8.277, P<0.001. The individual p values are ACS-T2DM vs. ACS non 
DM 0.023, ACS-T2DM vs. T2DM+stable CAD+ aspirin p= 0.006, ACS-T2DM vs. 
T2DM+stable CAD+ aspirin and clopidogrel p=0.001, ACS non DM vs. 
T2DM+stable CAD+ aspirin and clopidogrel p=0.016, ACS non DM vs. 
T2DM+stable CAD+aspirin p=0.742, and T2DM + stable CAD+aspirin and 
clopidogrel vs. T2DM+stable CAD+aspirin p<0.001. 
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4.1.4 Discussion - Platelet dependent thrombosis in CAD study 
In the study on patients with stable CAD and T2DM, clopidogrel reduced 
thrombus area significantly when added to aspirin 75 mg. In this double blinded 
RCT, those treated with placebo had no changes in thrombus. Our group has 
earlier shown  higher thrombus area in diabetic compared to non-diabetic 
individuals with stable CAD taking aspirin (Natarajan et al., 2008a). This current 
study was aimed at exploring thrombus when clopidogrel is added to aspirin in 
patients with T2DM and stable CAD. 
These findings can have significant implications in the management of patients 
with T2DM and CAD. To achieve a significant reduction of thrombus with DAPT 
in the chosen population with stable CAD which has been very well treated with 
lipid control, hypertension control and good (but not very tight) glycaemic control 
is clinically important. Clopidogrel and aspirin therapy (DAPT) reduced 
thrombogenicity without any increase in bleeding complications.  The benefits are 
likely to be sustained if DAPT is continued beyond the protocol duration and it 
remains to be seen if long term benefits may outweigh the bleeding risks. My 
findings are in contrast to the findings of a similar but large scale, multi centre, 
CHARISMA (Clopidogrel for High Atherothrombotic Risk and Ischemic 
Stabilization, Management, and Avoidance) study and its subsequent T2DM sub 
group analysis (Bhatt et al., 2006). My study population differed from CHARISMA 
population by a number of ways. CHARISMA population had a 20% 
discontinuation rate for clopidogrel, nearly one sixth of them were current 
smokers and only three fourths had statin therapy. However, in their sub study on 
patients with established cardiovascular disease, clopidogrel showed benefits by 
reducing MI, stroke or death (relative risk, 0.88; 95% CI, 0.77 to 0.998; P=0.046). 
In addition, a subgroup analysis of the CHARISMA study showed that the 
benefits of clopidogrel are greater in population with T2DM and a previous 
cardiovascular event (relative risk reduction 17.1%, 95% CI: 4.4-28.1) (Bhatt et 
al., 2007). 
Of interest, among those treated with current guideline based antiplatelet therapy, 
I found that patients with T2DM and CAD (treated with aspirin only) had 
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numerically almost equal thrombus area compared to those non diabetic ACS 
patients (treated with aspirin and clopidogrel). When stratified as four groups, 
patients with T2DM and ACS had the greatest thrombus, whereas those with 
stable CAD and treated with DAPT had the lowest thrombus (Table 4.5, Figure 
4.5). Haffner et al’s land mark study showed that patients with T2DM but no overt 
CAD had similar risks of cardiac events when compared to patients without 
T2DM but established CAD resulting in the term “T2DM is a coronary artery 
disease equivalent”(Haffner, 2000). My findings take this assumption further, 
suggesting that patients with T2DM and established stable CAD have similar 
thrombogenicity as non diabetic patients with ACS and thus suggesting “T2DM 
and clinically stable CAD is ACS equivalent”. This is a post hoc analysis of the 
data and should be interpreted with caution as ‘hypothesis generating’ and needs 
further validation. If these findings are proven in large scale studies, it 
strengthens the argument that T2DM patients with stable CAD should be 
managed with more powerful antiplatelet therapy to achieve similar clinical 
benefits seen in non diabetic population. These results show increased thrombus 
quantity in patients with T2DM and the qualitative aspects of diabetic thrombus 
are discussed vide infra. 
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4.2 Coagulation biomarkers 
4.2.1 Results – ACS study 
After NSTE-ACS, serum fibrinogen levels were higher in patients with T2DM 
(4.2±0.8 vs. 3.5±1.4, p=0.012). P selectin values were nearly 1.5 higher and 
CD40 ligand levels were twice as high in T2DM compared to non T2DM controls 
(Table 4.6). Post chamber effluent blood levels of P selectin and CD40 ligand 
(Figure 4.6) showed similar consistent results. PAI-1 levels were higher in T2DM 
both in pre and post chamber plasma samples. There was a significant difference 
between pre and post chamber values of soluble CD40 ligand (p=0.009). As 
mentioned before, serum fibrinogen had a significant correlation to thrombus    
(r= 0.283, p=0.013) but the correlation was lost when multiple regression analysis 
was performed. Interestingly, there were no significant correlations seen between 
soluble P selectin, soluble CD40 ligand and PAI-1 levels and thrombus area in 
venous blood samples and post chamber effluent samples (Table 4.7). 
4.2.2 Results – Stable CAD study 
In patients with established and stable CAD, levels of coagulation biomarkers, P 
selectin, CD40 ligand, PAI-1 and fibrinogen showed no statistically significant 
differences between the groups at baseline. Levels did not change following one 
week’s therapy with clopidogrel (Table 4.8). 
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 T2DM (n=40) Non T2DM (n=40)  
 Mean±SD Median 
(IQR) 
Mean±SD Median 
(IQR) 
P 
value 
Fibrinogen,g/l 4.2±0.8 4(4-5) 3.5±1.4 3(1-5) 0.012 
Venous               
P selectin, ng/ml 
76.1±25.6 76 (57-93) 56.7±20.5 52(42-69) 0.001 
Post chamber P 
selectin, ng/ml 
73.3±22.9 73 (57-87) 57.3±17.6 60(42-67) 0.001 
Venous CD40 
ligand, ng/ml 
5991±5258 4208(2042-
7186) 
2268±2960 1233(593-
2839) 
0.001 
Post chamber 
CD40 ligand, 
ng/ml 
4490±2851 4272(2446-
5582) 
2074±1772 1402(958-
2659) 
0.001 
Venous PAI-1, 
ng/ml 
96.9± 45.7 93.7  (58.3-
136.6) 
69.7± 31.3 68.2 (43.9-
91.8) 
0.016 
Post chamber 
PAI-1, ng/ml 
108.3        
± 55.2 
126.9 
(55.2-
155.2) 
67.9± 31.5 80.2 (30.8-
86.8) 
0.001 
Table 4.6 Coagulation biomarkers – ACS study.  
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Figure 4.6 P selectin levels in ACS Study.  
P selectin levels were higher in T2DM both in venous samples and post chamber 
“effluent” blood in T2DM compared to non DM one week after NSTE-ACS. The 
solid lines represent mean values. 
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Spearman rho, * p<0.05 Thrombus area 
Serum fibrinogen g/l 0.283* 
Venous P selectin, ng/ml 0.067 
Post chamber P selectin, ng/ml 0.101 
Venous CD40 ligand,  ng/ml 0.063 
Post chamber CD40 ligand, ng/ml 0.129 
Delta P selectin, ng/ml 0.038 
Delta CD40 ligand, ng/ml 0.086 
Venous PAI-1, ng/ml 0.071 
Post Chamber PAI-1, ng/ml 0.170 
Delta PAI-1, ng/ml 0.179 
Table 4.7 Correlations between coagulation biomarkers and thrombus area- ACS 
study.  
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 Clopidogrel+aspirin (n=45) Placebo+aspirin (n=45) 
Mean±SD Visit 1 Visit 2 P value Visit 1 Visit 2 P value 
Fibrinogen, g/l 3.4±0.6 3.3±0.6 0.091 3.4±0.8 3.3±0.7 0.910 
Venous              
P selectin, ng/ml 
77.0 
±30.2 
70.5 
±29.6 
0.251 75.0 
±28.7 
69.9 
±29.5 
0.256 
Post chamber    
P selectin, ng/ml 
72.9 
±26.1 
74.1 
±27.3 
0.752 71.3 
±32.1 
68.1 
±21.8 
0.455 
Venous CD40 
ligand, ng/ml 
1039 
±620 
939 
±707 
0.343 1175 
±862 
1143 
±972 
0.672 
Post chamber 
CD40 ligand, 
ng/ml 
1149 
±709 
1050 
±747 
0.409 995±689 1039 
±630 
0.621 
Venous PAI-1, 
ng/ml 
82.1      
±41.6 
74.3 
±39.3 
0.733 79.2 
±37.4 
81.4 
±40.8 
0.423 
Post chamber 
PAI-1, ng/ml 
57.8      
±41.7 
71.7 
±46.5 
0.797 55.2 
±41.4 
66.7 
±43.9 
0.652 
Table 4.8 Coagulation biomarkers- Stable CAD study.  
 
 
  
172 
4.2.3 Discussion - Coagulation biomarkers and platelet dependent 
thrombosis 
To explore the underlying mechanisms of PDT in T2DM, I studied coagulation 
markers namely fibrinogen, P selectin and CD40 and found that they were higher 
in T2DM after ACS despite current optimal secondary prevention therapy.  In 
patients with stable CAD, these levels were unaffected by clopidogrel treatment. 
In ACS study, there was a significant reduction of these biomarkers in both the 
groups in “effluent” post chamber blood also. These novel findings are supported 
by the fact that these biomarkers play an important role in enhancing PDT and 
stabilisation of the thrombus. It is possible that the gradient between pre and post 
chamber blood levels of soluble CD40 ligand reflects the incorporation of these 
biomarkers into the thrombus formed in Badimon chamber (vide infra). 
P selectin is a well studied surrogate marker of pro thrombotic state in CAD and 
T2DM. Raised levels of P selectin were reported as early as 1993 in patients 
immediately after acute MI and ischaemic stroke (Wu et al., 1993). Soluble P-
selectin was raised in patients with stable CAD and peripheral arterial disease 
(Blann et al., 1995) and unstable angina(Ikeda et al., 1995; Tomoda and Aoki, 
1998; Parker et al., 2001). T2DM influences P selectin levels. Newly diagnosed 
diabetic patients, who were treated with insulin, had five times increased levels of 
P selectin compared to healthy controls at baseline and remained higher despite 
insulin therapy(Tschoepe et al., 1995). Hyperglycaemia is an independent 
predictor of P selectin in patients with T2DM (Santilli et al., 2010)(Yngen et al., 
2001; Gresele et al., 2003; Neubauer et al., 2010) and these findings were 
confirmed in a recent study of patients with T2DM on aspirin therapy (Evangelista 
et al., 2007). Improvement in glycaemic control lowers P selectin levels, thus 
indicating a direct relationship between platelet activation and hyperglycaemic 
stress on platelets (Eibl et al., 2004). However, these findings were challenged by 
a study evaluating multifactorial intervention in patients with T2DM and CAD (Lim 
et al., 2004). In another study of 667 patients who underwent coronary stenting, 
platelet P-selectin was higher in patients with ACS, particularly in those with 
STEMI compared to those with stable CAD and correlated with myocardial 
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necrosis markers creatinine kinase (CK-MB) and troponin I. There were no 
differences seen in patients with or without T2DM who presented with ACS in that 
study (Stellos et al., 2010). In a landmark subgroup analysis of BARI-2D trial, 
only patients with T2DM and obesity were found to have higher P selectin thus 
suggesting that raised BMI contributes to heightened platelet activation 
(Schneider et al., 2009). A prospective case control study with 16 years of follow-
up showed higher serum P selectin levels in diabetic patients without prior history 
of CAD compared to non diabetics, but after adjusting for conventional  risk 
factors such as age, sex, smoking, lipid profile and socio-economic status, this 
difference ceased to exist (Sharma and Berger 2011). With the shift in definition 
and diagnostic criteria of T2DM recently, (American Diabetes Association, 2010) 
results from these long term follow up studies have to be interpreted with caution 
till the post hoc analysis data using current definitions of T2DM are available. 
The role of CD40 ligand (CD40L) has been extensively investigated in patients 
with coronary artery disease and the current literature supports my findings of 
higher soluble CD40L in patients with T2DM after ACS. In my cohort, these 
findings suggest that soluble CD40L is a surrogate marker of high 
thrombogenicity after ACS but not an independent risk factor (Tousoulis et al., 
2010). Levels of CD40L were higher in patients with CAD compared to healthy 
controls and the levels were higher in patients with unstable coronary artery 
disease compared to stable CAD. CD40L levels correlated with severity of 
atherosclerosis and the trans coronary gradient (levels in aorta –levels in 
coronary sinus) in patients with ACS (Wang et al., 2007). Multiple interventions to 
reduce the coronary artery risk factors in patients with CAD were associated with 
reduction in CD40L levels suggesting a causal link between reduction of platelet 
activation and inflammation and prognostic benefit. However, in a large cohort of 
healthy volunteers, sCD40L levels correlated poorly with both the individual risk 
factors and the calculated Framingham Coronary Heart Disease Risk 
Score(Verma et al., 2005), suggesting the need for long-term follow-up studies to 
answer the question if CD40L could be an additional biomarker of cardiovascular 
risk. In large and representative multi ethnic population studies, soluble CD40L 
was not associated with conventional atherosclerotic risk factors, questioning its 
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global utility as a screening tool (de Lemos et al., 2005). Findings from CD40 
ligand studies are summarised in a table modified from Antoniades et al (Table 
4.9) (Antoniades et al., 2009). 
T2DM is an independent factor associated with elevated CD40L (Varo et al., 
2003; Jinchuan et al., 2004; Cipollone et al., 2005; Gokulakrishnan et al., 2006). 
Literature on soluble CD40 ligand (CD40L) in patients with T2DM after NSTE-
ACS is minimal and my study findings are significant in that respect (Undas et al., 
2008). In patients with T2DM without overt CAD, CD40L levels correlated with 
urinary excretion rate of 11-dehydro-thromboxane B2 which is a marker of 
platelet hyperactivity (Santilli et al., 2006). Significant reduction in plasma CD40L 
was noted after 7 days of aspirin and intensive diabetes risk factor control 
(Desideri and Ferri, 2003; Cipollone et al., 2005).  In addition, the strong 
association between tissue factor release, interleukin 6 and levels of CD40L in 
T2DM with CAD suggests that CD40L perpetuates thrombogenicity in T2DM (Lim 
et al., 2004). 
Addition of clopidogrel did not reduce the levels of CD40L in my study of patients 
with stable CAD and T2DM. These findings are in contrast to some of the earlier 
studies. Administration of clopidogrel for one week after ACS reduced platelet 
monocyte interactions and CD40L levels (Xiao and Théroux, 2004). In patients 
who underwent percutaneous coronary intervention (PCI), clopidogrel pre-
treatment with 300-600mg was associated with lower serum CD40L levels 
immediately after PCI and these changes were more marked in flow cytometry 
assay after stimulation with ADP (Quinn et al., 2004). 
My study findings were also different to PROCLAIM study (A Pilot Study to 
Examine the Effects of Clopidogrel Compared to Placebo on Markers of 
Inflammation in Subjects with Metabolic Syndrome Who Are Receiving 
Background Therapy, including Low-Dose Aspirin), a pilot study to examine the 
effects of clopidogrel on inflammatory markers in patients with metabolic 
syndrome receiving low-dose aspirin. 
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Author Population and methods Outcome/Conclusion 
Aukrust et al. (Aukrust 
et al., 1999) 
26 patients with unstable 
angina, 29 with stable 
angina, and 19 controls 
Higher sCD40L levels and 
CD40L expression on T cells 
in patients with unstable 
angina; enhanced sCD40L 
release after platelet 
activation 
Wang et al. (Wang et 
al., 2007) 
20 patients with ACS, 10 
patients with stable 
angina, and 10 controls 
who underwent coronary 
angiography 
Higher sCD40L levels in 
ACS and stable angina; 
higher trans-coronary 
gradient of sCD40L in ACS; 
higher sCD40L in patients 
with complex lesions 
Yan et al. (Yan et al., 
2006) 
32 patients with ACS, 24 
with stable angina, and 16 
controls 
Elevated levels of sCD40L in 
stable angina and ACS; 
marked increase in sCD40L 
after percutaneous 
intervention 
Peng et al. (Peng et al., 
2002) 
27 patients with ACS, 23 
with stable angina, and 30 
controls 
Higher levels of sCD40L, in 
ACS; sCD40L positively 
correlated with cellular 
adhesion molecules like 
sICAM-1 and sVCAM-1, 
triglycerides, and lipoprotein 
B, and negatively correlated 
with HDL-C 
Garlichs et al. (Garlichs 
et al., 2001) 
40 patients with ACS, 15 
with stable angina, and 12 
controls who underwent 
coronary angiography or 
PCI 
Higher sCD40L levels and 
CD40L platelet expression in 
ACS and values reduced  
after 6 months  
Antoniades et al. 
(Tousoulis et al., 2007)  
109 patients with acute MI, 
201 patients with stable 
CAD, and 286 controls 
Higher sCD40L and IL-6 
levels in acute MI; higher 
adhesion molecules in AMI 
and stable angina group;    
IL-6 was independently 
associated with sCD40L only 
in controls 
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Author Population and methods Outcome/Conclusion 
Malarstig et 
al.(Malarstig et al., 
2006) 
24-month follow-up of 
2,359 patients with 
NSTEMI FRISC II trial, 
randomized to receive 
early invasive or 
conservative treatment 
with low molecular weight 
heparin, dalteparin or 
placebo 
In placebo group, sCD40L 
levels were associated with 
increased risk of myocardial 
infarction; dalteparin reduced 
this risk in patients with 
sCD40L levels above 
median.  
Ohashi et al.(Ohashi et 
al., 2006) 
17 patients with acute MI 
and 10 patients with 
unstable angina who 
underwent PCI. 
Thrombectomy was 
performed in MI patients 
Transcoronary gradient of 
sCD40L increased at 9 h in 
both groups; high CD40L 
expression in thrombi; 
association between sCD40L 
and MMP-9 activity in AMI; 
aspirating thrombectomy 
reduced sCD40L levels. 
Tayebjee et al. 
(Tayebjee et al., 2005) 
204 patients with stable 
CAD 
Higher sCD40L in CAD; no 
relation with severity of the 
CAD 
Rondina et al.(Rondina 
et al., 2008) 
909 patients undergoing 
angiography; 303 patients 
with CAD with a cardiac 
event within 1 year, 303 
with CAD without event, 
303 without CAD or event 
Higher sCD40L levels 
associated with decreased 
risk of CAD in non-ACS 
patients 
Martins et al. (Martins et 
al., 2006) 
865 patients with chest 
pain, with or without 
angiographically confirmed 
CAD, with or without AMI 
There was no difference in 
sCD40L levels between CAD 
and non-CAD patients 
Antoniades et al. 
(Antoniades et al., 
2006) 
219 patients with 
premature MI and 389 
controls; followed up for 1 
year 
Patients with MI had higher 
sCD40L levels compared 
with controls; sCD40L levels 
were significantly reduced 
after 1 year in the same 
subjects  
Plaikner et al.(Plaikner 
et al., 2009) 
1,089 consecutive patients 
in an emergency 
department for medical or 
neurologic emergencies 
sCD40L was not useful as a 
diagnostic marker for acute 
cardiac, cerebrovascular 
ischemic, or thromboembolic 
events 
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Author Population and methods Outcome/Conclusion 
Schonbeck et 
al.(Schonbeck et al., 
2001) 
130 healthy women, 
followed up for 4 years for 
CV events 
CD40L levels were higher in 
women who subsequently 
developed cardiovascular 
event and women with 
CD40L levels above 95% 
percentile had three times 
risk of cardiovascular events 
after adjustment of 
conventional risk factors 
De Lemos et al.(de 
Lemos et al., 2005) 
2811 subjects from the 
Dallas Heart Study, a multi 
ethnic population based 
cross-sectional study 
assessed by CT coronary 
calcium score and MRI of 
aortic media thickness 
No association was found 
between CD40L levels and 
atheroma severity. There 
was lack of correlation 
between CD40L and 
conventional CV risk factors 
Heeschen et al. 
(Heeschen et al., 2003) 
1088 patients with ACS 
and 626 patients with non 
cardiac chest pain 
admitted to emergency 
unit 
Higher sCD40L levels were 
associated with increased 
risk of death or MI in ACS 
group and controls. 
Abciximab(GpIIb IIIa 
inhibitor) reduced cardiac 
risk in patients with higher 
sCD40L levels 
Manenti ER et al. 
(Manenti et al., 2006) 
172 patients with non-ST-
elevation ACS 
No additional prognostic 
value of CD40L to TIMI risk 
score 
Apple FS et al.(Apple et 
al., 2009) 
457 patients with ACS 
were  studied for a  
multiple biomarkers based 
risk strategy 
No differences in mortality 
rates were observed 
between those with 
increased versus normal 
concentrations of CD40L 
Table 4.9 Summary of clinical studies on soluble CD40 ligand and CAD.  
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 With dual antiplatelet therapy, there was a reduction in the levels of CD40L over 
a six week period without changes in P selectin and inflammatory markers 
(Willerson et al., 2009). The contrasting findings from my study can be explained 
by lack of prolonged course of clopidogrel therapy (my study cohort took one 
week of clopidogrel therapy) and the differences in study population as I included 
patients with and without metabolic syndrome. There is heterogeneity of methods 
in evaluating CD40 levels and most of the studies which showed significant 
reduction after antiplatelet therapy have employed either serum or plasma 
samples. I used serum samples and employed ELISA method. It is unknown if 
the results would be different if I used plasma or novel flow cytometric analysis of 
CD40 (Halldórsdóttir et al., 2005). In a study by Dunzendorfer et al, which looked 
at cytokine triggered priming of endothelial cells, and a study by Hermann et al, 
which assessed platelet expression of CD40L, there were no significant effects of 
aspirin treatment on CD40L levels. The data on reduction of CD40L with 
clopidogrel treatment still remains controversial in stable CAD (Azar et al., 2006; 
Yip et al., 2006; Stellbaum et al., 2007). 
In patients with T2DM and NSTE-ACS, venous plasma plasminogen activation 
inhibitor-1 (PAI-1) levels were higher than those without diabetes. Similar findings 
were seen in post chamber (effluent) blood. It has been well recognised that PAI-
1 levels are elevated in T2DM (McGill et al., 1994),(Sobel et al., 1998). Elevated 
PAI-1 levels in T2DM not only favour persistence of thrombus but also are 
responsible for conversion of micro thrombus to macro thrombus and further 
propagation of thrombus (Schneider and Sobel, 2012). In their landmark IRAS 
(Insulin Resistance Atherosclerosis Study) study Festa et al showed that higher 
levels of PAI-1 predicted the incidence of T2DM and insulin resistance(Festa et 
al., 2002) and they concluded that PAI-1 in T2DM independently lead to an 
increased risk of coronary heart disease (Festa et al., 2006). These findings were 
confirmed in Framingham offspring study (Ingelsson et al., 2007) and there are 
suggestions that PAI-1, along with pro inflammatory mediators play a significant 
role in development of metabolic syndrome and its cardiovascular complications 
(Alessi and Juhan-Vague, 2006). 
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Higher PAI-1 levels in patients with acute coronary syndromes is well known 
(Yazici et al., 2005). Elevated PAI-1 levels in acute coronary syndrome was 
associated with higher major adverse cardiac events like (acute MI, stroke, 
death) (Collet et al., 2003b; Marcucci et al., 2006). Presence of higher 
concentration of PAI-1 in atherectomy specimen of patients with T2DM has led 
studies confirming its role in conversion of stable to unstable plaque. It has been 
proposed that PAI-1 plays a significant role in evolution and outcomes in patients 
after acute coronary syndrome in T2DM (Sobel et al., 1998; Sobel, 1999b; 
Schneider and Sobel, 2012). 
Various strategies were aimed in reducing the PAI-1 levels and thus reduce 
cardiac events in patients with T2DM. Improved glycaemic control, use of insulin 
sensitising agents and weight reduction were known to reduce the levels of PAI-1 
(Schneider and Sobel, 2012). There are studies showing reduction in PAI-1 levels 
after treatment with aspirin and clopidogrel (Sakata and Kario, 2011). My study 
on patients with stable CAD and T2DM (stable CAD) failed to show any effect of 
clopidogrel therapy on PAI-1 levels. My sample size was small and the duration 
of therapy was shorter (one week). It is possible that clopidogrel add on therapy 
(75mg od) can reduce thrombus formation in better controlled T2DM on regular 
aspirin but may be ineffective in reducing the hypofibrinolysis in these individuals. 
Overall, platelet activation markers were higher in T2DM after NSTE-ACS despite 
aspirin and clopidogrel therapy. This partly explains higher thrombus seen in 
these individuals. However, in stable CAD patients with T2DM, dual antiplatelet 
therapy has made no changes to these biomarkers. 
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4.3 Biomarkers of inflammation 
4.3.1 Results – ACS study 
Serum inflammatory biomarkers HsCRP, IL-6 and TNFα levels were significantly 
higher in diabetic compared with non-diabetic patients in standard venous blood 
samples. In the “activated-effluent” post chamber blood samples, only IL-6 values 
were higher in patients with T2DM (Table 4.10). IFNγ and IL-1 levels were 
numerically higher but not statistically different between both the groups. Venous 
levels of IL-6 (rho=0.251, p=0.27) and TNFα (rho=0.319, p=0.005) significantly 
correlated with thrombus area (Table 4. 11, Figure 4.7). The delta values of pre 
and post chamber blood, which may represent the amount of inflammatory 
cytokines consumed in the formed thrombus had significant correlation to 
thrombus (IL-6 delta: rho=0.371, p=0.001 and TNFα: rho=0.389, p=0.001, Table 
4.11). The association of inflammatory cytokines and coagulation markers with 
thrombus from Badimon chamber persisted after adjusting for diabetic state and 
body mass index. 
4.3.2 Results – Stable CAD study 
Clopidogrel therapy in T2DM with stable CAD failed to reduce inflammatory 
cytokines TNFα, IFNγ and IL-6. However, there was a very small but significant 
reduction in IL-1 levels (mean±SD, ng/ml, 0.12±0.22 vs 0.08±0.15, p=0.021, table 
4.12). 
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 T2DM (n=40) Non T2DM (n=40)  
 Mean±SD 
Median 
(IQR) 
Mean±SD 
Median 
(IQR) 
P 
value 
HsCRP mg/l 10.94 ±9.69 
10.76 
(3.05-
11.22) 
3.55±3.20 
2.77 
(2.00-
3.90) 
0.001 
Venous   
IFNγ ng/ml 
7.35 ±10.76 
4.68 
(3.19-
7.89) 
4.60±3.81 
3.51 
(2.88-
4.72) 
0.131 
Post chamber 
IFNγ ng/ml 
4.56 ±6.53 
3.47 
(1.89-
5.09) 
3.73±3.27 
2.79 
(2.46-
3.29) 
0.473 
Venous IL-1 
ng/ml 
3.10 ±13.01 
0.40 
(0.11-
2.21) 
0.90±0.60 
0.80 
(0.50-
1.30) 
0.284 
Post chamber 
IL-1 ng/ml 
0.65±0.45 
0.56 
(0.31-
0.86) 
0.71±0.65 
0.48 
(0.28-
1.06) 
0.636 
Venous IL-6 
ng/ml 
3.30±2.37 
2.24 
(1.70-
4.91) 
1.82±0.80 
1.61 
(1.46-
2.16) 
0.001 
Post chamber 
IL-6 ng/ml 
3.05±2.05 
2.29 
(1.68-
4.27) 
1.86±3.05 
1.84 
(1.31-
2.19) 
0.001 
Venous  
TNFα ng/ml 
9.48±3.77 
9.43 
(7.03-
10.90) 
7.65±3.31 
7.89 
(4.86-
10.03) 
0.024 
Post chamber 
TNFα ng/ml 
5.98±2.20 
5.83 
(4.34-
6.96) 
5.4±5.98 
5.24 
(4.43-
6.09) 
0.167 
Table 4.10 Inflammatory biomarkers – ACS study.  
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Table 4.11 Correlations between cytokines and thrombus area –ACS study.  
 HsCRP Venous 
IL-6 
Venous 
TNFα 
Post 
chamber 
IL-6 
Post 
chamber 
TNF 
Delta 
IL-6 
Delta 
TNFα 
Correlation 
with 
thrombus 
area 
0.151 0.251 0.319 0.126 0.073 0.371 0.389 
P value .189 .027 .005 .276 .527 .001 .001 
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 Clopidogrel+aspirin (n=45) Placebo+aspirin (n=45) 
Mean±SD Visit 1 Visit 2 P 
value 
Visit 1 Visit 2 P 
value 
Venous  
IFNγ, ng/ml 2.32±1.5 2.51 ±1.6 0.053 3.28 ±2.79 3.14±3.20 0.154 
Post chamber  
IFNγ, ng/ml 2.90±1.7 2.91 ±2.2 0.112 3.56±2.7 3.18±2.55 0.512 
Venous  
IL1, ng/ml 0.12±0.22 0.08 ±0.15 0.021 0.20 ±0.25 0.12±0.21 0.167 
Post chamber  
IL1, ng/ml 0.19±0.25 0.16 ±0.31 0.026 0.37 ±0.54 0.17±0.31 0.705 
Venous  
IL6, ng/ml 2.40±1.9 2.60 ±1.4 0.274 2.74 ±2.19 2.59±1.73 0.865 
Post chamber  
IL6, ng/ml 3.00±2.5 2.71 ±1.5 0.904 2.91 ±2.30 2.74±1.81 0.881 
Venous 
TNFα, ng/ml 10.20±5.3 10.51 ±4.9 0.835 10.31 ±5.20 10.41±4.87 0.865 
Post chamber 
TNFα, ng/ml 10.71±5.1 10.9 ±5.0 0.245 11.26 ±5.14 11.84±3.82 0.210 
Table 4.12 Inflammatory cytokines - Stable CAD study.  
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Figure 4.7 Correlation of TNFα and IL-6 levels and thrombus area in ACS study.  
Serum levels (Pre chamber-venous samples) of TNFα (rho=0.251, p=0.027) and 
IL-6 (rho=0.319, p=0.005) correlated with thrombus area. The delta values (pre 
chamber- effluent blood) levels also correlated with thrombus area (TNFα delta 
rho=0.389, p=0.001, IL-6 delta rho=0.371, p=0.001). 
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4.3.3 Discussion - Inflammation and platelet dependent thrombus  
I explored the role of inflammation, which is linked to both T2DM and CAD, in 
thrombosis as a “common soil” factor (Stern, 1995). High sensitivity CRP 
(HSCRP) and inflammatory cytokines TNFα and IL-6 were higher in patients with 
T2DM after ACS compared to non-diabetic patients and were directly correlated 
to thrombus. Clopidogrel therapy failed to reduce the levels of hsCRP, TNFα and 
IL-6 but reduced the levels of IL-1. 
Indirect evidence shows TNFα promotes thrombogenicity by inducing expression 
of tissue factor in monocytes, and platelet and leucocyte adhesion to endothelium 
(Lindmark et al., 2000). TNFα also increases the production of large multimers of 
van Willebrand factor (vWF) which in turn enhances thrombogenicity. TNFα plays 
a positive feedback role in the synthesis of fibrinogen and thereby indirectly 
increases thrombogenicity (Zhao et al., 2011). IL-6 induces synthesis of new 
platelets which are more thrombogenic and contribute to thrombogenicity in 
T2DM (Stratmann and Tschoepe, 2005). In addition, high levels of IL-6 delay the 
clearance of vWF and thus sustain the thrombogenicity (Bernardo et al., 2004). 
TNFα and IL-6 also down regulate naturally occurring antithrombotic substances 
such as protein C and thrombomodulin (Esmon, 2005). Inflammatory cytokines 
and hsCRP levels appear to fall after aspirin and clopidogrel therapy, but the 
majority of evidence was derived from patients who had NSTEMI and coronary 
stent procedures (Steinhubl et al., 2007; Antonino et al., 2009; Muhlestein, 2010). 
Findings from my ACS study confirm the available evidence of a pro-
inflammatory and pro-thrombotic state in T2DM and ACS (Dovio and Angeli, 
2001; Tousoulis et al., 2006) but also add that these findings remain unaltered 
despite current aggressive secondary prevention and there is a direct association 
between inflammatory cytokines and thrombus formation. 
My study on stable CAD showed that cytokine levels remain unchanged after a 
week of clopidogrel therapy in T2DM. Failure of DAPT to reduce these 
biomarkers of inflammation and thrombosis in patients with T2DM and CAD has 
been noted in two separate one year follow up studies namely Aspirin non-
responsiveness and Clopidogrel Endpoint Trial (ASCET) study and ELAPSE 
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(evaluation of long-term clopidogrel antiplatelet and systemic anti-inflammatory 
effects) study, both of which included patients with and without T2DM (Solheim et 
al., 2006; Saw et al., 2008). It is also possible that T2DM is associated with 
greater inflammation and 75mg of clopidogrel therapy is insufficient to suppress 
the levels of biomarkers. 
I found that the levels of TNFα and IL-6 were significantly associated with 
thrombus formed in Badimon chamber (IL6: rho=0.251, p=0.027, TNFα: 
rho=0.319, p=0.005). These findings are novel and may imply a simple 
association secondary to ACS (Tousoulis et al., 2006) or a causal factor for 
increased thrombogenicity in these high risk individuals (Young et al., 2002). 
4.3.4 Post chamber blood (“effluent” blood) from the Badimon chamber 
To explore the causal association of these biomarkers in patients with ACS and 
T2DM, I studied post chamber effluent blood. In simplistic terms, post chamber 
effluent blood represents “activated blood” after being subjected to high shear 
force inside the chamber and contact activation with collagen. As the chamber 
recreates the milieu of coronary vasculature, this may be equivalent to the blood 
sample from coronary sinus in these individuals. Similarly, for P selectin and 
CD40 ligand, the gradient between pre and post chamber blood might represent 
the amount of biomarkers used in the thrombus which was derived from venous 
(pre chamber) blood and those released from activated platelets inside the 
chamber. Delta values of P selectin and CD40L showed no correlation to 
thrombus area, perhaps because of the differential release of these substances 
from the cells in flowing blood. 
Since cytokines are neither synthesised nor released from the flowing blood 
inside the chamber, the delta values would solely represent the cytokines 
consumed in the chamber and probably been used in the formed thrombus. My 
findings are interesting as it validates a role of cytokines in the thrombus formed 
in Badimon chamber and also represents a novel model to assess the role of 
various biomarkers directly in the production of thrombus. As Badimon chamber 
represents flow conditions of coronary arteries, if my findings are validated in 
different clinical settings, it will be possible to substitute Badimon chamber 
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studies for highly invasive coronary sinus sampling for certain coronary flow 
experiments. The effluent blood can be used to quantitatively study the interplay 
of cytokines and thrombus after pharmacological intervention. 
Levels of inflammatory cytokines (TNFα, IL6, IL-1 and INFγ) remain unchanged in 
pre and post chamber samples before and after clopidogrel therapy in patients 
with stable CAD and T2DM. This negative finding can be due to    i) inflammatory 
markers were lower in T2DM with stable CAD ii) addition of clopidogrel did not 
reduce venous cytokines in patients with T2DM and stable CAD and iii) there was 
a lack of association between cytokines in venous blood and thrombus in patients 
with stable CAD and T2DM. 
For P selectin and CD40 ligand, the gradient between pre and post chamber 
blood may represent the amount of these biomarkers used in the thrombus. P 
selectin in the thrombus is likely derived from venous (pre chamber) blood and 
that released from activated platelets inside the chamber. However, I could not 
find any correlation between the venous soluble P selectin to thrombus. Delta 
values of P selectin and CD40L showed no correlation to thrombus area.  The 
negative values may be due to smaller sample size in my study. Soluble P 
selectin measured by ELISA methods (used in my study) show more 
heterogeneous spread compared to the measurements from flow cytometric 
methods (Ritchie et al., 2000). It is possible that the P selectin and CD40ligand 
levels may have shown better correlation to thrombus if flow cytometric methods 
were used in the study. 
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Study Intervention Results 
ALBION study, NSTEMI 
patients 
(n=103)(Montalescot et al., 
2006) 
Loaded with 300-
600-900mg 
clopidogrel in 
addition to aspirin 
No difference between 
HSCRP, CD40L in three 
arms 
NSTEMI, RCT and 
followed up for one month 
(n=115)(Chen et al., 2006) 
Aspirin vs. aspirin 
and clopidogrel 
HSCRP and TNF alpha 
reduced significantly in 
DAPT group 
NSTEMI patients, single 
blinded study, followed for 
9 months 
(n=86)(Vavuranakis et al., 
2006) 
Aspirin vs. aspirin 
and clopidogrel 
P selectin levels reduced 
with DAPT but only in 
those with higher 
baseline CD40L and 
hsCRP levels. 
Stable CAD, non 
randomised study, 
followed for 5 weeks 
(n=103)(Heitzer et al., 
2006) 
Aspirin vs. aspirin 
and clopidogrel 
CD40L and hsCRP 
reduced after DAPT 
Stable CAD, RCT 
(n=73)(Azar et al., 2006) 
Aspirin vs. aspirin 
and clopidogrel 
CD40L reduced 
significantly but hsCRP 
remain unchanged 
Table 4.13 Biomarker studies on aspirin and clopidogrel therapy 
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4.4 Obesity and platelet dependent thrombus in T2DM 
4.4.1 Results 
The effect of obesity in platelet dependent thrombus was studied in this sub 
group analysis. Patients were classified as obese if their BMI was >30.0 kg/m2. 
In ACS study, obese patients with T2DM had the highest thrombus (in µ2/mm, 
22801±13840, one way ANOVA p=0.02). Both HsCRP (11.2±3.5) and TNF-α 
levels (13.1±10.0) were the highest in this group (one way ANOVA p=0.009 and 
p=0.018, respectively, Table 4.14).The individual differences remained significant 
between the obese T2DM vs. non-obese DM and obese T2DM vs. non-obese 
controls upon applying Bonferroni’s correction. There were significant correlation 
between TNF-α levels and thrombus area in obese individuals (rho 0.413, 
p=0.015) and it persisted after adjusting for diabetic status (rho=0.361, p=0.042). 
In stable CAD study, thrombus area did not differ between obese and non obese 
individuals after clopidogrel therapy. There were no differences in inflammatory 
markers between the groups (Table 4.15). 
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 Obese+  
T2DM (n=23) 
Non obese+ 
T2DM 
(n=17) 
Obese+ 
non DM 
(n=16) 
Non obese+ 
non DM 
(n=24) 
P 
value 
 Mean S.D Mean S.D Mean S.D Mean S.D  
Thrombus 
area, 
µ2/mm 
22801 13840 20801 7111 12477 7001 14405 7507 0.002 
HSCRP 
mg/l 
13.1 10.0 7.7 9.2 9.7 14.2 3.5 3.6 0.009 
TNF-α, 
ng/ml 
11.2 3.5 9.1 2.2 8.9 2.1 9.3 1.8 0.018 
Table 4.14 Inflammation and thrombus of obese patients in ACS study 
Obesity was defined as BMI ≥ 30 kg/m2. 
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T2DM +stable 
CAD 
Aspirin+Clopidogrel  Aspirin+Placebo  
Obese (n=28) Non Obese 
(n=17) 
 Obese (n=30) Non Obese 
(n=15) 
 
 Mean S.D Mean S.D P value Mean S.D Mean S.D P value 
Thrombus area, 
baseline, µ2/mm 
13287 5521 15175 5442 0.296 13345 7564 15327 5729 0.406 
Thrombus area, 
visit 2, µ2/mm 
10446 3790 12485 3467 0.095 13789 7126 6101 15142 0.556 
Fibrinogen, g/l 3.4 0.7 3.4 0.6 0.977 3.4 0.6 2.9 0.9 0.544 
HsCRP, mg/l 4.8 4.9 3.7 3.6 0.469 3.4 3.3 3.5 4.2 0.885 
TNF-α, ng/l 10.7 5.4 9.7 5.0 0.540 10.0 4.1 11.2 6.3 0.469 
 
Table 4.15 Inflammation and thrombus in patients with T2DM and obesity (Stable CAD study).  
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4.4.2 Discussion 
Obesity and metabolic syndrome are independently associated with higher 
cardiovascular events in T2DM. Obesity increases the thrombotic tendency in 
T2DM by direct and indirect means. Higher levels of platelet activation, 
inadequate response to antiplatelet agents (e.g. aspirin) and reduced fibrinolysis 
were documented in T2DM (Santilli et al., 2012),(Das and Mukhopadhyay, 
2011),(Schneider et al., 2009),(Meerarani et al., 2007). Obesity is an independent 
risk factor for poor outcomes in patients after NSTE-ACS(Bhatt, 2008). My study 
has shown for the first time a direct relationship between whole blood thrombus 
and obesity in patients with T2DM after NSTE-ACS. 
Studies have shown a significant association between obesity and inflammation. 
It has been claimed that inflammatory mediators are responsible for the initiation 
and perpetuation of insulin resistance and islet cell damage in T2DM (Gregor and 
Hotamisligil, 2011). As discussed earlier, inflammation increased blood 
thrombogenicity (Levi and van der Poll, 2010). In obese individuals, it is possible 
that inflammation could have been the missing link between T2DM diabetes and 
resultant prothrombotic state (Doupis et al., 2011). Recently a long term follow up 
study on patients with obesity and T2DM failed to show significant benefits with 
strict weight reduction and it is possible that inflammation plays a crucial role in 
determining their cardiovascular outcomes (The Look Ahead Research Group, 
2013). Although my study was not aimed at establishing the causative role of 
inflammation in obese T2DM and blood thrombogenicity, my data may serve as a 
hypothesis generating tool which has to be confirmed by future studies. 
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4.5 VerifyNow® platelet reactivity indices and platelet dependent 
thrombus 
4.5.1 Results – ACS study 
I analysed platelet reactivity in 28 patients with T2DM and 14 patients without DM 
after NSTE-ACS, for VerifyNow® sub study to measure effects of aspirin and 
clopidogrel. Baseline characteristics of the patients were similar as seen in the 
main study (Table 4.16). Patients with T2DM had higher prevalence of treated 
hypertension and dyslipidaemia. On treatment platelet hyperactivity to aspirin 
was not statistically different between both the groups (ARU, mean±SD: T2DM 
411±31.1 vs. Non DM 423±63.9, p=0.584, Figure 4.8). All but one patient (in 
T2DM group) showed good response to aspirin using a cut off of 495 units. On 
treatment platelet hyperactivity index for clopidogrel therapy, PRUz, was 
numerically higher but showed no statistical significance between diabetic and 
non-diabetic patients (Mean±SD: 246±58.9 vs. 220±82.3, p=0.427, Table 4.17, 
Figure 4.8). Percentage inhibition as calculated by using the manufacturer’s 
formula for clopidogrel was 24% in T2DM and 31% in non DM (p=0.096). The 
distribution of PRUz values was highly skewed in both the groups (Figure 4.9). 
Using a PRUz cut off of ≥ 240 units, 43% (n=12) of T2DM and 29% (n=4) of 
those without DM were “hyporesponders” to clopidogrel but this difference was 
not statistically significant (p=0.505). PRUz values did not correlate with thrombus 
area (rho 0.269, p=0.089, Figure 4.11. There was also no correlation between 
thrombus area and ARU values (rho 0.034, p=0.849). Thrombus area was 
numerically lower between those who had a good response to clopidogrel (PRUz 
less than 240) and those who had low response to clopidogrel (thrombus area, 
µ2/ mm, mean±SD, 17017 ±11000 vs 20744±9132, p=0.263), but the difference 
lacked statistical difference. When stratified by clopidogrel response (cut off value 
of ≥ 240 PRUz) and diabetic status, patients with T2DM and low response to 
clopidogrel showed a trend for the highest thrombus whereas thrombus was 
lowest in those without T2DM and good response to clopidogrel (one way 
ANOVA F=2.177, p=0.107, Figure 4.10). 
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4.5.2 Results – Stable  CAD study 
Baseline characteristics of patients who had clopidogrel and placebo were 
discussed earlier (Table 4.3). Based on a PRUz cut-off value of ≥240, there were 
18 patients (44%) in whom a good response to clopidogrel was detected. After 
one week of clopidogrel 75 mg once daily, the absolute mean PRUz values fell 
from 321±40.2 at baseline to 258±61.5, p=0.001 and were unchanged in the 
placebo arm (mean±SD) 320±78.1 to 336±48.5, p=0.123 (Table 4.16). The mean 
absolute reduction of PRUz values in clopidogrel group was 78.2 (95% CI 52.8 to 
103.5, Figure 4.12, Figure 4.13). Platelet inhibition to clopidogrel, as measured by 
VerifyNow® showed a significant change from 1.5% at baseline to 20% after one 
week of clopidogrel therapy. For aspirin, ARU values at baseline for the treatment 
and placebo arms were (mean±SD), 456±53.9 vs. 468±73.2 and were not 
significantly altered in either group on the second visit 440±76.8 vs. 452±57.3 
respectively (Table 4.18). Thrombus area had no correlation with PRUz (rho 0.08, 
p=0.49, Figure 4.14) and was numerically higher in  clopidogrel hyporesponders 
but not statistically different when compared to those who had good response to 
clopidogrel (mean thrombus area±SD, µ2 per mm: 12186±4294 vs. 10438±3401; 
p=0.17, figure 4.15). In patients who received clopidogrel, change in thrombus did 
not correlate with change in PRUz (rho 0.172, p=0.30). After one week of 
clopidogrel therapy, there were significant associations between PRUz and 
HsCRP, CD40 ligand and TNFα, respectively [Figure 4.16]. Platelet count and 
fibrinogen levels had no relationships to PRUz values. BMI levels correlated with 
PRUz (r=0.383, p=0.012), percentage of platelet inhibition after clopidogrel 
therapy (r=-0.327, p=0.037) and delta values of PRUz (-0.309, p=0.047) but 
fibrinogen and diabetes control as assessed by HbA1c levels showed no 
association to PRUz values in stable CAD patients with T2DM. 
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 T2DM (n=28) Non DM (n=14)  
 Mean±SD Median 
(IQR) 
Mean±SD Median 
(IQR) 
P value 
Demographic data 
Age, years 64±11 66 (53-74) 58±8 57(52-64) 0.310 
Male gender, % (n) 50.0(14)  85.7(12)  0.207 
Body mass index, 
kg/m2 
35±9.9 31(27-40) 31±5.1 30(29-33) 0.989 
Waist to hip ratio 1.0±0.05 
1.0 (0.9-
1.1) 
1.0±0.05 
0.9 (0.9-
1.1) 
0.986 
Systolic BP, mmHg 130±15.2 
128(122-
140) 
121±12.1 
119(112-
130) 
 
0.090 
Diastolic BP, mm Hg 71±11.1 71(60-78) 71±6.2 72(68- 74) 0.566 
Risk profile: %(n) 
History of 
hypertension, %(n) 
17.9(5)  14.3  (4)  0.005 
History of 
dyslipidaemia 
64.3 (18)  42.9 (6)  0.007 
History of chronic 
kidney disease 
17.9(5)  21.4  (3 )  0.869 
History of acute 
myocardial infarction 
17.9(5)  7.1 (1)  0.055 
Medications: %,(n) 
B blockers, %,(n) 71.4 (20)  100 (14)  0.407 
Calcium channel 
blockers, %(n) 
32.1(14)  7.1 (1)  0.051 
Laboratory data:mean±SD 
HBA1c, % 7.5±1.6 
7.3(6.4-
8.2) 
5.7±0.3 
5.7(5.5-
5.9) 
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 T2DM (n=28) Non DM (n=14)  
 Mean±SD Median 
(IQR) 
Mean±SD Median 
(IQR) 
P value 
Random plasma 
glucose, mmol/l 
10.8±7.7 7.8(5.8 5.3±0.6 
6.9(5.3-
8.1) 
 
Fasting plasma 
glucose, mmol/l 
8.3±3.5 
7.4(5.9-
9.7) 
5.7±0.3 
5.2(4.9-
5.6) 
 
Haemoglobin, g/dl 12.9±1.9 
13.8(11.6-
14.1) 
13.6±1.5 
13.7(12.4-
15.1) 
0.946 
Platelets, x1000/mm3 272±101 
254(206-
316) 
287±105 
252(211-
347) 
0.695 
Fibrinogen, g/l 4.5±0.7 
4.4(4.2-
5.0) 
3.7±1 
3.6(3.0-
4.3) 
0.071 
eGFR (ml/min/1.73 
m2) 
67±23 63(57-78) 74±16 73(57-91) 0.462 
Total cholesterol, 
mmol/l 
3.1±0.9 
3.2(2.6-
3.7) 
3.6±1 
3.4(3.0-
4.1) 
0.659 
LDLc, mmol/l 1.4±0.6 
1.6(1.0-
1.9) 
2.1±0.8 
2.0 (1.4-
2.5) 
0.071 
HDLc, mmol/l 0.9±0.2 
0.9(0.8-
1.1) 
2.1±0.8 
0.9(0.8-
1.1) 
0.967 
Triglyceride, mmol/l 1.8±1.1 
1.4(1.0-
2.1) 
1±0.2 
1.3(1.1-
1.6) 
0.320 
Troponin I, µg/l 3.1±3.6 
1.7(0.1-
4.8) 
1.7±0.7 
0.6(0.2-
2.2) 
0.172 
hsCRP mg/l 14.2±14.1 
5.1(2.1-
28.9) 
3.4±2.5 
 
2.8(2.0-
4.0) 
0.390 
Table 4.16 Baseline characteristics of VerifyNow® sub study (ACS study).  
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Mean±SD T2DM (n=28) Non DM (n=14) P value 
ARU 411±31.1 423±63.9 0.584 
PRUz 246±58.9 220±82.3 0.427 
Platelet 
inhibition, % 
24±15.8 30.9±21.3 0.096 
Table 4.17 VerifyNow® indices for ACS study.  
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Figure 4.8 VerifyNow® platelet reactivity indices - ACS study 
The aspirin on treatment platelet reactivity was measured by a dimensionless unit 
ARU and clopidogrel on treatment platelet reactivity was measured by a similar 
index PRUz.  ARU values were nearly equal between the groups (mean±SD: 
T2DM 411±31.1 vs. Non DM 423±63.9, p=0.584). The mean values of PRUz was 
numerically higher but showed no statistical difference between T2DM and non-
diabetic participants (mean±SD: 246±58.9 vs. 220±82.3, p=0.427). Error bars 
represent 1X standard deviation. 
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Figure 4.9 PRUz levels in patients after NSTE-ACS.  
On treatment platelet hyperactivity to clopidogrel was measured by using a PRUz 
cut off of 240 units. 43% (n=12) of T2DM and 29% (4) of those without DM were 
“hyporesponders” to clopidogrel but this difference was not statistically significant 
(p=0.505). The clopidogrel response was heterogeneous in both the groups with 
a highly skewed distribution. The dotted line represents the cut off of PRUz units 
for high on treatment platelet hyperactivity. The solid bars represent mean values 
of PRUz and 2Xstandard deviation.  
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Figure 4.10 Thrombus area according to diabetic status and clopidogrel response 
after NSTE-ACS.  
When stratified according to clopidogrel response (cut off value of 240 PRUz) 
and diabetic status, patients with T2DM and low response to clopidogrel had the 
highest thrombus area whilst those without T2DM and good response to 
clopidogrel had the lowest area. However, this trend was not statistically 
significant. (One way ANOVA F=2.177, p=0.107). The solid bars represent 1X 
standard deviation. 
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Figure 4.11 Correlation between thrombus area and VerifyNow® PRUz values in 
ACS study. The correlation was not significant (rho 0.269, p=0.089). 
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Table 4.18 VerifyNow® indices of stable CAD study.  
 
 Clopidogrel (n=45) 
 
 Placebo (n=45) 
 
 
Mean±SD, 
units 
Baseline Visit 2 P 
value 
Baseline Visit 2 P 
value 
ARU 456(53.9) 440±76.8 0.124 468(73.2) 452±57.3 0.426 
PRUz  321±40.2 258±61.5 0.001 320±78.1 336±48.5 0.123 
% inhibition 2.3±5.9 20.4±16.1 0.001 1.5±3.4 1.14±2.5 0.380 
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Figure 4.12 PRUz values of patients in stable CAD study.  
Baseline values of patients in placebo and clopidogrel groups were similar. After 
one week of therapy, PRUz values were lower in clopidogrel group and remained 
unchanged in placebo group. (Clopidogrel, (mean±SD) 321±40.2 to 258±61.5, 
p=0.001; placebo 320±78.1 to 336±48.5, p=0.123). Response to clopidogrel 
showed a heterogeneous spread of PRUz from 46 (very good response) to 382 
(no response). 44% in clopidogrel group had PRUz values lower than 240 (good 
clopidogrel response) and there was a considerable variation in reduction of 
PRUZ values. Solid lines represent mean of the values. 
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Figure 4.13 Changes in PRUz after clopidogrel therapy in stable CAD study.  
Mean (mean±SD) PRUz values reduced from 321±40.2 to 258±61.5 in 
clopidogrel group. There was a considerable variability in reduction of PRUz 
values, mean reduction was 78.2 (95% CI 52.8 to 103.5). 
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Figure 4.14 Correlation between PRUz values and thrombus area in stable CAD 
study.  
PRUz values and thrombus area in patients with T2DM and CAD who had 
clopidogrel in addition to routine aspirin therapy showed no correlation (rho= 
0.08, p=0.49).   
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Figure 4.15 Thrombus area based on PRUz values in stable CAD study 
Patients with T2DM who had one week of clopidogrel therapy have been defined 
as clopidogrel hyporesponders if their PRUz values were ≥ 240. Thrombus area 
did not differ between clopidogrel hypo responders and clopidogrel responders 
(mean thrombus area±SD, µ2 per mm: 12186±4294 vs. 10438±3401; p=0.17).  
Whisker plot shows median (central line), 25-75 interquartile range and the solid 
bars represent the range between minimum and maximum values. 
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Figure 4.16  PRUz values and biomarkers in stable CAD study.  
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There were significant associations between HSCRP (r= 0.1168, p=0.0446), 
soluble CD40 ligand (r=0.2676, p=0.0015) and tumour necrosis factor α 
(r=0.2676, p=0.0369). Platelet count, plasma fibrinogen and serum P selectin 
valued had no significant correlation to PRUz. 
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4.5.3 Discussion 
My study showed a trend towards higher PRUz index in patients with T2DM who 
had NSTE-ACS treated with aspirin and clopidogrel (75mg of each daily) and a 
significant reduction in PRUz platelet reactivity index in patients with T2DM and 
stable CAD following one week of clopidogrel (75mg od) therapy. For the first 
time, VerifyNow® indices were compared to platelet dependent thrombus (PDT) 
from the Badimon chamber. Comparison of point of care device indices to whole 
blood thrombus generated from the ex vivo chamber (mimicking flow conditions 
in coronary arteries) is novel and logical and will be of interest to clinicians 
considering using these devices to tailor antiplatelet therapy. 
Thrombus (measured as total thrombus area) failed to show any correlation to 
PRUz levels and there was no correlation to changes in PRUz values (delta 
PRUz) to changes in thrombus (delta thrombus). These data suggest that PRUz 
values cannot serve as a surrogate marker for reduction in thrombus area in 
T2DM. When stratified according to presence or absence of T2DM and response 
to clopidogrel, there was a non-significant trend showing that those with T2M and 
“hyporesponse” had greater thrombus. 
Numerous studies have evaluated the use of VerifyNow® in routine clinical 
practice to guide the choice and monitoring of antiplatelet therapy in patients with 
coronary artery disease. My data confirms that on treatment platelet hyperactivity 
to clopidogrel as measured by PRUz has high variability in patients with T2DM 
after NSTE-ACS and in those with stable CAD. Mean PRUz values were non-
significantly higher in T2DM after ACS reflecting inadequate antiplatelet response 
in these high risk individuals. Majority of the studies showed 20-25% patients had 
adequate platelet inhibition after clopidogrel therapy in the ACS and stable CAD 
groups. Difficulty in comparing data from various studies arises from their 
heterogeneity in study design, varying dosing regimens (e.g. 75mg, 150mg), and 
different baseline characteristics. International cardiac societies, for the same 
reasons, have urged a note of caution in adopting VerifyNow® assessment as 
standard care in patients with cardiovascular disease (Bonello et al., 2010). 
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Platelet reactivity to clopidogrel as measured by PRUz was normally distributed 
in my cohort in both the studies but with a heterogeneous spread. Only 44% 
patients showed a good response to clopidogrel in my cohort based on PRUz cut 
off of < 240 units with a trend towards higher PRUz in T2DM after NSTE-ACS. 
BMI, fibrinogen and HbA1c showed no correlation to PRUz in patients after 
NSTE-ACS but BMI showed good correlation to PRUz in stable CAD patients. 
Previous studies have shown that in T2DM, elevated fibrinogen and raised BMI 
were independent predictors of high on treatment platelet reactivity in individuals 
with stable CAD (Ang, Palakodeti et al. 2008). 
Dose of clopidogrel other than 75mg is controversial in patients with T2DM. A 
small study tested the role of 150mg of clopidogrel in T2DM and found that 
platelet inhibition increased from 27.1 ± 12% to 40.6 ± 18% (p = 0.009). However, 
a significant number of patients still had PRUz values above 240 at this dosage 
(Angiolillo et al., 2008a). Newer agents such as ticagrelor or prasugrel which 
showed superiority over clopidogrel in VerifyNow® sub-studies(Alexopoulos et 
al., 2013) might have resulted in better platelet inhibition in my subjects but these 
agents were not available when the study protocol was approved. 
To address the variability and “hyporesponse” to clopidogrel, The SWAP 
(SWitching Anti Platelet) study examined the role of changing patients to 
prasugrel instead of clopidogrel and found that prasugrel achieved earlier and 
better platelet inhibition in those who exhibited high on treatment platelet 
reactivity to clopidogrel (Angiolillo et al., 2010). Similar results were shown by 
Gurbel et al when they used ticagrelor in patients who showed hypo 
responsiveness to clopidogrel. In addition to overcoming hypo responsiveness to 
clopidogrel, its antiplatelet effects were greater in both clopidogrel responders 
and hyporesponders. Nearly all clopidogrel hyporesponders and responders 
treated with ticagrelor had PRUz values less than 235 (Gurbel et al., 2010a)and 
the variability and low response to clopidogrel were attributed to its metabolite. 
Attempts made to assess levels of the thiol derivative active metabolite of 
clopidogrel and its relationship to PRUz of clopidogrel yielded inconsistent results 
due to its pharmacokinetic properties. However, Bouman et al showed thiol active 
metabolite levels correlated well with PRUz values (Bouman et al., 2010). 
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VerifyNow® has been evaluated for prediction of clinical events in many studies. 
Patients with T2DM and high on treatment platelet reactivity (HOTR)  as 
measured by PRUz had the highest incidence of peri-procedural MI compared to 
those with low  HOTR (p for trend = 0.0008). PRUz value of ≥240 was an 
independent predictor of peri-procedural MI (odds ratio 8.34, 95% confidence 
interval 2.60 to 26.76, p = 0.0003) (Migliorini et al., 2009). In the Gauging 
Responsiveness With A VerifyNow® P2Y12 Assay: Impact on Thrombosis and 
Safety (GRAVITAS) trial, patients who had PRUz ≥230 were given 150mg of 
clopidogrel instead of 75mg od. At 6 months, high-dose clopidogrel did not 
reduce cardiovascular events compared with standard-dose clopidogrel (Price et 
al., 2009). This negative study cautioned clinicians not to use VerifyNow® to tailor 
clopidogrel treatment. It is possible that high on treatment platelet reactivity to 
clopidogrel is an independent marker of future cardiovascular events which may 
not be reduced simply by dose adjustment. In a post hoc  analysis of the study, 
the investigators found that after adjustment for other significant predictors of 
outcome, PRUz <208 units remained independently protective of the primary end 
point at 60 days (hazard ratio 0.23; 95% CI, 0.05 to 0.98; P=0.047) and at 6 
months (hazard ratio, 0.54; 95% CI, 0.28 to 1.04; P=0.065) (Price et al., 2011). In 
a study by Park et al, patients with ≥235 PRUz units had significantly higher rates 
of cardiac death and spontaneous MI (2.5% vs. 0.5%, p = 0.022) and 
multivariate-adjusted analysis showed that it was an independent predictor of the 
composite of cardiac death and nonfatal MI at one year. Interestingly, the 
predictability of this test was stronger in those without risk factors for 
cardiovascular disease, such as hypertension, diabetes mellitus, or dyslipidaemia 
compared to those with conventional CV risk factors. Conversely, in a larger 
study by the same group on more than 2000 patients who had drug eluting stents 
for CAD followed for 2 years showed, the occurrence of the primary endpoint 
(cardiac mortality, fatal or non fatal myocardial infarction) did not significantly 
differ among patients with and without high PRUz values (HOTR, PRUz ≥235) 
[2.8% vs. 2.4% at 2 years; hazard ratio [HR]: 1.33, 95% confidence interval [CI]: 
0.88 to 2.01; p = 0.18] (Jeong et al., 2011; Oh et al., 2012; Park et al., 2012). The 
same group showed that predictability of VerifyNow® with regard to future 
cardiac events was better in patients after ACS (Park et al., 2013). Recently 
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published landmark ARCTIC trial (Assessment by a Double Randomization of a 
Conventional Antiplatelet Strategy versus a Monitoring-guided Strategy for Drug-
Eluting Stent Implantation versus Continuation One Year after Stenting) studied 
the role of routine platelet monitoring and dose adjustment in those who are 
hyporesponders to clopidogrel. 2440 patients who underwent elective stent 
implantation for CAD had been randomised to a VerifyNow® based dose 
adjustment for clopidogrel or conventional treatment arm. There were no 
differences in composite end point of death, acute myocardial infarction, stent 
thrombosis, stroke, or need for urgent revascularisation (OR  1.13; 95% CI, 0.98 
to 1.29; P=0.10) and bleeding in both the arms at one year. Interestingly 37.5% 
patients were hyporesponders to clopidogrel using a cut off of PRUz 208 and 
7.5% to aspirin using a ARU value of 550 (Collet et al., 2012). ADAPT-DES study 
(Assessment of Dual AntiPlatelet Therapy With Drug Eluting Stents) showed that 
among 11,000 patients who were entered on a registry, 42.7 % had poor 
response to clopidogrel based on a VerifyNow® cut off value of 208 PRUz. Stent 
thrombosis was higher (1.3% vs. 0.5%, p=0.005) but bleeding events were lower 
(5.6% vs. 6.7%, p=0.04) in those who had high platelet reactivity after clopidogrel 
therapy. Incidence of acute MI was higher in these patients (3.9% vs. 2.7%, 
p=0.001). One year mortality was higher in patients (2.4% vs. 1.5%, p=0.001) 
who had high platelet reactivity after clopidogrel therapy but in multivariable 
analysis, no independent association was seen between clopidogrel 
hyporesponsiveness and mortality (Stone et al., 2013).  However, in a meta-
analysis of 6 studies, incremental PRUz values predicted higher cardiovascular 
events and on a continuous scale, every 10-U increase in PRU was associated 
with a significantly higher rate of the composite primary endpoint death, 
myocardial infarction or stent thrombosis.(HR: 1.04; 95% CI: 1.03 to 1.06; p < 
0.0001). PRUz value ≥230 appeared to best predict the combined end-point of 
death, MI, or stent thrombosis (p < 0.001). A PRUz value ≥230 was associated 
with individual endpoints of death (HR: 1.66; 95% CI: 1.04 to 2.68;     p = 0.04), 
MI (HR: 2.04; 95% CI: 1.51 to 2.76; p < 0.001), and stent thrombosis (HR: 3.11; 
95% CI: 1.50 to 6.46; p = 0.002). These findings suggest that  VerifyNow® may 
be useful in predicting short to medium CAD risk in patients up to 1 year after 
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they had percutaneous coronary intervention but not after 2 years (Brar et al., 
2011). 
In contrast to clopidogrel, aspirin induced platelet inhibition as measured by ARU 
units showed a very narrow range of values and less variability in T2DM. In my 
study, ARU values were similar between T2DM and non DM and were unaffected 
after clopidogrel therapy in stable CAD patients. Only one patient had HOTR with 
aspirin after NSTE-ACS (non DM) and 13.4% (12 patients out of 90) had HOTR 
in stable CAD study. Using an ARU cut off value of ≥550, in a small study of 
healthy volunteers and those with stable CAD, no patient was hyporesonsive to 
aspirin (Nielsen et al., 2008). In an another study of patients with stable CAD on  
75mg of aspirin, T2DM patients showed significantly higher levels of platelet 
aggregation compared to non-diabetic patients, where increased levels of platelet 
activation was measured by P selectin (Mortensen et al., 2010). Aspirin use at 
standard doses of 75-100mg per day has been detected by VerifyNow® in all the 
subjects (100%) and its levels highly correlated with ‘gold standard’ LTA assay in 
a study by Blais et al  (Blais et al., 2009). Gurbel et al showed that in patients with 
stable CAD with T2DM had higher on treatment platelet reactivity (PRUz values) 
when treated with aspirin 81mg which was partly overcome at dose of 150mg, 
and 325mg dose showed even greater responsiveness. VerifyNow® ARU values 
correlated with traditional light transmission aggregometry data (LTA) and urinary 
thromboxane levels. Interestingly, for each aspirin dosage (e.g. 81mg, 150mg, 
325mg) ARU levels were higher in T2DM compared to those without DM  
(DiChiara et al., 2007). Multiple measurements of platelet reactivity were tested 
with arachidonic acid in healthy individuals taking 75mg of aspirin. VerifyNow® 
results when compared to LTA showed significantly less coefficient of variation 
but correlated well with serum thromboxane levels (Grove et al., 2010). However, 
there was no correlation between ARU and thrombus area in both my studies, 
implying that ARU at levels <495 is a poor marker of thrombogenicity in those on 
aspirin therapy and may explain some of these variability observed in previous 
studies. 
I studied the role of inflammation in predicting platelet reactivity using 
VerifyNow®. I found that there was a strong association between inflammation 
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and VerifyNow® PRUz values after clopidogrel therapy. There was a significant 
relationship between inflammation and thrombus as discussed before (vide 
supra: 4.3.3, Discussion chapter on platelet dependent thrombosis). One week 
therapy with clopidogrel did not reduce the levels of inflammatory cytokines 
TNFα, IL-1, IL-6 and IFNγ. It is possible that persistent inflammation in 
clopidogrel treated individuals can play a significant role in future thrombotic 
event in patients with T2DM irrespective of PRUz values.  My results underscore 
the point that VerifyNow® results are very “platelet centric” and I suggest caution 
should be exercised when using the values to tailor individualised therapy. 
VerifyNow® did not account for non platelet mediators of thrombus and thus 
lacked correlation to thrombus in my cohort. My findings re-iterate the concerns 
expressed in the current guidelines which suggest VerifyNow® should remain as 
a research tool and is not for routine clinical practice (Bonello et al., 2010). 
  
215 
4.6 Thromboelastography® (TEG) and Platelet Mapping™ 
4.6.1 Results - Viscoelastic properties and thrombus architecture in ACS 
study 
Baseline characteristics are presented in Table 4.19. By virtue of selection, T2DM 
patients demonstrated the typical metabolic syndrome phenotype with higher 
triglycerides, HbA1c and systolic blood pressure and lower LDL cholesterol in 
T2DM. 
T2DM was associated with formation of higher thrombus in both rheological 
conditions in the ex-vivo chamber. More specifically, at high shear rate conditions 
thrombus area were (median, µ2/mm, interquartile range), 14861 (8003-30161) 
vs. 8908 (6812-11996) for T2DM and control groups, respectively p=0.045 and 
low shear thrombus was 10715 (6562 – 15932) v 6062 (3865-6312), p=0.007. A 
significant association was seen between fibrinogen plasma levels and thrombus 
in the combined cohort (rho 0.551, p=0.002) (Figure 4.17). There were no 
significant correlations between thrombus and HbA1c, LDL cholesterol, body 
mass index and duration of diabetes. 
In thromboelastography, the time to form stable thrombus (a marker of initiation 
of fibrin polymerisation) was prolonged in T2DM whilst clot index (CI), a measure 
of the thrombus strength, was lower [median (inter quartile range), -0.2(-1.7 to 
0.7) vs. 1.0(-0.9 to 3.3), p=0.044). On the other hand, the rate of thrombus 
retraction, measured over 90 minutes (L parameter) in T2DM was slower, [rate of 
thrombus retraction mm/min, median (inter quartile range), 27.8(11.7 – 70.7) vs. 
78.8(68.5-109.6) p=0.002)].  All other TEG® parameters showed no statistically 
significant differences between the groups (Table 4.20). There was a negative 
correlation between rate of thrombus retraction and thrombus area in low shear 
state in the combined cohort (rho -0.450, p=0.016, Figure 4.17), but not in the 
high shear chamber (rho -0.153, p=0.436). 
VerifyNow® studies were performed for these patients and aspirin reactive units 
(ARU) were almost similar between the groups. However, P2Y12 reactive units 
were higher in T2DM [PRUZ: median (IQR) 259 (222-311) vs. 205 (189-232), 
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p=0.028]. One patient (with T2DM) had high on treatment reactivity (HOTR) to 
aspirin.  13 patients [9 (64.2 %) with T2DM and 4 (28.6 %) non DM] had HOTR to 
clopidogrel. The biochemical markers of platelet reactivity, P selectin was 
numerically higher and CD40 ligand was numerically lower in T2DM and the 
differences lacked statistical significance (Table 4.20). There was no correlation 
between PRUz values and thrombus area (rho=0.153, p=0.544)  
Scanning electron microscopy (SEM) showed thrombus architecture was different 
in T2DM. In the non T2DM, thrombus appeared well organized with thick fibrin 
fibres were arranged longitudinally in one direction, with few side branches. In 
contrast, in patients with T2DM, thrombus appeared disorganised. Fibrin fibres 
were thinner, with more side branches, giving a tangled, web or mesh like 
appearance (Figure 4.18). 
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Median (interquartile 
range) or %[n] 
T2DM (n=14) Non T2DM 
(n=14) 
P 
value 
Demographic data: 
Age, years 62 (51-68) 54 (51-63) 0.401 
Male gender, 71.4[10] 92.9[13] 0.331 
Body mass index, kg/m2 33.4(29.3-43.4) 30.6 (27.4-30.7) 0.114 
Waist to hip ratio 1.0(0.9-1.0) 1.0(0.9-1.0) 0.781 
Systolic BP, mmHg 134 (124-147) 120 (112-136) 0.031 
Diastolic BP, mmHg 77(72-82) 72 (68-80) 0.227 
Risk profile %(n):  
Hypertension  64.3[9] 21.4[3] 0.052 
Chronic Kidney Disease 21.4[3] 7.1[1] 0.601 
Medications:  
B blockers  85.7[12] 100 [14] 0.483 
Calcium channel blockers 28.6 [4] 7.1 [1] 0.331 
Laboratory data: 
HbA1c, % 6.6 (6.2 -8.2) 5.6 (5.3-6.1) -- 
Random plasma glucose, 
 mmol/l 
8.2 (6.3-11.4) 6.9 (4.9 -7.8) 
-- 
Fasting plasma glucose, 
 mmol/l 
7.3 (5.6-10.9) 5.1 (4.6-5.5) 
-- 
Haemoglobin, g/dl 13.8 (12.8-15.4) 13.7 (12.9-15.3) 0.865 
Platelets, x1000/mm3 252 (191-309) 257 (209-354) 0.448 
Fibrinogen, g/l 4.4 (4.1-4.6) 3.6 (2.9-4.4) 0.095 
Creatinine, µmol/l 100(86-110) 99 (81-106) 0.603 
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Median (interquartile 
range) or %[n] 
T2DM (n=14) Non T2DM 
(n=14) 
P 
value 
Total cholesterol, mmol/l 3.2 (2.6-4.4) 3.4 (3.0-4.0) 0.667 
LDLc, mmol/l 1.3 (1.0-1.7) 1.9 (1.6-2.5) 0.023 
HDLc, mmol/l 0.9 (0.7-1.1) 0.9 (0.8-1.2) 0.769 
Triglyceride, mmol/l 1.8 (1.4-3.4) 1.1 (0.9 -1.5) 0.002 
Troponin I, µg/l 1.2 (0.1 – 10.1) 2.0 (1.1-4.1) 0.408 
Table 4.19 Baseline characteristics of Thromboelastography in ACS sub study.  
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Median  
(interquartile range) 
 T2DM (n=14)  Non T2DM (n=14)  
P 
value 
Thrombus kinetics 
R time, min 
7.3 (6.6 to 8.5) 6.6 (4.6 to 7.1) 
 
0.021 
Maximum amplitude, 
MA, mm 
67.7(62.0 to 70.1) 67.4 (63.8 to 74.1) 0.573 
K time, min 1.8 (1.7to 2.2) 1.6 (1.2 to 2.3) 0.476 
α-angle 64.5 (54.5 to 73.1) 68.6 (58.0 to 66.8) 0.306 
Clot index -0.2 (-1.7 to 0.7) 1.0 (-0.9 to 3.3) 0.044 
Rate of thrombus 
retraction (L) mm/min 
27.8 (11.7 to 70.7) 78.8 (68.5 to 109.6) 0.002 
Platelet Reactivity    
ARU 419(398-422) 403(390-404) 0.623 
PRUz 259(222-311) 205 (189-232) 0.028 
Percentage inhibition, % 20(9-32) 32(22-34) 0.083 
P selectin, µg/ml 74.8(59.3 – 77.0) 53.1 (39.7 – 68.9) 0.062 
CD40 ligand, µg/ml 2934 (2046-3520) 3512 (1674-4220) 0.711 
Table 4.20 Thromboelastography parameters and biomarkers in ACS study.  
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Figure 4.17 Fibrinogen, thrombus retraction and PRUz correlations to thrombus 
area.  
Plasma fibrinogen was positively correlated to thrombus area (rho= 0.551, 
p=0.002). Thrombus retraction (autolysis) had a negative correlation (rho= -
0.450, p=0.016). There was no correlation between VerifyNow® values and 
thrombus area (rho=0.153, p=0.544).   
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Figure 4.18 Thrombus images from Badimon Chamber and scanning electron 
microscopy in ACS study 
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4.6.2 Discussion - Viscoelastic properties and thrombus architecture in 
ACS study  
In this pilot study I studied the impact of T2DM on the magnitude as well as 
structural and mechanical characteristics of thrombus from NSTE-ACS patients. I 
found increased thrombus formation, and altered thrombus kinetics in patients 
with T2DM after NSTE-ACS, a finding not hitherto reported in whole blood 
testing. Studies undertaken with the perfusion chamber rendered larger thrombus 
area both at high and low local shear rate condition in T2DM patients. Of interest, 
the observations on the different structural and kinetic characteristics of the 
thrombus have not been previously reported in whole blood testing.  The most 
striking difference in thrombus kinetics was an approximately three fold slower 
rate of clot retraction in diabetic participants and the rate of retraction correlated 
inversely with thrombus area. The time to form stable clot was also increased 
whilst clot index (a measure of strength) decreased. The rate of thrombus 
retraction was negatively correlated to thrombus quantity in this study which 
suggests that thrombus, in addition to being higher in quantity, also persists 
longer after initial formation. In vivo, persistence of thrombus would provide a 
nidus for more thrombus formation and this may lead to a pathophysiological 
cycle of ‘thrombus begetting thrombus’ in patients with T2DM. Although in vitro 
studies show impaired fibrinolysis (later phase of autolysis) in T2DM (Grant, 
2007), little is known of thrombus retraction which represents the early phase of 
autolysis. 
 SEM analysis of the thrombus (qualitative analysis) as a pilot study illustrated 
some important ultrastructural characteristics further explaining these findings. In 
the early stages of thrombogenesis (5 minutes of Badimon chamber study), 
thrombus in T2DM was composed of less compact and loosely arranged fibrin to 
fibrin structure. Scanning electron microscopy of thrombus revealed a markedly 
different architecture between the diabetic and non diabetic patients. Earlier 
studies using reconstituted plasma have shown altered fibrin structure in patients 
with T2DM, with reduced elasticity (Pieters et al., 2006). This arrangement of the 
fibrin fibres was similar to that seen in my study using whole blood in a surrogate 
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model of plaque rupture. The differing ultrastructural characteristics may in part 
explain the differences in thrombus kinetics seen on TEG®.  Thrombus in T2DM 
had thinner fibrin fibres, with more lateral aggregations, occurring in a 
disorganised, tangled or web like fashion. This may favour propagation of 
thrombus by trapping more cellular elements, and in addition, may make clot 
retraction and degradation more difficult.  Thus the increased thrombus quantity 
in T2DM may be due to both increased blood thrombogenicity generating larger 
thrombus and decreased degradation.  The presence of thinner fibrin fibres in 
T2DM may result in lower viscoelastic strength of diabetic thrombus and could be 
one explanation for the differences seen on TEG® (Pieters et al., 2008). The 
finding of loosely bound but persistent thrombus in diabetes may increase the 
potential for embolisation to distal arteries resulting in increased end organ 
damage. In addition, a less compact and loosely bound fibrin fibre arrangement is 
a marker of poor fibrinolysis (Alzahrani and Ajjan, 2010). Presence of less 
longitudinal twisting in T2DM could result in lower visco elastic strength of 
diabetic thrombus and can thus explain the differences seen in TEG® studies 
(Ajjan et al., 2009). T2DM is a prothrombotic state reportedly associated with 
higher on treatment platelet reactivity (HOTR). More patients with T2DM had 
HOTR with VerifyNow®, findings similar to main study. 
My findings provide additional mechanistic support for the proposal that 
‘perpetuation and propagation of diabetic thrombus’, with a pathophysiological 
cycle of “thrombus begets thrombus”, is responsible for increased recurrent acute 
coronary events in T2DM patients (Hess et al., 2012).  It is known that patients 
with T2DM have ‘vulnerable blood’ which is responsible for more major adverse 
cardiovascular events after NSTE-ACS (Bhatt, 2008).There are no published 
studies of differences in the viscoelastic properties and fibrin structure of 
thrombus in patients with and without T2DM after NSTE-ACS. It is possible that 
loosely bound diabetic thrombus which is higher in quantity may also embolise 
easily to distal arteries. Nevertheless, once formed, the diabetic thrombus was 
slower to undergo clot retraction (early autolysis) and along with the well known 
defects in fibrinolysis (late autolysis), these findings support the view that 
‘perpetuation and propagation of diabetic thrombus’ is responsible for recurrent 
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acute coronary events (Moreno and Fuster, 2004).  Thus my findings, in a small 
cohort, are novel, hypothesis generating and require further validation. 
This study showed the feasibility of measurement of blood thrombogenicity both 
qualitatively and quantitatively, in patients, optimally managed after NSTE-ACS, 
using a combination of point of care and laboratory assays. The differences seen 
in the ultrastructure and mechanistic properties of thrombus provide a focus for 
further studies that may lead to novel pharmacological treatments. 
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4.6.3 Results - Viscoelastic properties of thrombus in stable CAD study 
The differences in baseline characteristics between the groups who had 
clopidogrel and placebo were minimal and statistically non significant (Table 
4.21). Baseline TEG® and Platelet Mapping™ parameters also showed a similar 
trend between the groups. One week clopidogrel therapy reduced thrombus area 
in this sub-study (Table 4.22). Standard TEG® parameters (e.g. R, MA to kaolin, 
clot index) remained unchanged after a week of clopidogrel therapy, as did the 
results in placebo group (Table 4.23). Platelet mapping™ studies showed a 
significant reduction of maximum viscoelastic strength of thrombus after 
treatment with clopidogrel as measured by maximum amplitude (MA-ADP, in 
mm) upon stimulation by 10µl of ADP (59.9±7.4 vs. 54.0±10.8, p=0.007) (Table 
4.24). These values remain unchanged in placebo group. Despite being on 
chronic aspirin therapy, response to aspirin also improved significantly in my 
cohort of patients prescribed additional clopidogrel therapy. Reduction in 
maximum amplitude of the thrombus (MA-AA, in mm) upon stimulation with 10µl 
of arachidonic acid (34.7±19.2 vs. 25.9±15.7, p=0.002) was seen in my cohort in 
those who had clopidogrel (Figure 4.19). MA-AA was unchanged in those who 
were randomised to placebo (37.8±19.4 vs. 32.5±19.2, p=0.399). The thrombus 
lysis parameters clot retraction: L parameter and time to achieve maximum rate 
of lysis were not statistically different between both the groups after one week of 
therapy (Figure 4.19). 
There were significant albeit moderate correlations between thrombus area and 
various TEG® parameters as shown in the Figure 4.20 and Table 4.25. 
Importantly, platelet aggregation, as measured by the ‘percentage change in 
maximum amplitude to ADP stimulation after 1 week of clopidogrel therapy’ 
negatively correlated with reduction in thrombus area (delta thrombus) in 
clopidogrel treated individuals (rho=-0.482, p=0.009). In addition, maximum 
strength (MA) of the thrombus correlated with thrombus area (rho=0.260, 
p=0.041) and thrombus retraction (L parameter) negatively correlated with 
thrombus area (rho=-0.251, rho 0.047). 
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 Clopidogrel + 
aspirin (n=33) 
Placebo + 
aspirin (n=33) 
P value 
Demographic data: Mean±SD or %(n) 
Age, years 63.6±7.2 62.8±7.3 0.662 
Male gender, % (n) 84.8 (28) 87.9 (29) 1.000 
Body mass index, kg/m2 32.5±4.9 33.5±6.6 0.475 
Waist to hip ratio 1.0±0.1 1.0±0.1 0.139 
Systolic BP, mmHg 142±19.9 138±21.8 0.464 
Diastolic BP, mmHg 77±10.5 77±9.5 0.854 
Duration of diabetes, years 10±6.0 8±4.6 0.129 
Risk profile: %(n) 
Angina 75.8 (25) 66.7 (22) 0.589 
Previous MI 48.5 (16) 42.4 (14) 0.805 
PCI 30.3 (10) 24.2 (8) 0.783 
CABG 27.3 (9) 18.2 (6) 0.558 
Chronic kidney disease 6.1 (2) 24.2 (8) 0.082 
Medications: %,(n) 
Sulphonylurea 24.2 (8) 30.3 (10) 0.783 
Metformin 60.6 (20) 57.6 (19) 1.000 
Insulin 33.3 (11) 27.3 (9) 0.789 
Laboratory data:mean±SD 
Haemoglobin,  g/dl 13.6±1.3 13.9±1.2 0.369 
Platelets X1000 cells/ mm3 228±57.2 225±55.0 0.858 
Fibrinogen, g/ml 3.4±0.6 3.4±0.8 0.883 
HbA1c, % 7.5±1.3 7.6±1.0 0.856 
Fasting plasma glucose, mmol/l 8.6±5.1 8.1±2.2 0.562 
  
227 
 Clopidogrel + 
aspirin (n=33) 
Placebo + 
aspirin (n=33) 
P value 
eGFR,  ml/min/1.73m2 73±22.2 77±21.0 0.497 
Total cholesterol, mmol/l 3.6±0.7 3.6±0.6 0.716 
LDLc, mmol/l 1.9±0.6 1.8±0.5 0.395 
HDLc, mmol/l 1.1±0.3 1.1±0.3 0.885 
Triglyceride, mmol/l 1.6±0.8 1.7±0.9 0.815 
HsCRP, mg/l 4.3±4.5 3.6±3.9 0.525 
Table 4.21 Baseline characteristics of thromboelastography (stable CAD) sub  
study.  
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 I compared VerifyNow® assay and TEG® Platelet mapping™ in T2DM patients. 
There was a significant reduction in PRUz values in those who were randomised 
to clopidogrel. There was a significant correlation between ARU indices of 
VerifyNow® and maximum amplitude of the thrombus formed in TEG® upon 
stimulation by arachidonic acid (rho 0.376, p=0.044). In addition, there were small 
but significant negative correlations seen between ARU and thrombus lysis (rho -
0.389, p=0.028) and thrombin generation parameters (-0.356, p=0.045) (Figure 
4.21). PRUz (which measured clopidogrel response) showed no correlation to 
any of the TEG® or Platelet Mapping™ parameters (Table 4.25)  
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 Clopidogrel+Aspirin 
(n=33) 
Placebo+Aspirin (n=33) 
Mean±SD 
(μ2/mm) 
Baseline Visit 2 P value Baseline Visit 2 P 
value 
Thrombus in 
high shear 
chamber 
14014 
±5230 
11025
±4050 
0.001 13250 
±5501 
13723±
5693 
0.266 
Thrombus in 
low shear 
chamber 
9482 
±3842  
6707 
±2930 
<0.001 7142 
±3227 
6885 
±2424 
0.619 
Table 4.22 Thrombus area in Thromboelastography (stable CAD) sub study.  
 
 Clopidogrel n=33 Placebo n=33 
 Baseline  
1-week 
after 
therapy 
P 
value 
Baseline  
1-week 
after 
therapy 
P 
value 
R, min 6.1±1.5 6.6±1.7 .442 6.4±1.5 6.3±1.8 .389 
K, min 1.8±0.5 2.0±0.6 .646 1.8±0.5 1.8±0.8 .134 
MA, mm 65.2±4.0 64.1±4.4 .226 64.3±5.7 64.6±4.8 .304 
G 
dynes/sec 
9.6±1.7 9.1±1.7 .283 9.3±2.0 9.4±2.0 .219 
CI 0.5±2.0 0.1±2.0 .403  0.3±2.0 0.2±2.3 .452 
Table 4.23 Standard TEG® measurements (CAD study).  
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 Clopidogrel n=33 Placebo n=33 
 Baseline  
1-week 
after 
therapy 
P 
value 
Baseline  
1-week 
after 
therapy 
P 
value 
MA – CK, 
mm 
65.2±4.0 64.3±6.0 0.151 64.1±4.4 64.3±4.9 0.389 
MA-A, mm 11.4±6.6 11.8±4.1 0.703 15.1±9.2 14.3±7.7 0.968 
MA –AA, 
mm 
34.7 
±19.2 
25.9 
±15.7 
0.002 37.8 
±19.4 
32.5 
±19.2 
0.399 
MA-ADP, 
mm 
59.9±7.4 54.0 
±10.8 
0.007 59.9±8.7 57.1±9.2 0.338 
% 
Aggregation 
to AA 
43.9 
±33.6 
27.8±30.
7 
0.002 49.3 
±34.4 
41.5 
±37.4 
0.296 
% 
aggregation 
to ADP 
88.6 
±12.5 
80.0 
±18.2 
0.018 89.3 
±12.1 
83.5 
±19.3 
0.205 
Thrombin 
generation 
739 
±295.2 
741 
±269.3 
0.954 780 
±55.7 
783 
±56.1 
0.428 
Maximum 
rate of 
thrombin 
generation, 
min 
16.8 
±27.3 
12.7±3.9 0.391 11.7±2.8 12.8±4.6 0.290 
Thrombus 
retraction, L 
parameter 
mm/min 
75.3 
±22.8 
78.6 
±12.9 
0.150 82.4 
±16.2 
75.3 
±17.6 
0.153 
Maximum 
rate of 
thrombus 
retraction, 
min 
0.3±0.2 0.4±0.6 0.868 0.3±0.3 0.3±0.1 0.612 
Table 4.24 Platelet Mapping™ and V-curve data in stable CAD study. 
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Rho, (2-tailed p value) ARU PRUz 
R, min 0.043 -0.282 
 (0.816) (0.119) 
K 0.257 -0.237 
 (0.156) (0.192) 
MA for Kaolin -0.213 0.341 
 (0.242) (0.056) 
G dynes/sec -0.215 0.345 
 (0.238) (0.053) 
CI -0.220 0.268 
 (0.227) (0.138) 
MA for AA, mm 0.376* 0.069 
 (0.044) (0.722) 
MA for ADP, mm 0.300 0.109 
 (0.114) (0.572) 
Thrombin generation -0.148 0.300 
 (0.418) (0.095) 
Maximum rate of thrombin 
generation, min 
-0.356* -0.276 
 (0.045) (0.125) 
Rate of thrombus retraction, L 
mm/min 
-0.389* 0.112 
 (0.028) (0.540) 
Maximum rate of thrombus 
retraction, min 
0.124 0.160 
 (0.613) (0.513) 
*P<0.05   
Table 4.25 Correlations between VerifyNow® and thromboelastography (CAD 
study).  
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Figure 4.19 Changes in TEG®-Platelet Mapping™ platelet aggregation indices 
after 1 week of clopidogrel therapy 
Maximum amplitude of thrombus upon stimulation with Kaolin (MA_CK) and 
Activator F did not change with clopidogrel therapy in stable CAD study. There 
were significant changes in maximum amplitude of thrombus upon stimulation 
with arachidonic acid (MA-AA) and ADP (MA_ADP) after clopidogrel (MA-AA, in 
mm: 34.7±19.2 vs. 25.9±15.7, p=0.002 and MA-ADP, in mm, 59.9±7.4 vs. 
54.0±10.8 p=0.007). These changes were mirrored in the derived parameters 
namely percentage aggregation to arachidonic acid and ADP respectively. 
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Figure 4.20 Correlation between VeifyNow® indices and TEG® Platelet 
Mapping™ indices.  
PRUz indices did not show correlation to maximum amplitude of the thrombus 
formed in TEG® Platelet Mapping™ upon stimulation by ADP (MAADP, in mm), 
rho 0.109, p=0.572. ARU indices of VerifyNow® and maximum amplitude of the 
thrombus formed in TEG® Platelet Mapping™ upon stimulation by arachidonic 
acid (MAAA, in mm) showed significant correlation, rho 0.376, p=0.044. 
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Figure 4.21 Correlation between TEG® - Platelet Mapping™ indices and 
thrombus after clopidogrel therapy.  
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Maximum strength (MA) of the thrombus correlated with thrombus area (rho 
0.260, p=0.041) and thrombus retraction (L parameter) negatively correlated with 
thrombus area (rho=-0.251, p= 0.047). Platelet aggregation, as measured by the 
‘percentage change in maximum amplitude to ADP stimulation after 1 week of 
clopidogrel therapy’ negatively correlated with reduction in thrombus area (delta 
thrombus) in clopidogrel treated individuals (rho=-0.482, p=0.009). 
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4.6.4 Discussion - Viscoelastic properties of thrombus in stable CAD study 
I found that conventional TEG® parameters remained unaltered in T2DM with 
stable CAD after addition of clopidogrel 75mg OD for a week. However, upon 
stimulation by 10 µl of ADP, there was a significant decrease in viscoelastic 
strength of the thrombus. Interestingly, in those who were randomised to 
clopidogrel, the effect of aspirin on viscoelastic strength of thrombus was more 
pronounced, resulting in a decrease in maximum amplitude of the thrombus (MA, 
mm) upon stimulation with 10 µl of arachidonic acid. 
The negative finding of unaltered kaolin stimulated TEG® parameters (standard 
TEG®) after clopidogrel therapy is not surprising. Kaolin stimulates 
thrombogenesis via the powerful pro-coagulant thrombin, which acts in the final 
common pathway bypassing the effects of ADP on coagulation cascade. There 
are independent reports showing that clopidogrel therapy reduces thrombin 
generation but there is no literature evidence to support the findings from kaolin 
stimulated TEG® assay (Wegert et al., 2002). Standard TEG® assay performed 
by Gurbel et al in patients on dual antiplatelet therapy who underwent elective 
coronary stenting showed that those with higher MA and longer R values had 
more clinical events but this study did not report any pre and post clopidogrel 
values (Gurbel et al., 2005). CLEAR PLATELETS-2 study (Clopidogrel With 
Eptifibatide to Arrest the Reactivity of Platelets) showed the usefulness of TEG® 
in assessing platelet reactivity in patients who received clopidogrel, bivalirudin 
and eptafibatide, a glycoprotein IIb IIIa inhibitor. Addition of eptifibatide to 
bivalirudin therapy showed an immediate and marked reduction in maximum 
amplitude as measured by TEG® and the values correlated with peri-procedural 
myonecrosis (Gurbel et al., 2009).  Literature on the usefulness of TEG® to guide 
blood product transfusion post cardiac surgery did not report any differences in 
standard TEG® parameters in those taking clopidogrel (Hertfelder et al., 2005; Ak 
et al., 2009). It is possible that clopidogrel is not powerful enough to demonstrate 
any changes in kaolin stimulated TEG® tracings and it remains to be seen if 
modern antiplatelet drugs (prasugrel and ticagrelor) will have any effect on 
standard TEG® parameters. 
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The results from modified TEG® assay namely Platelet Mapping™ (PM) have 
shown significant reduction in the maximum viscoelastic strength of thrombus 
upon stimulation by ADP (MA-ADP) and arachidonic acid (MA-AA). Using a cut 
off of 50% platelet inhibition as a marker of adequate clopidogrel or aspirin 
response respectively, results of the PM assay showed 89% (30/33)  had 
inadequate response (ADP inhibition) to clopidogrel in contrast to 18% (12/66) to 
aspirin (AA inhibition). I also found a significant variability in individual clopidogrel 
response in T2DM ranging from 0% to 90%. 
In a study employing various dose regimes of clopidogrel, along with aspirin 
75mg od, TEG-PM showed significant reduction in MA-AA and MA-ADP (Swallow 
et al., 2006). In a study by Bliden et al (Bliden et al., 2007), 87% patients showed 
inadequate response to clopidogrel after elective PCI and inadequate response 
was a significant predictor of future cardiac events. In an unselected cohort of 
patients taking clopidogrel and scheduled for urgent non cardiac surgery, a wide 
variability of PM values were observed, confirming the heterogeneous antiplatelet 
effect of clopidogrel (Collyer et al., 2009). 
An MA(ADP) of >47 mm was identified as a predictor of future thrombotic events 
in a 3 year follow up study of patients with coronary stents (Gurbel et al., 2010b). 
In a study of 18 young women with previous history of stent thrombosis, higher 
MA-ADP  was observed compared to healthy volunteers and these patients  had 
greater baseline MA-ADP, reduced response to clopidogrel, and higher post-
treatment reactivity while on aspirin and clopidogrel therapy (Hobson et al., 
2009). 
It is well known that aspirin response is underestimated by TEG-PM, which may 
explain the higher than expected aspirin resistance in my cohort (Tantry et al., 
2005). I found that the antiplatelet effects of aspirin therapy were enhanced upon 
addition of clopidogrel. This is supported by the findings in a smaller TEG-Platelet 
Mapping study (Alstrom et al., 2006). The mechanisms underlying the augmented 
aspirin response as measured by a pathway specific agonist arachidonic acid 
remain unknown and are beyond the scope of this thesis. 
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In my sub-study, thrombus area as determined by Badimon chamber and platelet 
reactivity as measured by VerifyNow® were compared to TEG® parameters. In 
patients with T2DM and stable CAD, this comparison is novel, and based on 
post-hoc analysis. Whole blood thrombus was significantly reduced in both high 
shear and low shear chambers after the addition of clopidogrel and these findings 
are in keeping with the results of the main study. Badimon chamber evaluates 
predominantly platelet component of the thrombus i.e. platelet dependent 
thrombus and TEG® evaluates fibrin components of thrombus. The timing of 
thrombus assessment is different in both these tests as Badimon chamber 
evaluated thrombus in early phase (5 minutes) and TEG® measures thrombus 
properties continuously for 90 minutes. Baseline kaolin stimulated viscoelastic 
strength as measured by MA parameter in TEG® study showed a significantly 
positive but modest correlation to thrombus. Elastic force as measured by shear 
elastic modulus also showed similar correlation. It is possible that in early phase 
of thrombogenesis, higher elasticity contributed by individual fibrin fibres may 
allow further platelet trapping and thus can increase the thrombus quantity. There 
were significant correlations between rate of autolysis (thrombus retraction) and 
thrombus area in these individuals at baseline. Baseline platelet hyper activation 
is well known in patients with T2DM and this may contribute directly to fibrin 
synthesis. It is also possible that the findings of altered autolysis may be 
indicative of global impairment of fibrinolysis seen in T2DM. These interesting 
findings of the association between early phase of thrombogenesis and late 
phase of autolysis imply a potential role of TEG® in assessment of novel 
pharmacologic agents targeting different pathways of coagulation. 
My findings showed that there was a good correlation in the assessment of 
aspirin response by both the studies but poor correlation with clopidogrel 
response between the assay methods. VerifyNow® has been shown to be 
superior to TEG® in measuring the responsiveness to antiplatelet therapy 
(Madsen et al., 2010) as TEG® showed higher prevalence of aspirin resistance 
compared to VerifyNow® (Blais et al., 2009).  
Data on TEG® in patients with T2DM is scanty. TEG® results correlated with light 
transmission aggregometry in assessing clopidogrel hyporesponse in patients 
  
239 
with T2DM on 75mg maintenance therapy.  R time and the time to generate 
maximum thrombin were prolonged. These variables improved on doubling 
clopidogrel dose, suggesting the usefulness of TEG® in long term monitoring of 
antiplatelet therapy in T2DM (Angiolillo et al., 2009).  My findings show that TEG-
Platelet Mapping™ assay can identify response to antiplatelet therapy in patients 
with T2DM and CAD and testify to its use in clinical research of pharmacological 
agents. 
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4.7 Multiplate® Impedance aggregometry indices and platelet dependent 
thrombus 
4.7.1 Results - Platelet reactivity by Multiplate® in CAD study 
Baseline characteristics did not differ between those who had clopidogrel and 
placebo in view of the randomisation (n= 14 each). All the Multiplate® parameters 
showed no statistical difference between the groups at baseline (Table 4.26, 
4.27). After one week of therapy, ADP aggregation units, measured upon 
stimulation with 10µl of ADP, showed a significant reduction in the clopidogrel 
group and remained unchanged in placebo group (Median IQR: Clopidogrel 
group, from 748 (598-905) to 412 (307-676), p=0.003; Placebo group: from 845 
(677-987) to 804 (596-954), p=0.337, Figure 4.22). There was a trend towards 
reduction in ASP aggregation units, measured upon stimulation with arachidonic 
acid in the clopidogrel group. Platelet aggregations upon stimulation with collagen 
and thrombin receptor activated peptide (TRAP) remained unchanged in both the 
groups (Table 4.25). 
Thrombus area measured from high shear chamber reduced from [in µ2/mm, 
median (IQR)] 14662 (10231-20774) to 11489 (8712-13272), p= 0.001 in 
clopidogrel group and remained unchanged from 12285 (9130-15864) to 12033 
(10723-15269), p=0.782 in placebo group. There was a moderate correlation 
between Multiplate® indices and thrombus area (For ASP AU, rho =0.574, 
p=0.032 and for ADP AU rho=0.556, p=0.039). There were significant 
correlations between VerifyNow® indices and Multiplate® indices (for ASP AU vs. 
ARU, rho=0.541, p=0.004 and ADP AU vs. PRUz, rho=0.557, p=0.003, Figure 
4.24)  
Using a published cut off of 460 AU for clopidogrel response, 8 patients (57%) 
had adequate response to clopidogrel. When stratified according to the cut off 
ADP AU values, there were no statistically differences in the reduction of 
thrombus area in both high shear and low shear between those who had good 
response and those who had low response (Δ high shear thrombus, in µ2/mm, 
median (IQR), 3732 (2092-8203) vs. 3936 (402-6521); Δ  low shear thrombus in 
µ2/mm, median (IQR), 1640 (81-2372) vs. 2259 (573-3877), Figure 4.23). 
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  Clopidogrel + 
aspirin (n=14) 
Placebo + 
aspirin (n=14) 
P value 
Demographic data: Median (IQR) or %(n) 
Age, years 63(60-71) 63(58-65) 0.982 
Male gender, % (n) 85.7(12) 85.7(12) 1.000 
Body mass index, kg/m2 32.1(30.6-35.8) 30.9(29.2-
34.2) 
0.571 
Waist to hip ratio 1.0 (1.0-1.1) 1.0(1.0-1.1) 0.910 
Systolic BP, mmHg 130(122-139) 129(117-140) 0.603 
Diastolic BP, mmHg 75(67-81) 73(70-79) 0.839 
Duration of diabetes, years 8(5.8-12.8) 6.0(3.8-8.7) 0.265 
Risk profile: %(n) 
Angina 85.7(12) 50.0(7) 0.063 
Previous MI 35.7(5) 50.0(7) 0.445 
PCI 21.4(3) 28.6(4) 0.663 
CABG 28.6(4) 7.1(1) 0.139 
Chronic kidney disease 0 28.6(4) 0.051 
Medications: %,(n) 
Sulphonylurea 21.4(3) 28.6(4) 0.663 
Metformin 57.1(8) 57.1(8) 1.000 
Insulin 35.7(5) 21.4(3) 0.403 
Laboratory data:mean±SD 
Haemoglobin,  g/dl 13.8 (13.2-14.5) 13.3 (12.6-
13.8) 
0.512 
Platelets X1000 cells/ mm3 224 (220-249) 219 (172-225) 0.223 
Fibrinogen, g/ml 3.1(2.7-3.8) 3.3 (2.8-4.7) 0.468 
HbA1c, % 7.1(6.4-7.4) 7.7 (6.8-8.2) 0.320 
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  Clopidogrel + 
aspirin (n=14) 
Placebo + 
aspirin (n=14) 
P value 
Fasting plasma glucose, 
mmol/l 
7.6 (5.4-8.6) 7.2 (6.9-8.6) 1.000 
eGFR,  ml/min/1.73m2 81 (66-98) 88 (67-98) 0.734 
Total cholesterol, mmol/l 3.4 (2.8-3.9) 3.4 (3.1-3.5) 0.820 
LDLc, mmol/l 1.7 (1.2-2.2) 1.6 (1.4-2.1) 1.000 
HDLc, mmol/l 1.0 (1.0-1.1) 1.0 (1.0-1.2) 0.569 
Triglyceride, mmol/l 1.0 (1.3-2.0) 2.0 (1.1-2.2) 0.865 
HsCRP, mg/l 1.2 (0.6-3.2) 1.9 (1.0-5.4) 0.443 
Table 4.26 Baseline characteristics - Multiplate® sub study.  
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Median 
(IQR) 
Clopidogrel n=14 Placebo n=14 
 Baseline  
1-week 
after 
therapy 
P 
value 
Baseline  
1-week 
after 
therapy 
P 
value 
ASP AU 
347 
(222-499) 
216  
(176-300) 
0.174 299  
(185-533) 
260  
(124-460) 
0.497 
ADP AU 
748  
(598-905) 
412  
(307-676) 
0.003 845  
(677-987) 
804  
(596-954) 
0.337 
Collagen 
AU 
547  
(435-685) 
495  
(409-619) 
0.537 678  
(495-891) 
604  
(324-764) 
0.082 
TRAP 
AU 
1007 
(822-1141) 
1022 
(914-1151) 
0.598 1232  
(970-
1411) 
1162  
(1000-
1356) 
0.649 
Table 4.27 Results of Multiplate® sub study.  
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Figure 4.22 Changes in Multiplate® indices after clopidogrel therapy (stable CAD 
study).  
After one week of clopidogrel therapy, there was a significant reduction in ADP 
aggregation units whereas there was no change in those who took placebo 
therapy. Solid bars represent median and error bars represent interquartile range. 
ADP AU [median (IQR)] changed from 748 (598-905) to 412 (307-676), p=0.003 
in the clopidogrel group. In the placebo group, the values remain unchanged. 
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Figure 4.23 Changes in thrombus area based on response to clopidogrel in 
Multiplate® sub study  
When stratified according to the cut off ADP AU values (good responders ≤460 
AU), there were no differences in reduction of thrombus area in high shear 
thrombus. (Δ high shear thrombus, in µ2/mm, median (IQR), 3732 (2092-8203) 
vs. 3936 (402-6521). The solid bars represent interquartile range and the error 
bars represent maximum to minimum range.  
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Figure 4.24 Correlations between Multiplate® and VerifyNow® indices in stable 
CAD study. 
There were significant correlations between VerifyNow® indices and Multiplate® 
indices (for ASP AU vs. ARU, rho=0.541, p=0.004 and ADP AU vs. PRUz, 
rho=0.557, p=0.003).  
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4.7.2 Discussion – Platelet reactivity by Multiplate® in CAD study 
I report the findings of my Multiplate® pilot study (sub study) which showed a 
significant reduction in platelet aggregation upon stimulation with ADP in patients 
with T2DM and stable CAD who were randomised to clopidogrel. I performed 
comparative analysis of the indices derived from Multiplate® and VerifyNow® to 
the whole blood thrombus generated from Badimon chamber. This comparison 
has not hitherto been reported.  
Multiplate® has been shown to be useful in monitoring clopidogrel therapy in my 
small cohort of patients with T2DM, similar to the findings from a large scale 
study of both diabetic and non diabetic individuals. In a large study of 1000 
consecutive patients who received stent implantation after 600mg of clopidogrel 
loading, 11.8% had low response to clopidogrel. Independent predictors of low 
response were acute coronary syndrome  (OR = 6.54), diabetes mellitus (OR = 
2.07), and male gender (OR = 1.83) (Behr et al., 2011). Multiplate® was strongly 
correlated with light transmission aggregometry (LTA) in a study of patients who 
had clopidogrel therapy prior to stent insertion (rho= 0.7; P< 0.0001) (Sibbing et 
al., 2010a). Multiplate® was used to predict bleeding risks in patients taking 
clopidogrel. Enhanced risk of bleeding was observed (OR 2.6) in patients who 
had very low AU values to clopidogrel. This was the first study to quantify hyper-
response to P2Y12 antagonists as a marker for major bleeding (Sibbing et al., 
2010b). In a healthy volunteer study comparing various point of care tests, 
Multiplate® was superior to LTA and VerifyNow® to assess clopidogrel response 
(Chen et al., 2011).  Using a cut off of 460 AU, nearly half of the patients were 
hyporesponders to clopidogrel, mirroring findings from an earlier study (Mueller et 
al., 2007). There was a trend towards improvement in aspirin induced platelet 
suppression in those who were randomised to clopidogrel. In an unselected 
population of patients who were prescribed aspirin 75-100mg a day for secondary 
prevention, using Multiplate®, high on treatment platelet reactivity was found in 
26% of patients (Awidi et al., 2011). However, my results were similar to another 
study where aspirin compliance was controlled, the prevalence of high on-
treatment platelet reactivity being 3.6% (Pedersen, Grove et al. 2009), 
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(Mortensen, Larsen et al. 2010). This confirms the current belief that true aspirin 
resistance is lower in patients with good compliance. Multiplate® indices had 
good correlation with the findings of ‘gold standard’ LTA assay in larger scale 
studies (Siller-Matula, Delle-Karth et al. 2012). 
Both arachidonic acid and ADP stimulated platelet aggregation correlated with 
thrombus in Badimon chamber at baseline. This is not only a testament to the 
usefulness of Multiplate® in assessment of thrombosis but also proof of the 
significant role played by platelets in the early phase of thrombogenesis in T2DM. 
However, post clopidogrel therapy platelet function indices did not correlate with 
the thrombus area in T2DM. 
In addition, using a cut off of 460 ADP AU, thrombus area did not differ between 
those who had good and low response to clopidogrel. These findings are novel 
and can be explained by  
i) the inadequacy of Multiplate® to assess non platelet related factors 
(e.g. fibrin) in thrombogenesis 
ii) pleiotropic action of clopidogrel which cannot be quantified by 
Multiplate® 
iii) reconstituted thrombus in cuvette is different from real time thrombus 
generated from Badimon chamber 
In a meta-analysis, Multiplate® assay had higher probability of prediction of acute 
MI (OR 4.03 95%CI [1.16-14.00]), and stent thrombosis (OR 13.89 95%CI [2.63-
73.45], p = 0.002), but only a trend was observed for its role in predicting cardiac 
mortality (OR 3.21 95%CI [0.86-12.00], p = 0.08) (Aradi, Komócsi et al. 2010). 
Because of its better reproducibility data and lower coefficient of variation, I 
suggest Multiplate® is a better assay to monitor pharmacodynamic status in drug 
development studies. 
 
 
  
249 
4.8 Ultrastructural analysis thrombus by scanning electron microscopy 
(SEM) 
4.8.1 Results - SEM Analysis of thrombus in stable CAD study 
I conducted a sub-study to quantify ultrastructural characteristics of thrombus in 
patients with T2DM and stable CAD using scanning electron microscopy (SEM). 
Demographic, cardiovascular and metabolic profiles are shown in Table 4.28. 
Briefly, those who had clopidogrel had numerically lower BMI, higher blood 
pressure values and a longer duration of T2DM. However, none of these reached 
statistical significance. Baseline characteristics of this randomly chosen study 
population in subgroup (n=10+10) were similar to those of main study group 
(n=45+45). Platelet dependent thrombus (PDT) obtained from the Badimon 
chamber was reduced after clopidogrel therapy and remained unchanged in 
placebo group (Table 4.29). SEM analysis of the thrombus showed that at 
baseline, thrombus was mainly composed of platelets. Quantitatively, platelet 
content of the thrombus, measured as the proportion of platelet rich areas to 
fibrin rich areas in the SEM images of high shear thrombus at 60X magnification, 
was similar between both the groups at the baseline visit (84.4% vs. 84.6%, 
Figure 4.24). After one week of clopidogrel therapy there was 9.5 % relative 
reduction in platelet content of the thrombus (absolute values: 84.4% to 76.4%, 
mean difference: 7.98% (95%CI 1.5 to 14.5, p=0.022). There was no change in 
platelet content of the thrombus in patients who took placebo (84.6% vs. 84.8%, 
p= 0.948, Figure 4.25). 
Fibrin diameter was increased after clopidogrel therapy (nm, mean±SD, from 
171.3±11.7 to 186.8±14.4, mean difference: 15, 95% CI 3-27, p=0.016).  Fibrin 
diameter did not change in the placebo group (Figure 4.26). Platelet diameter 
remained unchanged in both the groups (Table 4.30). Clopidogrel produced 
significant changes to fibrin architecture of the thrombus. Qualitatively, there were 
more fibres in thrombus organised in a linear fashion with less sieves or mesh 
like arrangement (Figure 4.28). Quantitatively, individual fibrin fibre density was 
increased in the clopidogrel group, with higher number of hubs and spokes per µ2 
of the thrombus (Table 4.31 Figure 4.29). Platelet content of the thrombus had a 
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significant correlation to thrombus area in the Badimon chamber (rho=0.614, 
p=0.007) and fibrin diameter correlated with thrombus lysis and G value (Figure 
4.30). 
I then proceeded to the platelet reactivity analysis using three novel point of care 
assays, namely Thromboelastography (TEG®), VerifyNow® and Multiplate®. The 
results of this sub group analysis mirrored those seen in the whole group (Table 
4.32), although because of the smaller number of patients, differences did not 
reach statistical significance. TEG® showed a trend towards reduction in shear 
elastic modulus (viscoelastic force), increase in rate of thrombus lysis and 
reduction in the composite measurement clot index (Table 4.32) in patients 
treated with clopidogrel. The maximum amplitude of the viscoelastic force upon 
stimulation with kaolin and ADP was lower in the clopidogrel group. 
I compared the viscoelastic force of thrombus from TEG® to the fibrin data from 
SEM. Shear elastic force of the thrombus (G value), as measured by TEG® 
showed a strong negative correlation to the fibrin diameter (rho -0.609, p=0.007). 
Fibrin diameter had a negative correlation with the maximum amplitude of the 
viscoelastic force generated upon stimulation with ADP in TEG® (rho -0.491, 
p=0.033). The rate of thrombus lysis was similar at baseline in these randomly 
selected 20 patients with a trend towards improvement in rate of lysis in 
clopidogrel group. Thrombus lysis parameter, L, showed a moderate but 
significant correlation to the diameter of the fibrin fibre (rho 0.461, 
p=0.047).VerifyNow® results showed a significant reduction in PRUz values and 
platelet inhibition upon stimulation with ADP in clopidogrel group with no changes 
in placebo group. After clopidogrel therapy, PRUz values negatively correlated 
with fibrin diameter (rho= -0.601, p= 0.008), fibrin fibre density (rho -0.488, 
p=0.006) and number of spokes (rho= -0.476, p= 0.046). ARU both at baseline 
and after therapy levels remained unchanged in both the groups with no 
significant correlation to SEM measurements. Results from Multiplate® assay 
showed reduction of ADP aggregation units without any changes in arachidonic 
acid aggregation units in the clopidogrel group. Multiplate® indices did not show 
any correlations with fibrin fibre data from SEM both at baseline and after 
clopidogrel.
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 Clopidogrel
+aspirin 
(n=10) 
 Placebo+
aspirin 
(n=10) 
 P value 
 Mean±SD Median 
(IQR) 
Mean±SD Median 
(IQR) 
P value 
Demographic data: 
Age, years 64±8 65(56-72) 63±5 63 (61-66) 0.881 
Male gender, % (n) 80.0 (8)  90.0 (9)  0.937 
Body mass index, 
kg/m2 
31±3.5 32 (30.0-
34.2) 
34±6.6 34.0 
(28.7-
38.3) 
0.274 
Waist to hip ratio 1.0±0.1 1.0 (1-1) 1.0±0.1 1.0 (1-1) 0.904 
Systolic BP, mmHg 135±25 133(122-
139) 
129±23.3 125 (113-
141) 
0.903 
Diastolic BP, mmHg 78±16.9 69 (65-
86) 
72±6.8 71.5 
(65.8-
78.3) 
0.598 
Duration of diabetes, 
years 
11.1±6.6 8 (6-19) 6.3±3.2 7 (4-9) 0.072 
Risk profile: %(n) 
Angina 80.0 (8)  60.0 (6)  0.405 
Previous MI 70.0 (7)  50.0 (5)  0.809 
PCI 40.0 (4)  30.0 (3)  0.701 
CABG 20.0 (2)  20.0 (2)  0.906 
Chronic kidney 
disease 
0 (0)  20.0 (2)  
0.156 
Medications: %,(n) 
Sulphonylurea 10.0 (1)  10.0(1)  0.937 
Metformin 60.0 (6)  50.0 (5)  0.463 
Insulin 40.0 (4)  20.0 (2)  0.252 
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 Clopidogrel
+aspirin 
(n=10) 
 Placebo+
aspirin 
(n=10) 
 P value 
Laboratory data:mean±SD, Median (IQR) 
 Mean±SD Median 
(IQR) 
Mean±SD Median 
(IQR) 
P value 
Haemoglobin,  g/dl 
13.8±0.8 
13.9 
(13.2-
14.5) 13.3±0.8 
13.3 
(12.6-
13.8) 0.175 
Platelets X1000 cells/ 
mm3 227±38 
224 (209-
260) 218±61 
220 (183-
255) 0.750 
Fibrinogen, g/l 
3.0±0.5 
3.0 (2.6-
3.6) 3.4±0.8 
3.3 (2.8-
4.2) 0.326 
HbA1c, % 
7.4±1.6 
7.1 (6.4-
8.7) 7.4±0.8 
7.6 (6.9-
7.8) 1.000 
Fasting plasma 
glucose, mmol/l 7.8±3.3 7.2 (5-9) 7.8±1.8 8 (7.1-9.2) 0.965 
eGFR,  
ml/min/1.73m2 
84±26.0 
76 (66-
109) 81±19.6 
81.5 
(75.3-
95.5) 0.785 
Total cholesterol, 
mmol/l 3.2±0.6 
3.05 (2.7-
3.8) 3.2±0.5 
3.4 (2.7-
3.5) 0.978 
LDLc, mmol/l 
1.6±0.5 
1.5 (1.2-
2.2) 1.7±0.4 
1.7 (1.4-
2.1) 0.777 
HDLc, mmol/l 
1.0±0.2 
1.0 (0.9-
1.2) 1.0±0.2 
0.9 (0.8-
1.2) 0.594 
Triglyceride, mmol/l 
1.4±0.6 
1.6 (1.2-
2.4) 1.6±0.6 
1.3 (1.3-
2.2) 0.710 
HsCRP, mg/l 
1.5±1.5 
0.9 (0.4-
3.0) 3.0±3.3 
1.7 (0.8-
6.0) 0.276 
Table 4.28 Baseline characteristics of SEM study (Stable CAD).  
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Platelet dependent thrombus at baseline Platelet dependent thrombus after one 
week of clopidogrel therapy 
  
Figure 4.25 Platelet content of thrombus in electron microscopy.  
SEM analysis of the platelet dependent thrombus generated from Badimon 
chamber thrombus showed that at baseline, thrombus was mainly composed of 
platelets. Quantitatively, platelet content of the thrombus, measured as the 
proportion of platelet rich areas to fibrin rich areas in the SEM images of high 
shear thrombus at 60X magnification was 84.4% and after one week of 
clopidogrel therapy there was 9.5 % relative reduction in platelet content of the 
thrombus (absolute values: 84.4% to 76.4%, mean difference: 7.98%, 95%CI 1.5 
to 14.5, p=0.022). Solid white arrows represent platelet rich areas. 
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 Clopidogrel 
(n=10)  
 
 Placebo (n=10) 
 
 
Thrombus area,         
µ2/mm, Mean±SD 
Baseline Visit 2 P 
value 
Baseline Visit 2 P 
value 
High shear chamber 13637 
±5252 
10656 
±3586 
0.013 13282 
±4756 
11635 
±3127 
0.128 
Low shear chamber  8756 
±4565 
6298 
±2578 
0.018 8610  
±3631 
7309  
±2451 
0.126 
Table 4.29 Thrombus area in SEM sub study.  
 
 Clopidogrel 
(n=10)  
 
 Placebo (n=10) 
 
 
Mean±SD Baseline Visit 2 P 
value 
Baseline Visit 2 P 
value 
Fibrin diameter, nm 171.3 
±11.7 
186.8 
±14.4 
0.016 171.6 
±7.2 
176.3 
±13.3 
0.406 
Platelet diameter, µm 1.7 ±0.11 1.6 
±0.05 
0.894 1.8±0.03 1.6 
±0.07 
0.448 
Table 4.30 Fibrin and platelet diameters of SEM sub study.  
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Fibrin at baseline Fibrin after one week of clopidogrel 
therapy 
  
Figure 4.26 Fibrin fibre diameter after clopidogrel therapy.  
Ultrastructure of fibrin derived from the thrombus in the Badimon chamber was 
studied at 13X103 times magnification using scanning electron microscopy.  
Fibrin diameter increased after clopidogrel therapy, (nm, mean±SD) from 
171.3±11.7 at baseline to 186.8±14.4, p=0.016. Solid arrows represent individual 
fibrin fibre. 
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Platelets at baseline  Platelets after clopidogrel therapy 
  
Figure 4.27 Platelet ultrastructure in thrombus after clopidogrel therapy.  
Scanning electron microscopic images of platelets (at 3.5X103 to 3.6 X103 
magnifications)  from the thrombus generated from Badimon chamber of a patient 
with type 2 diabetes mellitus and coronary artery disease, at baseline and after 
clopidogrel therapy. Platelet diameter remained unchanged after clopidogrel 
therapy (diameter in µm, mean±SD, from 1.7±0.11 to 1.6±0.05, p=0.894). Solid 
white arrows show platelets in various stages of activation, with granules and 
pseudopodia on their surfaces. 
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Table 4.31 Quantitative analysis of Fibrin in SEM sub study.  
 
 Clopidogrel (n=10) Placebo (n=10) 
Mean±SD, number 
per µ2 of thrombus 
Baseline Visit 2 P 
value 
Baseline Visit 2 P 
value 
Fibrin fibre density 32.3±4.8 41.0±10.2 0.023 29.7±6.7 29.5±9.9 0.348 
Spokes of fibrin  29.5±4.4 36.6±8.3 0.030 28.9±8.9 26.9±9.5 0.852 
Hubs of fibrin 15.5±1.5 16.7±1.4 0.022 14.9±3.0 13.1±4.1 0.574 
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Fibrin architecture at baseline Fibrin after clopidogrel therapy 
  
Figure 4.28 Fibrin fibre architecture after clopidogrel therapy 
Fibrin fibre arrangement was studied at 3.4X103 magnification using scanning 
electron microscopy. After clopidogrel therapy, there was more number of fibrin 
fibres in thrombus and fibrin arrangement showed densely packed and compact 
fibres. Quantitatively, individual fibrin fibre density was increased in the 
clopidogrel group, with higher number of hubs and spokes. Solid white arrows 
show individual fibrin fibres whereas patterned arrows show hub and spoke 
arrangement.  
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Figure 4.29 Quantitative analysis of fibrin fibre in whole blood thrombus (a,b,c). 
The fibrin density (number of fibres per µ2 thrombus) was higher with increased 
numbers of hubs and spokes. Qualitatively, these findings represent a more 
organised and compact fibrin arrangement. The fibrin arrangement remained 
unchanged in placebo group. ** p <0.05. Error bars represent one SD. The 
changes seen in clopidogrel group are (mean, ±SD, per µ2 of thrombus) fibrin 
fibre density from  32.3±4.8 to 41.0±10.2, spokes of fibrin  from 29.5±4.4 to 
36.6±8.3, hubs of fibrin from 15.5±1.5 vs 16.7±1.4, all are statistically significant 
at p<0.05. The values remained unchanged in placebo group. 
c 
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Figure 4.30 Correlations between fibrin fibre diameter and viscoelastic properties 
of thrombus.  
Shear elastic force of the thrombus (G value), as measured by TEG® showed a 
strong negative correlation to the fibrin diameter (rho= -0.609, p=0.007) at 
baseline. Thrombus lysis parameter (L), showed a significant correlation to the 
diameter of the fibrin fibre (rho= 0.461, p=0.047). 
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 Clopidogrel (n=10)   Placebo (n=10)  
Mean±SD Baseline Visit 2 p value Baseline Visit 2 p 
value 
Thromboelastography data: 
R, minutes 6.2±1.9 6.1±1.9 0.972 7.2±1.6 6.3±2.3 0.090 
Maximum 
amplitude-
Kaolin,  mm  
65.3±4.8 62.0±6.0 0.159 65.4±5.4 65.8±5.9 0.764 
Maximum 
amplitude-
AA,mm  
36.3 
±13.5 
30.1±17.2 0.338 34.4 
±19.9 
38.0±16.7 0.575 
Maximum 
amplitude-
ADP,mm 
57.4±6.2 49.3±12.7 0.114 59.2±9.3 57.2±7.7 0.424 
Shear elastic 
force, 103 
dynes/cm2 
9.7±2.1 8.4±2.0 0.117 8.8±2.3 10.0±2.6 0.648 
L parameter, 
mm/min 
76.1±7.2 85.2±8.1 0.079 73.9±7.8 76.0±10.0 0.440 
Clot index 0.56±2.5 -0.07±2.8 0.159 0.21±2.2 1.08±2.5 0.181 
VerifyNow® data: 
ARU 440±35.7 434±67.6 0.804 479 
±93.7 
462±71.1 0.601 
PRUz 317±43.5 251±63.1 0.007 340.7 
±48.1 
340.6 
±52.8 
0.996 
Platelet 
inhibition,% 
33.1 
±10.1 
18.2±18.1 0.017 33.1 
±10.2 
30.1±10.1 0.412 
Multiplate® data: 
Arachidonic 
acid, AU 
313±173 320±166 0.912 328±229 269±196 0.570 
ADP,  AU 804±460 451±211 0.050 811±227 684±338 0.178 
Table 4.32 Point of care tests of SEM sub study.  
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4.8.2 Discussion – SEM Analysis of thrombus in stable CAD study 
I report qualitative and quantitative analysis of the ultra structural properties of 
whole blood thrombus formed in Badimon chamber of patients with T2DM and 
stable CAD for the first time. Significant changes in density, diameter and 
arrangement of fibrin fibres in whole blood thrombus following clopidogrel therapy 
in T2DM with CAD were shown. The methods of assessment were novel and 
every step of the process has been validated internally in detail. From an earlier 
pilot study on patients with NSTE-ACS, I found that in patients with T2DM, 
qualitative SEM analysis of thrombus showed thinner fibrin fibres with 
predominant “lattice and sieve” arrangements when compared to non diabetic 
patients. This has resulted in higher thrombus, weaker viscoelastic recoil and 
slower thrombus autolysis. The current study quantitatively analysed the 
ultrastructure of the thrombus in T2DM. 
After one week of clopidogrel therapy, the proportion of platelet content in 
thrombus decreased,   paralleling my findings from the main study that platelet 
dependent thrombus was reduced in those who were treated with clopidogrel. 
Thrombus formed in Badimon chamber was heterogeneous, with fibrin rich and 
platelet rich areas. It is well known that thrombus formed in coronary arteries of 
individuals with T2DM sustaining an MI  is rich in platelets which is known as  
“white thrombus” (Davies and Thomas, 1984). My results suggest that one of the 
mechanisms of reduction in thrombus quantity is by way of changes in 
composition of thrombus and reduction in the cellular content of the thrombus. My 
findings of reduced platelet rich areas in thrombus after clopidogrel therapy is 
novel and are supported by indirect evidence from SEM studies showing  that 
less platelet activation, smaller platelet volume and low platelet counts altered the 
ultrastructure of the thrombus following antiplatelet therapy (Standeven et al., 
2005; Undas and Ariëns, 2011). 
Fibrin fibre content and architecture were also altered by clopidogrel therapy. The 
diameter of individual fibrin fibres was higher after clopidogrel therapy and 
multiple studies have shown that this feature enables favourable fibrinolysis 
(Collet et al., 2003a; Collet et al., 2006; Weisel, 2007).  Fibrin fibre density per 
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square micron was increased after clopidogrel therapy in patients with T2DM and 
CAD.  There were significant differences in fibrin fibre arrangements in the form 
of higher number of “hub and spoke” type arrangement in patients who received 
clopidogrel and aspirin compared to those receiving aspirin alone. Alterations in 
fibrin structure in patients with T2DM have been attributed to non enzymatic 
glycation of fibrinogen. Glycated fibrinogen enhances thrombogenicity by 
increasing fibrin polymerisation  and cross-linking,   reducing tissue plasminogen 
activator and plasminogen binding, and slowing plasminogen to plasmin 
conversion (Dunn et al., 2005). Antiplatelet therapy with aspirin improves fibrin 
architecture in T2DM by acetylation of the alpha chain of fibrinogen (Dunn et al., 
2005),(Ajjan et al., 2009). Pieters et al showed improvement in glycaemic control 
reduced glycation of fibrinogen (Pieters et al., 2007), favourably altered fibrin 
architecture and improved fibrinolysis in a purified fibrinogen model (Pieters et al., 
2008). Fibrin fibres, upon polymerisation, produce definitive ultra structural re-
arrangements which include twisting, knotting, lateral linking and stretching, 
which have been demonstrated by SEM, TEM, confocal microscopy and 
polarised light microscopy. Viscoelastic force is lower when there is excess 
twisting of fibrin fibres around an axis (“hub”), as this structure limits elastic recoil.  
When fibrin fibres branch out of the hub, instead of forming straight fibres in a 
pleated arrangement, binding sites for the fibrinolytic peptides tissue plasminogen 
activator and plasmin are more exposed and therefore this arrangement favours 
fibrinolysis (Ajjan et al., 2009). Clopidogrel, by increasing the number density of 
hubs and spokes in the thrombus, renders the thrombus easier to undergo 
fibrinolysis. This concept is supported by findings from my viscoelastic study of 
thrombus using thromboelastography(vide supra), and by published literature 
(Gabriel et al., 1992). 
It has been shown that the viscoelastic properties of fibrin polymers determine 
clot stability in healthy individuals and in patients and relatives of those with 
premature coronary artery disease (Collet et al., 2006; Standeven et al., 2007; 
Weisel, 2007). I measured viscoelastic properties of the platelet rich thrombus 
using thromboelastography (TEG®) and Platelet Mapping™. I demonstrated a 
significant negative correlation between fibrin fibre diameter and shear modulus 
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viscoelastic force of the whole blood thrombus (G parameter). Fibrin fibres use 
their maximum energy while undergoing polymerisation and formation of thicker 
fibrin fibres limits the energy available to undergo further elastic recoil. Thicker 
fibrin fibres formed in reconstituted thrombus using fibrinogen have reduced 
viscoelasticity (Collet et al., 2005; Gersh et al., 2009). These findings were 
replicated in my study by using a point of care native whole blood assay (TEG®) 
and directly measuring fibrin diameter from whole blood thrombus generated in 
Badimon chamber. I also found that there was a similar relationship between the 
rate of whole blood thrombus lysis (L parameter) and fibrin diameter, findings 
which were akin to those described in thrombus regenerated from plasma (Collet 
et al., 2000; Hess et al., 2011).  Differences in the individual TEG® parameters 
after clopidogrel therapy did not reach statistical significance in my cohort of 33 
patients (vide supra). However, the association between individual fibrin diameter 
and the maximum amplitude of the viscoelastic force (MA mm) measured (by 
stimulating native whole blood with by ADP) by TEG® is novel. If these data can 
be validated in further large scale experiments, this model may serve as a useful 
tool to study the effect of novel antithrombotic therapies including those targeting 
the fibrinolytic pathway in whole blood thrombus of patients with T2DM and CAD. 
PRUz, the most validated measurement from VerifyNow® assay, showed a 
negative association between fibrin diameter and the number of fibrin fibres. 
Patients with higher PRUz reflecting high on treatment platelet hyperactivity, had 
thinner fibrin fibres and vice versa. Similarly, the number of fibrin fibres was 
higher in those with lower PRUz, indicating that patients with lower platelet 
reactivity are likely to have fibrin rich thrombus compared to platelet rich 
thrombus in non responders. This finding is hypothesis generating and needs 
validation. 
Multiplate® results showed significant reduction in electrical impedance upon 
stimulation with ADP in those treated with clopidogrel. However, no significant 
associations were noted between Multiplate® indices and SEM measurements. 
These findings are not entirely surprising. Individual fibrin fibres in thrombus are 
held together in a gel which is a good conductor of electricity. Electrical 
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impedance is less likely to be influenced by changes in the fibrin assembly or 
diameter of fibrin fibres (Jung et al., 2009). 
Platelet diameter remained unchanged after clopidogrel therapy in T2DM (Figure 
4.27). Platelets of patients with T2DM had larger platelet volume compared to 
published data on healthy volunteers (Rao et al., 1984; Watala et al., 1999). 
Large diabetic platelets are secondary to increased platelet turnover and larger 
sized “neo platelets” produced from bone marrow (Jagroop and Mikhailidis, 
2005). Platelet diameter decreased after antiplatelet therapy in non diabetic 
subjects and healthy volunteers (Papanas et al., 2004). The absence of this 
response in my cohort of patients with T2DM and stable CAD who were treated 
with clopidogrel needs to be confirmed in large scale studies. It is possible that 
diabetic “angry platelets” are under constant stimulation by a variety of naturally 
occurring agonists (Bhatt, 2008) or by pathways involving inflammatory mediators 
(Hess et al., 2011). Treatment of T2DM by an ADP antagonist like clopidogrel for 
a week may not be enough to reduce their size. 
Point of care assays are increasingly used by clinical researchers and I have 
shown for the first time an association between the ultra structural characteristics 
of whole blood thrombus and platelet reactivity indices measured using these 
instruments. As newer and more powerful ADP antagonists are licensed for use 
(e.g. ticagrelor, prasugrel), my data provides a focus for studying the effect of 
newer drugs on the structural and functional changes in thrombus. 
My findings from SEM are novel and interesting but have some limitations. Firstly, 
the patient cohort is small in number which makes the generalisation of these 
findings impossible. The strict eligibility criteria, adherence to medications and 
cardiovascular risk factor control observed in my study population is not 
commonly seen in day to day clinical practice. It is unknown if similar findings can 
be seen with the use of newer antiplatelet agents. The computational model used 
in my study for quantification of fibrin architecture is yet to be validated on 
heterogeneous larger population cohorts including healthy volunteers and non 
diabetic patients with CAD. 
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4.9 Coronary atheroma burden and platelet dependent thrombosis 
4.9.1 Results – Coronary atheroma burden and thrombus in ACS study 
Coronary atheroma as quantified by the Gensini score was calculated for 80 
patients (40 T2DM) in the ACS study who successfully completed Badimon 
chamber studies. Ten patients had previous CABG and were excluded from the 
analysis as the score has not been well validated in this population. Final analysis 
included 70 patients (34 T2DM). Coronary atheroma burden as quantified by 
Gensini score was higher in T2DM patients with NSTE-ACS compared to non DM 
(mean±SD, 46.1±20.6 vs. 37.5±13.0, p=0.042). Number of arterial segments with 
atheroma of more than 25% as measured by modified Gensini score was higher 
in T2DM [6.2±2.7 vs. 4.6±1.9, p=0.004] (Table 4.33, Figure 4.31). Gensini score 
did not correlate with thrombus area. However, modified Gensini score showed 
significant correlations with thrombus area in both the high shear and low shear 
chambers (High shear thrombus rho=0.293, p=0.017; low shear rho=0.325, 
p=0.007, Figure 4.32). Of the baseline characteristics, only age showed positive 
correlations to Gensini score (rho=0.240, p=0.045, Table 4.34) with no 
relationship observed with HbA1c, blood glucose, BMI, fibrinogen and serum 
creatinine. 
I then classified atheroma burden in to two main groups, those with at least one 
occlusive plaque (more than 75% luminal narrowing) and those with non 
occlusive plaque disease (25-75% luminal narrowing). All the 80 subjects were 
included and for those who had CABG, the surgical conduits were studied for 
atheromatous plaque. The subjects were divided in to four groups namely: 
i. T2DM and occlusive plaque (n=25) 
ii. T2DM and non occlusive plaque (n=15) 
iii. non diabetic and obstructive plaque (n=24) 
iv. non diabetic and non obstructive plaque (n=16) 
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When stratified according to CAD status, thrombus area was highest in T2DM 
and non occlusive plaque (F=5.26, p=0.002, Table 4.35). Inflammatory cytokine 
interleukin 6 (F=6.759, p=0.001) and high sensitivity CRP (HSCRP, F=4.347, 
p=0.007) were the highest in this group.  P selectin (F4.728, p=0.004) and 
soluble CD40 ligand (F=9.593, p=0.004) were also the highest in this group 
(Figure 4.33). Interleukin 1, interferon gamma and TNFα levels were numerically 
higher in this group but showed no statistical significance. 
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Mean±SD T2DM Non T2DM P value 
Gensini score 49.7±21.3 37.5±13.0 0.042 
Modified Gensini score 6.2±2.7  4.6±1.9  0.004 
Table 4.33 Gensini score in ACS study.  
 
 Gensini Score Modified Gensini score 
 rho P value rho P value 
HbA1c,% 0.193 0.123 0.334 0.006 
Age, in years 0.240 0.045 0.339 0.004 
BMI, kg/m2 0.016 0.902 0.001 0.997 
Random plasma 
glucose, mmol/l 
0.004 0.972 0.037 0.731 
Fasting plasma glucose, 
mmol/l 
0.048 0.711 0.123 0.345 
Serum Creatinine, 
mmol/L 
0.062 0.614 0.042 0.732 
Fibrinogen, g/L 0.054 0.658 0.071 0.558 
High shear thrombus, 
µ2/mm 
0.117 0.351 0.293 0.017 
Low shear thrombus, 
µ2/mm 
0.134 0.243 0.325 0.007 
Table 4.34 Correlation between standard Gensini score and baseline variables.  
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Table 4.35 Biomarkers in patients with and without occlusive coronary 
atheromatous plaques 
 
T2DM with 
non occlusive 
plaque (n=15) 
T2DM with 
occlusive 
plaque (n=25) 
Non DM with 
non occlusive 
plaque (n=16) 
Non DM with 
occlusive 
plaque (n=24) 
P 
values 
Thrombus 
area, µ2/mm 18645±12103 24412±11813 10927±4284 12633±3495 0.002 
P selectin, 
pg/ml 80.2±21.6 68±28.6 52.9±12.1 62.6±13.7 0.004 
sCD40 
ligand, pg/ml 8020±6649 3952±3656 2250±2099 1895±1189 0.004 
IL-6 ng/ml 4.4±2.6 2.9±2.0 2.1±1.1 2.2±0.7 0.001 
HSCRP mg/L 12.0±14.3 7.7±7.1 2.4±2.2 11.7±7.4 0.007 
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Figure 4.31 Gensini and modified Gensini scores in ACS study.  
Patients with T2DM had higher Gensini (each arterial segment with lesions 
scored with an individual weightage factor) and modified Gensini (each arterial 
segment with lesions scored equally). The Gensini scores are (value±SD), T2DM 
49.7±21.3 vs. non DM 37.5±13.0, p=0.042 and modified Gensini scores are 
T2DM (value±SD) 6.2±2.7 vs. non DM 4.6±1.9, p=0.004. Error bars represent 
1XSD. 
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Figure 4.32 Gensini scores and thrombus area. 
Scatter plot diagram of Gensini scores vs.  High shear thrombus area showing no 
correlation with Gensini score (rho=0.117, p=0.351) and significant correlation 
with modified Gensini score (rho = -0.293, p=0.017). 
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Figure 4.33 Biomarkers in patients with obstructive and non obstructive 
atheromatous plaques.  
Patients were grouped according to the presence of obstructive plaque (>75% 
luminal diameter) or non obstructive (25%-75% luminal diameter). Inflammatory 
cytokine interleukin 6 (F=6.759, p=0.001) and high sensitivity CRP (HSCRP, 
F=4.347, p=0.007) were the highest in patients with non obstructive plaque and 
T2DM. P selectin (F=4.728, p=0.004) and soluble CD40 ligand (F=9.593, 
p=0.004) were also the highest in this group. 
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4.9.2 Discussion – Coronary atheroma burden and thrombus in ACS study 
Gensini score is a very well validated tool to assess coronary artery disease 
severity (Austen et al., 1975; Gensini, 1983). By combining luminal narrowing 
with site of stenosis, this score better reflects the prognostic significance of CAD. 
I found that Gensini score was significantly higher in T2DM. These findings are 
unsurprising as T2DM is associated extensive atheroma burden quantified in 
autopsy studies. In addition, multiple lesions in T2DM are often seen with diffuse 
atheromatous process. My results were similar to those published recently in 
patients with and without T2DM (Saleem et al., 2008; Gui et al., 2012). There 
were no correlations between the glycaemic indices such as HbA1c and blood 
glucose and Gensini score. This is in contradiction to earlier results which 
showed direct linear relationship between Gensini score and blood glucose 
control in stable CAD patients (Mi et al., 2012). This may be due to two reasons 
i. my cohort is small (T2DM n=34) 
ii. glycaemic control in my study population was better than in the 
published literature(Saleem et al., 2008) 
In addition, NSTE-ACS in poorly controlled T2DM is often secondary to the 
rupture of non obstructive plaques and thereby glycaemic indices are less likely 
to reflect true flow limiting atheroma. 
There was no relationship between standard Gensini score and thrombus burden 
but a modified Gensini score (measuring the number of diseased segments each 
with a 1X score) was significantly associated with thrombus. Though the 
relationship between atheroma burden and thrombogenicity is documented 
(Zaman et al., 2000), there is paucity of literature on Gensini score and 
thrombogenicity. I speculate that any unweighted score (e.g. modified Gensini 
score) will predict thrombus better in view of the simplified reflection of the 
number of atheromatous segments whereas a weighted score is more 
appropriate for future events and prognosis. I propose that atheroma burden is 
directly related to thrombus but Gensini score may not be the right scoring 
system in the context of ACS to explain the relationship between atheroma and 
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higher blood thrombogenicity. It is possible that the results may have been 
different if I had used a different scoring system such as SYNTAX score (Sianos 
et al., 2005; Valgimigli et al., 2007; Farooq et al., 2011). Syntax scoring system is 
mainly designed to evaluate the outcomes of various revascularisation strategies 
in patients with complex coronary anatomy rather than atheroma burden and is 
validated only in patients with multivessel coronary artery disease, whereas my 
cohort included patients with single vessel disease (Serruys et al., 2009). My 
results in a smaller cohort of patients are novel and hypothesis generating. 
Patients with T2DM and non-occlusive coronary atheromatous plaque had the 
highest thrombus and markers of platelet activation and inflammation. These 
results support the view that a “biochemical mechanism” is more often associated 
with acute coronary syndrome in these patients than a conventional “plaque 
rupture-biomechanical mechanism” (Lee and Libby, 1997; Geng and Libby, 
2002). Detailed discussion on pathophysiology of inflammation, thrombosis and 
atheroma are presented vide supra. Presence of non obstructive plaques in 
T2DM in combination with higher blood thrombogenicity is associated with poorer 
outcomes. Moreno et al have shown extensive infiltrates of inflammatory 
macrophages in coronary atheromatous specimens of patients with diabetes and 
these have been confirmed in subsequent non invasive studies calling for a 
change in definition of vulnerable plaque in these individuals (Naghavi et al., 
2003; Moreno and Fuster, 2004). Inflammation in diabetes was proposed as a 
“common soil” mechanism for CAD (Stern, 1995) and inflammatory markers were 
associated with thrombosis in T2DM (Hess and Grant, 2011). My findings support 
the view that biochemical changes are responsible for thrombosis in patients with 
T2DM (Hess et al., 2012; Libby, 2013). 
A causal link, if confirmed by large-scale experimental and observation studies, 
may offer us an opportunity to identify therapeutic targets such as individualised 
antithrombotic and anti inflammatory therapy in these high risk population. 
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Chapter 5 Conclusion 
5.1 General discussion  
The studies in this thesis have upheld my two hypotheses, that blood 
thrombogenicity is higher in patients with T2DM after non ST-elevation acute 
coronary syndrome (NSTE-ACS) despite currently recommended therapy with 
dual antiplatelet agents, aspirin and clopidogrel and that dual antiplatelet therapy 
with aspirin and clopidogrel reduces blood thrombogenicity compared to aspirin 
monotherapy in patients with T2DM and stable coronary artery disease (CAD).  
The results demonstrate that in type 2 diabetes, thrombus quantity and quality 
are abnormal. Qualitative differences in thrombus suggested potential 
mechanisms for the changes in thrombus quantity in both the studies. Changes in 
viscoelastic property and fibrin fibre arrangement resulted in greater thrombus 
and these changes also reflected impairment in autolysis of the formed thrombus 
in T2DM. Thrombus structural analysis showed a disorganised thrombus, with 
thin fibrin fibres and reduced fibrin fibre density. The inverse relationship between 
fibrin fibre diameter and viscoelastic strength of the clot suggest that in diabetes, 
the abnormal structure of the thrombus alters clot strength. The physical 
derangement of the thrombus may make access of thrombolytic enzymes more 
difficult, thus slowing thrombus lysis time. 
The findings in patients with NSTE-ACS and T2DM study are important for the 
following reasons: 
i. this is the largest cohort of patients studied after NSTE-ACS using the 
Badimon chamber  
ii. participants were on all recommended secondary prevention therapy 
and were chosen based on strict eligibility criteria to minimise 
confounding variables  
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iii. the data provide a focus for studies of mechanisms underlying the 
observational data of higher recurrent thrombotic event rates in T2DM 
following NSTE-ACS.  
My findings argue against the current identical recommendations for secondary 
prevention therapy in patients with and without T2DM, and suggest that either a 
more targeted and or more aggressive approach to antithrombotic treatment is 
required in T2DM patients after NSTE-ACS.  
Addition of a second antiplatelet agent, clopidogrel 75mg daily, reduced thrombus 
in patients with T2DM and stable CAD. To achieve a significant reduction of 
thrombus with dual antiplatelet therapy in population of T2DM with stable CAD 
which has good lipid and hypertension control and good (but not very tight) 
glycaemic control is clinically important. The effect of clopidogrel in suppressing 
platelet reactivity has been confirmed by three point of care platelet function 
studies.  
Multiple factors could have attributed to higher platelet dependent thrombus 
(PDT) in T2DM. The platelets of patients with T2DM are in a constant state of 
hyperactivation and in the context of NSTE-ACS, aspirin and clopidogrel therapy 
was not adequate to reduce platelet hyperactivity, and thus PDT, to the levels 
seen in non DM. Similar findings were earlier shown by our group in stable CAD 
patients who were taking aspirin monotherapy (Natarajan et al., 2008a). Platelet 
dysfunction is likely the major factor contributing to higher PDT in T2DM. In my 
studies, platelet hyperactivation in T2DM were shown by biochemical markers, 
platelet reactivity indices and higher amount of thrombus. Various factors could 
have contributed to platelet hyperactivation in T2DM. Hyperglycaemic state 
reduces the threshold of the platelets to various agonists. Inflammation plays a 
significant role in initiation and also sustains platelet activation. Qualitative 
analysis of the platelets from T2DM showed various stages of activation including 
pseudopodia formation and change of discoid shape of platelets. These findings 
were observed despite dual antiplatelet therapy in T2DM after NSTE-ACS. This 
could have occurred in conjunction with inadequate response and impaired 
pharmacokinetics of antiplatelet agents. It is possible that blood thrombogenicity 
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would have been different if I had prescribed a more powerful agent like ticagrelor 
or prasugrel. It can also be argued that higher doses of antiplatelet agents could 
have resulted in less PDT in this population.  
Mediators of inflammation were associated with PDT in T2DM and more so in 
obese subjects. This may have favoured higher thrombogenesis and impaired 
autolysis of thrombus. In obese individuals, inflammation could have been the 
missing link between T2DM and the resultant prothrombotic state. The 
significance of inflammation in thrombogenicity is yet to be fully evaluated. My 
findings showed a direct association of inflammatory biomarkers to thrombus and 
also the failure of one week of additional antiplatelet therapy (e.g. clopidogrel) in 
stable CAD patients with T2DM to reduce the inflammation. Presence of 
“vulnerable blood” in T2DM as shown by higher levels of inflammation and 
hyperactive platelets could have played a significant role in pathogenesis of 
NSTE-ACS, especially in those with non flow limiting atheromatous plaques. 
These results support the view that a “biochemical mechanism” secondary to pro 
thrombotic mediators is associated with acute coronary syndrome in these 
patients. T2DM is associated with persistent low grade inflammation and my 
findings reveal that despite good control of diabetes the levels of inflammatory 
cytokines remained higher in T2DM compared to non DM.  I have shown for the 
first time a significant association between whole blood thrombus created from 
experimental conditions of coronary blood flow and the markers of inflammation. 
Persistent inflammation may harbinger thrombotic events in T2DM. Body mass 
index and inflammation are strongly associated and my data showed higher 
thrombus burden and inflammatory markers in obese T2DM individuals. 
Inflammation not only promotes thrombus at local vascular endothelium by 
plaque rupture event but also interferes with various pathways of thrombogenesis 
and autolysis of the formed thrombus. In addition, by studying effluent blood 
(“post chamber”) blood, I have shown that circulating inflammatory mediators 
may play a direct role in thrombus formation in T2DM. A causal link, if confirmed 
by large-scale experimental and observation studies, may offer us an opportunity 
to identify therapeutic targets such as individualised anti thrombotic and anti 
inflammatory therapy in T2DM patients with non flow limiting atheroma in 
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coronary arteries. The central and powerful role played by inflammation has to be 
proven by mechanistic studies in patients with T2DM. It is possible that in 
addition to risk factor modification, targeting inflammatory pathways in these high 
risk patients may reduce blood thrombogenicity. Powerful anti inflammatory 
agents (e.g. anti TNFα agents) remain untested in a large cohort of T2DM and 
their therapeutic potential may be substantial. 
Significant differences in viscoelastic properties, supported by changes in 
thrombus architecture, could have resulted in greater PDT. Increased thrombus 
quantity seen in T2DM may be due to both higher blood thrombogenicity 
generating greater thrombus quantity and decreased thrombus degradation. I 
showed novel qualitative changes in the thrombus of patients with T2DM after 
NSTE-ACS. Findings of differential ultrastructural properties in diabetic thrombus 
may in part explain the differences in thrombus kinetics seen on TEG. 
Viscoelastic properties of thrombus are determined by ultrastructural 
characteristics at the level of the fibrin molecule and manifest changes in 
individual fibrin fibres, and their branching network. I have shown for the first 
time, both those changes in fibrin from whole blood thrombus of patients with 
T2DM. Thrombus in T2DM had thinner fibrin fibres, with more lateral 
aggregations, occurring in a disorganised, tangled or web-like fashion. This may 
favour increase in thrombus quantity by trapping more cellular elements, and in 
addition, may make clot retraction and degradation more difficult. Altered fibrin 
diameter and arrangement has been documented in patients with T2DM and 
CAD using plasma samples and reconstituted fibrinogen (Ajjan et al., 2009). I 
have shown for the first time, changes in fibrin after clopidogrel therapy in whole 
blood samples. My study documented that in patients with T2DM and stable 
CAD, clopidogrel therapy has changed fibrin fibre to be more favourable to 
autolysis. Fibrin fibres directly contribute to viscoelastic properties of the 
thrombus. I have also shown novel findings of viscoelastic properties of diabetic 
thrombus after NSTE-ACS and these findings were backed up by my electron 
microscopic studies on fibrin architecture. Presence of loosely bound thrombus 
with lower viscoelasticity, generated in flow conditions similar to those in the 
coronary artery, would favour distal embolisation.  Lower viscoelastic property of 
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diabetic thrombus results from thinner fibrin fibres and inability of the fibrin to 
undergo further stretching. These physical properties of the thrombus result in 
further entrapment of cellular elements and increase the potential of micro 
embolisation.  
The presence of thinner fibrin fibres in T2DM may result in lower viscoelastic 
strength of diabetic thrombus and this could be one explanation for the 
differences seen on TEG. SEM findings could not only explain the changes in 
TEG but also can provide mechanisms for changes observed in quantitative 
measurement of whole blood PDT. Overall my findings showed that diabetic 
thrombus after NSTE-ACS was greater in quantity, less compactly organised with 
lower viscoelastic force and thus more likely to undergo embolisation. In addition, 
thrombus from T2DM could have persisted longer in the vasculature as it 
undergoes autolysis much more slowly. Thin and highly branched fibrin fibres 
seen in T2DM in my study could result in less permeability of the thrombus to 
fibrinolytic enzymes and render thrombus less susceptible to autolysis. 
Conversely, after clopidogrel therapy, thrombus was made of thick fibres that 
favour higher permeability of fibrinolytic enzymes and better autolysis. In addition, 
a less compact and loosely bound fibrin fibre arrangement is a marker of poor 
fibrinolysis. Presence of less longitudinal twisting in T2DM could be another 
explanation for lower viscoelastic strength of diabetic thrombus seen in TEG 
studies. 
 Quantification of fibrin architecture in whole blood thrombus has been reported 
for the first time. This was possible due to a novel application of modern software 
(Image ProPlus®, MA, USA) based on a standard fibre quantification model used 
by the international cotton industry. The protocol of quantification of SEM 
changes to thrombus has been rigorously evaluated with internal quality control. 
Semi quantitative assessment of the fibrin fibre arrangement in whole blood 
thrombus is novel and has shown favourable response of clopidogrel to fibrin 
architecture. Prospective studies with long term follow up are needed to establish 
if these fibrin fibre parameters can predict response to antiplatelet and risk factor 
modification in T2DM. Moreover, studies are required to investigate if these 
measurements can be used as a tool to assess the future risk of thrombotic 
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events and clinical outcomes in T2DM and the general population. Mechanisms 
behind the fibrin structure and function are yet to be fully understood. My novel 
method of assessment of fibrin in whole blood thrombus needs validation in 
different patient cohorts, and can potentially help the clinicians to develop 
strategies to modulate fibrin structure with novel pharmacological agents. The 
relationship between viscoelastic properties of fibrin fibres and their interactions 
with platelets and other cellular components of thrombus, shear force of blood 
flow, and resistance to autolysis need to be explored further in this high risk 
population.  
Point of care platelet function tests namely VerifyNow®, thromboelastography 
with platelet mapping and Multiplate® aggregometry devices were evaluated in 
my study. The pathophysiology of thrombogenesis is complex and involves a 
significant proportion of non platelet mediators, especially in T2DM. Platelet 
reactivity indices from these assays did not account for non platelet mediators of 
thrombus and thus lacked correlation to thrombus in my cohort. My results 
underscore the point that results from current platelet function tests are very 
“platelet centric”. These findings may also explain the lack of clinical benefits 
observed in large scale studies attempting to tailor antiplatelet therapy based on 
these assays. I have used three platelet function tests measuring different 
aspects of thrombosis namely, platelet aggregation (Verify Now® and 
Multiplate®) and platelet fibrin linkage (TEG®). These platelet function tests 
reflect different specific pathways in thrombosis. Thrombus measurement from 
the Badimon chamber is a composite measure of various pathways involved in 
coagulation and is likely to be a superior assessment of thrombogenicity than 
these individual platelet function tests. However, Badimon chamber study cannot 
be performed as a bed side test and will only remain as a research tool. A single 
bed side test reflecting all the combined pathways of coagulation has so far been 
unavailable. Researchers in this field acknowledge these limitations (Bonello et 
al., 2010). A hybrid platelet function test combining thrombus structure and 
quality along with genotyping from a single whole blood sample can overcome 
the pitfalls observed in currently available tests and will prove to be of more 
clinical benefits. The goal of personalised antiplatelet therapy at individual levels 
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helped by a bedside test still remains an idealistic strategy not yet proven to be 
practical.  
It is possible that the effects of antiplatelet therapy go beyond direct effects on 
platelets. Pleiotropic effects of the antiplatelet agents are recently recognised in 
the form of improvement in vascular endothelial function (Bundhoo et al., 2011)( 
and anti inflammatory activity (Antonino et al., 2009). My study was not aimed to 
explore extra thrombotic activity of these agents and the clinical relevance of the 
reduction in thrombus quantity needs to be studied in long term follow up studies. 
It is possible that persistent inflammation in clopidogrel treated individuals plays a 
significant role in future thrombotic event in patients with T2DM irrespective of 
platelet reactivity indices. One week therapy with clopidogrel did not reduce the 
levels of inflammatory cytokines in T2DM with stable CAD.  Despite reduction in 
platelet function test indices, persistent inflammation could result in future 
thrombotic events and thus my findings may also explain the lack of clinical 
benefits observed in large scale studies attempting to tailor antiplatelet therapy 
based on these assays. I suggest caution should be exercised when using these 
values from point of care platelet function studies to tailor individualised therapy. 
My findings reiterate the concerns expressed in the current guidelines which 
suggest platelet function assays like VerifyNow® should remain as a research 
tool and are not to be used for routine clinical practice (Bonello et al., 2010).  
5.2 Limitations 
My study was a single centre study and I studied a small cohort of 170 patients 
only. Though the patients were carefully selected to ensure 100% adherence to 
secondary prevention, these patients may not represent real world population. My 
study subjects were predominantly Caucasians (168 out of 170) and thus the 
results may not be generalised to the global diabetic population. I used 
clopidogrel as my study drug which is still the most widely used antiplatelet agent 
next to aspirin in patients with T2DM and CAD. However, clopidogrel is inferior to 
newer antiplatelet agents like prasugrel and ticagrelor, both of which were 
unlicensed at the time of the study approval. My studies were approved by the 
authorities in 2008. Prasugrel and ticagrelor were licensed in UK in 2009 and 
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2010 respectively. The study population had a week of clopidogrel therapy and 
effects of longer duration of therapy were not addressed. Serum and plasma 
assays were used in studying various biomarkers and I did not use the more 
accurate but time consuming flow cytometric methods. Finally, I did not record 
long term clinical outcomes of my participants. 
5.3 Future directions 
My results suggest that in addition to current secondary prevention strategies, 
novel approaches to reduce recurrent thrombotic events in T2DM are essential.  
In patients with NSTE-ACS, newer and more potent antiplatelet agents have 
shown further reduction in cardiac events in T2DM but the outcomes still 
remained poorer than in the non-diabetic population. However the dosages used 
in T2DM are similar to non DM (e.g. prasugrel 10 mg and ticagrelor 90 mg bd). 
Findings from my ACS study showed that prescribing similar antiplatelet dosage 
regimes to T2DM resulted in greater thrombus. It remains to be seen if higher 
dosage of these agents will reduce thrombus in T2DM to levels similar to those 
without DM, with subsequent reduction in clinical events. Differential dosing 
regimes in T2DM has not been studied in large patient cohorts. This concept has 
been tested in my second study (patients with stable CAD), where dual 
antiplatelet therapy with aspirin and clopidogrel in T2DM with stable CAD 
reduced thrombus burden.  
Personalising antiplatelet therapy has limited success at individual patient’s level, 
but large patient cohort trials are required. Different cardiovascular risk 
modification regimes (e.g. lipid and blood pressure controls) for T2DM reduce 
cardiac events and it is possible similar success can also be achieved in 
antithrombotic therapy. It is logical and biologically plausible that the group of 
individuals with higher blood thrombogenicity (vulnerable blood) would benefit the 
most from aggressive pharmacotherapy. If carefully controlled studies could 
prove this concept in T2DM, changes to the guidelines issued by international 
cardiac societies on antithrombotic prescription to T2DM will become necessary. 
  
285 
I have shown that thrombus lysis is impaired in T2DM after NSTE-ACS and may 
have resulted from differential fibrin fibre arrangement. Pharmacotherapy to 
promote thrombus lysis is not recommended in patients outside the setting of ST 
elevation MI and with the widespread implementation of primary angioplasty 
services, thrombolytic agents are used less frequently. I have shown differential 
fibrin fibre arrangement in T2DM and changes in fibrin fibre ultrastructure with 
antiplatelet therapy are associated with reduction of thrombus in patients with 
T2DM. Identification and use of novel pharmacotherapy to modify these less 
explored pathways of coagulation in T2DM may result in better outcomes in 
T2DM. 
A change in platelet content of thrombus was associated with reduction in 
thrombus quantity in T2DM. Clopidogrel which indirectly alters platelet content of 
the thrombus reduced thrombus quantity. The results are likely to be more 
pronounced with novel pharmacological agents which reduce platelet count.  
Rafigrelide is a newer analogue of anagrelide which suppresses platelet 
synthesis and results in lower platelet count. Our group has shown in a phase 
one study with rafigrelide that reduction in platelet count is strongly associated 
with reduction in thrombus quantity (In Press). It is possible that modification of 
platelet synthesis and reduction of platelet count to optimal levels in T2DM may 
reduce thrombogenicity and improve cardiac outcomes.  
My thesis has made a small but a significant contribution to the understanding of 
complex pathophysiology of thrombosis in T2DM. My data has highlighted some 
of the unique features seen in this high risk population with regard to blood 
thrombogenicity. My findings hold the promise of development of future strategies 
beyond conventional antiplatelet and anticoagulant medications to improve blood 
thrombogenicity and thereby improve their clinical outcomes in T2DM.  
I propose these following studies to carry forward my findings from this thesis: 
i. Multicentre study in patients with and without T2DM who had CAD, to 
evaluate platelet dependent thrombogenicity using newer antiplatelet 
agents like prasugrel and ticagrelor will be helpful to assess the 
benefits of these agents over clopidogrel. 
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ii. A study designed to assess the long term benefits of dual antiplatelet 
therapy in patients with stable CAD and T2DM is needed for the 
international societies to issue guidelines on antiplatelet therapy 
specifically for T2DM with stable CAD. 
iii. Interventional studies are needed to explore the role of novel 
pharmacotherapy to improve blood thrombogenicity in T2DM. Anti 
inflammatory agents, fibrin specific antagonists, agents that suppress 
synthesis of platelets and direct thrombin inhibitors in the ex-vivo 
chamber should all be studied.  
iv. A prospective study on the role of blood thrombogenicity in atheroma 
progression and future cardiac events in T2DM with and without overt 
CAD will be helpful in understanding the role of “vulnerable blood” in 
these high risk individuals.   
v. An interventional study primarily designed to assess the role of 
pharmacological and lifestyle interventions in improving ultrastructure 
characteristics and mechanical properties of whole blood thrombus in 
T2DM would expand our knowledge of the thrombus kinetics in this 
high risk population. 
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Appendix 1: Prizes and Awards 
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1. Diabetes UK type 2 diabetes research award, London, March 2011. 
2. Short listed for Raftery award in Cardiology, Royal society of Medicine, 
London, February 2011. 
3. Best researcher award, Welsh Deanery Cardiology Trainees’ meeting, Clwb 
Calon Cymru, Cardiff, November 2011. 
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